"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 853227 A,001-338-421-247-533,1907-05-14,1907,US 1906/0332461 A,1906-08-29,US 1906/0332461 A,1906-08-29,LOADING AND UNLOADING APPARATUS.,,CUFF JOHN KENNEDY,CUFF JOHN KENNEDY,,https://lens.org/001-338-421-247-533,Granted Patent,no,0,0,1,1,0,A01D87/003;;A01D87/003,,,0,0,,,,EXPIRED
2,CA,A,CA 127006 A,187-855-223-922-21X,1910-07-19,1910,CA 127006D A,1910-03-07,CA 127006T A,1910-03-07,"ABDOMINAL SUPPORT, ETC.",,CUFF JOHN F,CUFF JOHN F,,https://lens.org/187-855-223-922-21X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
3,US,A1,US 2003/0093931 A1,001-664-919-762-384,2003-05-22,2003,US 98921001 A,2001-11-19,US 98921001 A,2001-11-19,Card holder,"
   A transparent card holder covers only a portion of a card while a portion of the card protrudes from the card holder allowing it to communicate with appropriate device interfaces. The dimensions and stretchy nature of the card holder provide a snug fit to prevent the card from falling out. A tab on the card holder allows it to be attached to a display device attached to a user's clothing to provide quick access to the card while minimizing the risk of loss. 
",CUFF JOHN L.,CUFF JOHN L,J.A.M. PLASTICS INC (2001-11-19),https://lens.org/001-664-919-762-384,Patent Application,yes,3,22,1,1,0,A45C11/182;;A45F5/00;;A45F5/004;;A45F2003/002;;A45F2200/055;;A45C11/182;;A45F5/00;;A45F5/004;;A45F2003/002;;A45F2200/055,A45C11/18;;A45F3/00;;A45F5/00,40/1.6,0,0,,,,DISCONTINUED
4,US,A,US 1060538 A,136-937-092-618-769,1913-04-29,1913,US 1911/0667636 A,1911-12-26,US 1911/0667636 A,1911-12-26,DITCHING-MACHINE.,,CUFF JOHN KENNEDY,CUFF JOHN KENNEDY,,https://lens.org/136-937-092-618-769,Granted Patent,no,0,0,1,1,0,E02F3/50;;E02F3/50,,,0,0,,,,EXPIRED
5,US,S,US D0474595 S,146-853-774-906-412,2003-05-20,2003,US 15029901 F,2001-11-19,US 15029901 F,2001-11-19,Combined card holder and card,,J A M PLASTICS INC,CUFF JOHN L,DUAL CORE LLC (2009-01-26);;COMPREHENSIVE IDENTIFICATION PRODUCTS INC (2007-07-26);;J.A.M. PLASTICS INC (2001-11-19),https://lens.org/146-853-774-906-412,Design Right,no,0,4,1,1,0,,,D 3247,0,0,,,,EXPIRED
6,US,A1,US 2018/0200809 A1,013-154-346-929-890,2018-07-19,2018,US 201815868171 A,2018-01-11,US 201815868171 A;;US 201762447523 P,2017-01-18,PLUNGE SLITTING WITH ENHANCED SCRAP THREADING CAPABILITY USING NOTCHING SHEARS,A slitting machine for threading scrap material includes first and second arbors; rotary knives disposed on each of the first and second arbors; and a pair of notching modules positioned on opposite ends of the first and second arbors. The notching modules each has a pair of shear knives for making multiple cuts in a strip of material passing through the slitting machine forming notches to enable threading of material to scrap chutes from the slitting machine.,BUTECH INC,BUTA JOHN R;;CUFF JASON,BUTECH INC. (D/B/A BUTECH BLISS) (2018-01-23),https://lens.org/013-154-346-929-890,Patent Application,yes,0,5,2,2,0,B21C47/006;;B21B2015/0021;;B65H2301/4148;;B65H2701/173;;B21C47/267;;B23D31/02;;B23D19/06;;B21C47/267;;B23D35/007;;B23D31/008;;B21C47/006;;B21B2015/0021;;B65H2301/4148;;B65H2701/173,B23D31/02;;B21C47/26;;B23D19/06;;B23D31/00;;B23D35/00,,0,0,,,,ACTIVE
7,US,B2,US 10583503 B2,042-279-326-229-038,2020-03-10,2020,US 201815868171 A,2018-01-11,US 201815868171 A;;US 201762447523 P,2017-01-18,Plunge slitting with enhanced scrap threading capability using notching shears,A slitting machine for threading scrap material includes first and second arbors; rotary knives disposed on each of the first and second arbors; and a pair of notching modules positioned on opposite ends of the first and second arbors. The notching modules each has a pair of shear knives for making multiple cuts in a strip of material passing through the slitting machine forming notches to enable threading of material to scrap chutes from the slitting machine.,BUTECH INC;;BUTECH BLISS,BUTA JOHN R;;CUFF JASON,BUTECH INC. (D/B/A BUTECH BLISS) (2018-01-23),https://lens.org/042-279-326-229-038,Granted Patent,yes,41,0,2,2,0,B21C47/006;;B21B2015/0021;;B65H2301/4148;;B65H2701/173;;B21C47/267;;B23D31/02;;B23D19/06;;B21C47/267;;B23D35/007;;B23D31/008;;B21C47/006;;B21B2015/0021;;B65H2301/4148;;B65H2701/173,B23D31/02;;B21B15/00;;B21C47/00;;B21C47/26;;B23D19/06;;B23D31/00;;B23D35/00,,0,0,,,,ACTIVE
8,DE,A1,DE 2850435 A1,199-299-018-125-036,1979-06-13,1979,DE 2850435 A,1978-11-21,US 85988277 A,1977-12-12,VERFAHREN ZUM FUELLEN EINER FORM ZUM KUNSTSTOFFORMPRESSEN UND FUELLKASTEN ZUR DURCHFUEHRUNG DES VERFAHRENS,,UNITED TECHNOLOGIES CORP,CUFF FREDERICK LAWRENCE;;WALEK WALTER JOHN,,https://lens.org/199-299-018-125-036,Patent Application,no,0,0,7,7,0,B29C43/34;;B30B15/302;;B30B15/302;;B29C43/34,B29C31/04;;B29C43/00;;B29C33/00;;B29C43/02;;B29C43/34;;B29C43/58;;B30B15/30,,0,0,,,,DISCONTINUED
9,US,S,US D0562775 S,162-307-685-136-569,2008-02-26,2008,US 28391007 F,2007-08-27,US 28391007 F,2007-08-27,Electrical connector,,AIRBORN INC,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2007-08-17),https://lens.org/162-307-685-136-569,Design Right,no,0,13,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
10,US,B2,US 6877992 B2,165-755-751-298-127,2005-04-12,2005,US 28577702 A,2002-11-01,US 28577702 A,2002-11-01,Area array connector having stacked contacts for improved current carrying capacity,An area array connector adapted to connect contact pads on a first generally planar circuit element to corresponding contact pads on a second generally planar circuit element is described. The area array connector includes an interposer housing and at least one electrical interconnector positioned within the interposer housing. The at least one electrical interconnector is comprised of a plurality of electrical contacts stacked in a substantially parallel relationship to one another. The at least one electrical interconnector is positioned to make contact with a first contact pad on the first generally planar circuit element and a second contact pad on the second generally planar circuit element to provide an electrical interconnection therebetween.,AIRBORN INC,GRANT JOHN L;;CUFF MICHAEL P,AIRBORN INC (2002-10-31),https://lens.org/165-755-751-298-127,Granted Patent,yes,28,32,4,4,0,H01R13/2435;;H01R12/52;;H01R12/714;;H01R12/73;;H01R13/2435;;H01R12/52;;H01R12/714,H01R12/04;;H01R13/24,439/66;;439/91;;439/591,0,0,,,,EXPIRED
11,US,S,US D0561108 S,193-940-831-194-555,2008-02-05,2008,US 28391207 F,2007-08-27,US 28391207 F,2007-08-27,Electrical connector,,AIRBORN INC,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2007-08-17),https://lens.org/193-940-831-194-555,Design Right,no,0,11,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
12,US,B2,US 7187076 B2,114-838-137-764-128,2007-03-06,2007,US 91374304 A,2004-08-06,US 91374304 A;;US 49401303 P,2003-08-07,Interposer with integral heat sink,An area array connector for providing a thermal and an electrical interconnection between a first circuit element and a second circuit element is described. The area array connector includes at least one electrically conductive interconnector adapted to provide an electrical interconnection between the first circuit element and the second circuit element. The area array connector also includes at least one thermally conductive member adapted to provide thermal interconnection between the first circuit element and the second circuit element.,AIRBORN INC,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2004-08-04),https://lens.org/114-838-137-764-128,Granted Patent,yes,9,11,2,2,0,H01L23/367;;H05K7/1053;;H01L2924/0002;;H01L23/367;;H05K7/1053;;H01L2924/0002,H01L23/34;;H01L23/367;;H05K7/10,257/713,2,0,,,"U.S. Appl. No. 10/285,777, filed Nov. 1, 2002, Grant et al.;;Polyplastics, ""Molding Technology for Fortron"", Copyright 2001-2002, Polyplastics Co., Ltd., http://www.polyplastics.com/en/support/tech/pps<SUB>-</SUB>mold/index.html, (1 page).",ACTIVE
13,US,A1,US 2005/0029652 A1,162-360-951-616-278,2005-02-10,2005,US 91374304 A,2004-08-06,US 91374304 A;;US 49401303 P,2003-08-07,Interposer with integral heat sink,An area array connector for providing a thermal and an electrical interconnection between a first circuit element and a second circuit element is described. The area array connector includes at least one electrically conductive interconnector adapted to provide an electrical interconnection between the first circuit element and the second circuit element. The area array connector also includes at least one thermally conductive member adapted to provide thermal interconnection between the first circuit element and the second circuit element.,CUFF MICHAEL P.;;GRANT JOHN L.,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2004-08-04),https://lens.org/162-360-951-616-278,Patent Application,yes,9,11,2,2,0,H01L23/367;;H05K7/1053;;H01L2924/0002;;H01L23/367;;H05K7/1053;;H01L2924/0002,H01L23/367;;H05K7/10,257/712;;438/125;;257/713;;257/719,0,0,,,,ACTIVE
14,US,A1,US 2004/0087189 A1,003-611-417-575-419,2004-05-06,2004,US 28577702 A,2002-11-01,US 28577702 A,2002-11-01,Area array connector having stacked contacts for improved current carrying capacity,"
   An area array connector adapted to connect contact pads on a first generally planar circuit element to corresponding contact pads on a second generally planar circuit element is described. The area array connector includes an interposer housing and at least one electrical interconnector positioned within the interposer housing. The at least one electrical interconnector is comprised of a plurality of electrical contacts stacked in a substantially parallel relationship to one another. The at least one electrical interconnector is positioned to make contact with a first contact pad on the first generally planar circuit element and a second contact pad on the second generally planar circuit element to provide an electrical interconnection therebetween. 
",GRANT JOHN L.;;CUFF MICHAEL P.,GRANT JOHN L;;CUFF MICHAEL P,AIRBORN INC (2002-10-31),https://lens.org/003-611-417-575-419,Patent Application,yes,5,9,4,4,0,H01R13/2435;;H01R12/52;;H01R12/714;;H01R12/73;;H01R13/2435;;H01R12/52;;H01R12/714,H01R12/04;;H01R13/24,439/66,0,0,,,,EXPIRED
15,US,S,US D0561698 S,087-358-414-882-238,2008-02-12,2008,US 28390507 F,2007-08-27,US 28390507 F,2007-08-27,Electrical connector,,AIRBORN INC,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2007-08-17),https://lens.org/087-358-414-882-238,Design Right,no,0,11,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
16,US,S,US D0561107 S,060-890-807-539-941,2008-02-05,2008,US 28390807 F,2007-08-27,US 28390807 F,2007-08-27,Electrical connector,,AIRBORN INC,CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2007-08-17),https://lens.org/060-890-807-539-941,Design Right,no,0,12,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
17,US,B2,US 7021942 B2,112-843-617-042-603,2006-04-04,2006,US 9931405 A,2005-04-05,US 9931405 A;;US 28577702 A,2002-11-01,Area array connector having stacked contacts for improved current carrying capacity,An area array connector adapted to connect contact pads on a first generally planar circuit element to corresponding contact pads on a second generally planar circuit element is described. The area array connector includes an interposer housing and at least one electrical interconnector positioned within the interposer housing. The at least one electrical interconnector is comprised of a plurality of electrical contacts stacked in a substantially parallel relationship to one another. The at least one electrical interconnector is positioned to make contact with a first contact pad on the first generally planar circuit element and a second contact pad on the second generally planar circuit element to provide an electrical interconnection therebetween.,AIRBORN INC,GRANT JOHN L;;CUFF MICHAEL P,AIRBORN INC (2002-10-31),https://lens.org/112-843-617-042-603,Granted Patent,yes,5,27,4,4,0,H01R13/2435;;H01R12/52;;H01R12/714;;H01R12/73;;H01R13/2435;;H01R12/52;;H01R12/714,H01R12/00;;H01R12/04;;H01R13/24;;H05K1/00,439/66;;439/91;;439/591,0,0,,,,EXPIRED
18,US,A1,US 2005/0176269 A1,068-873-017-871-313,2005-08-11,2005,US 9931405 A,2005-04-05,US 9931405 A;;US 28577702 A,2002-11-01,Area array connector having stacked contacts for improved current carrying capacity,An area array connector adapted to connect contact pads on a first generally planar circuit element to corresponding contact pads on a second generally planar circuit element is described. The area array connector includes an interposer housing and at least one electrical interconnector positioned within the interposer housing. The at least one electrical interconnector is comprised of a plurality of electrical contacts stacked in a substantially parallel relationship to one another. The at least one electrical interconnector is positioned to make contact with a first contact pad on the first generally planar circuit element and a second contact pad on the second generally planar circuit element to provide an electrical interconnection therebetween.,AIRBORN INC,GRANT JOHN L;;CUFF MICHAEL P,AIRBORN INC (2002-10-31),https://lens.org/068-873-017-871-313,Patent Application,yes,0,2,4,4,0,H01R13/2435;;H01R12/52;;H01R12/714;;H01R12/73;;H01R13/2435;;H01R12/52;;H01R12/714,H01R12/04;;H01R13/24,439/66,0,0,,,,EXPIRED
19,FR,A1,FR 2411080 A1,088-101-283-739-695,1979-07-06,1979,FR 7832809 A,1978-11-21,US 85988277 A,1977-12-12,PROCEDE POUR CHARGER UN MOULE POUR LE MOULAGE PAR COMPRESSION,"<P>LA PRESENTE INVENTION CONCERNE UN PROCEDE ET UN DISPOSITIF DE DISTRIBUTION POUR REMPLIR UN MOULE POUR LE MOULAGE PAR COMPRESSION.</P><P>LE DISPOSITIF DE DISTRIBUTION A LA MEME FORME QUE LA CAVITE DU MOULE ET COMPREND UN FOND AMOVIBLE PAR GLISSEMENT DE SORTE QUE LA MATIERE SE TROUVANT DANS LE DISPOSITIF DE DISTRIBUTION PEUT TOMBER DANS LE MOULE PAR ENLEVEMENT DU FOND COULISSANT, UNE GRILLE ETANT DISPOSEE DANS LE DISPOSITIF DE DISTRIBUTION POUR SERVIR A MAINTENIR LA MATIERE DANS LE DISPOSITIF DE DISTRIBUTION EN PLACE DE SORTE QU'ELLE NE SE DEPLACERA PAS LATERALEMENT LORSQUE LE FOND COULISSANT EST ENLEVE.</P><P>L'INVENTION EST PAR EXEMPLE UTILISABLE POUR LE MOULAGE PAR COMPRESSION DE MATIERES THERMOPLASTIQUES ET THERMODURCISSABLES.</P>",UNITED TECHNOLOGIES CORP,CUFF FREDERICK LAWRENCE;;WALEK WALTER JOHN,,https://lens.org/088-101-283-739-695,Patent Application,no,2,0,7,7,0,B29C43/34;;B30B15/302;;B30B15/302;;B29C43/34,B29C31/04;;B29C33/00;;B29C43/00;;B29C43/02;;B29C43/34;;B29C43/58;;B30B15/30,,0,0,,,,DISCONTINUED
20,WO,A1,WO 2013/112211 A1,151-880-854-925-87X,2013-08-01,2013,US 2012/0059425 W,2012-10-10,US 201261591511 P;;US 201213458439 A,2012-01-27,LOCATION SERVICES GAME ENGINE,"A location services game engine (LSGE) that is concerned with the geographic location of the wireless devices used to play in the game. The operations performed by players on wireless devices inside the location services game engine have location proximity requirements on the wireless devices being played in the game, and other wireless devices they interact with. A common game experience provides a virtual game instance including a plurality of geographically remote playing wireless devices virtually gathered together within the virtual game to physically interact with one another, and traveling relative to one another within the virtual game. A location update of each of the plurality of playing wireless devices active within the virtual game is obtained, with any movement from a last reported position applied against a virtual origin point within the virtual reality game.",TELECOMM SYSTEMS INC,LOCKEBY CAMRON;;CUFF MICHAEL;;HINES GORDON JOHN,,https://lens.org/151-880-854-925-87X,Patent Application,yes,6,0,2,2,0,A63F2300/204;;A63F2300/5573;;H04W4/023;;A63F13/216;;A63F13/79;;A63F13/533;;A63F13/46;;A63F13/332;;H04L67/131;;A63F13/216;;A63F13/79;;A63F2300/204;;A63F2300/5573;;H04W4/023;;H04L67/131,A63F9/24,,0,0,,,,PENDING
21,US,A1,US 2018/0200909 A1,108-870-401-513-022,2018-07-19,2018,US 201815872311 A,2018-01-16,US 201815872311 A;;US 201762447613 P,2017-01-18,PLUNGE SLITTING WITH ENHANCED SCRAP THREADING CAPABILITY USING MULTIPLE SIZE KNIVES,"A slitting machine for threading scrap material has first and second arbors. A first set of rotary knives are disposed on each of the first and second arbors having a first diameter. A second set of rotary knives are disposed on each of the first and second arbors having a second diameter. The second diameter is smaller than the first diameter. As the arbor gap is closed, the first set of rotary knives cut edge trim and when the arbor gap is further closed, the second set of rotary knives cut mutts from the strip.",BUTECH INC,BUTA JOHN R;;CUFF JASON;;GUSTWILLER JASON,BUTECH INC. (D/B/A/ BUTECH BLISS) (2018-01-23),https://lens.org/108-870-401-513-022,Patent Application,yes,17,0,1,1,0,B26D7/20;;B26D7/20;;B23D19/06;;B23D19/06;;B23D31/04;;B23D31/04;;B26D1/245;;B26D1/245;;B26D2007/202;;B26D2007/202,B26D7/20,,0,0,,,,DISCONTINUED
22,US,A1,US 2013/0196773 A1,169-120-319-866-910,2013-08-01,2013,US 201213458439 A,2012-04-27,US 201213458439 A;;US 201261591511 P,2012-01-27,Location Services Game Engine,"A location services game engine (LSGE) that is concerned with the geographic location of the wireless devices used to play in the game. The operations performed by players on wireless devices inside the location services game engine have location proximity requirements on the wireless devices being played in the game, and other wireless devices they interact with. A common game experience provides a virtual game instance including a plurality of geographically remote playing wireless devices virtually gathered together within the virtual game to physically interact with one another, and traveling relative to one another within the virtual game. A location update of each of the plurality of playing wireless devices active within the virtual game is obtained, with any movement from a last reported position applied against a virtual origin point within the virtual reality game.",LOCKEBY CAMRON;;CUFF MICHAEL;;HINES GORDON JOHN,LOCKEBY CAMRON;;CUFF MICHAEL;;HINES GORDON JOHN,TELECOMMUNICATION SYSTEMS INC (2012-05-30),https://lens.org/169-120-319-866-910,Patent Application,yes,39,14,2,2,0,A63F2300/204;;A63F2300/5573;;H04W4/023;;A63F13/216;;A63F13/79;;A63F13/533;;A63F13/46;;A63F13/332;;H04L67/131;;A63F13/216;;A63F13/79;;A63F2300/204;;A63F2300/5573;;H04W4/023;;H04L67/131,A63F9/24,463/42,0,0,,,,DISCONTINUED
23,US,A,US 5892216 A,189-410-821-790-668,1999-04-06,1999,US 84373597 A,1997-04-21,US 84373597 A,1997-04-21,Smart card reader with electrostatic discharge protection,"A smart card reader having several advantageous grounding techniques and several techniques to insure proper electrical isolation of the electrical components of the card reader is disclosed. The smart card reader has a base and a cover. In certain techniques, a non-conductive base is grounded to a conductive, grounded cover. In another technique, a grounded base formed of a statically dissipative composite material is utilized.",AIRBORN INC,GRANT JOHN LINCOLN;;CUFF MICHAEL PATRICK;;FOLTA CLAUDE GRANT,AIRBORN INC (1997-04-30),https://lens.org/189-410-821-790-668,Granted Patent,yes,10,27,2,2,0,G06K7/0021;;G06K7/0082;;G06K7/0082;;G06K7/0021,G06K7/00,235/492;;235/441,4,0,,,"Bekaert Corporation product literature for Beki Shield conductive plastics, Nov. 1996, 2 pages.;;Statically Dissipative Thermoplastic Polyester, Stat Kon W Series Technical Data, LNP Engineering Plastics, Inc., Jan. 25, 1996, 2 pages.;;Stat Kon, A guide to LNP s Line of Thermoplastic Composites for Electrostatic Dissipation , LNP Engineering Plastics, Bulletin 223 894, 1994, 12 pages.;;Stainless Fibers Add Shielding to Housing , Bekaert Fibre Technologies, Jan. 1991, 1 page.",EXPIRED
24,US,B1,US 6308889 B1,181-787-009-644-220,2001-10-30,2001,US 22306498 A,1998-12-30,US 22306498 A;;US 84373597 A,1997-04-21,Smart card reader with electrostatic discharge protection,"A smart card reader having several advantageous grounding techniques and several techniques to insure proper electrical isolation of the electrical components of the card reader. The smart card reader has a base and a cover. In certain techniques, a non-conductive base is grounded to a conductive, grounded cover. In another technique, a grounded base formed of a statically dissipative composite material is utilized.",AIRBORN INC,GRANT JOHN LINCOLN;;CUFF MICHAEL PATRICK;;FOLTA CLAUDE GRANT,AIRBORN INC (1997-04-30),https://lens.org/181-787-009-644-220,Granted Patent,yes,18,4,2,2,0,G06K7/0021;;G06K7/0082;;G06K7/0082;;G06K7/0021,G06K7/00,235/441;;235/492;;439/630,0,0,,,,EXPIRED
25,US,S,US D0560614 S,104-390-753-937-509,2008-01-29,2008,US 24847406 F,2006-08-17,US 24847406 F,2006-08-17,Electrical connector,,AIRBORN INC,MCEVOY HERBERT J;;CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2006-08-07),https://lens.org/104-390-753-937-509,Design Right,no,0,12,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
26,US,S,US D0560613 S,178-954-147-274-181,2008-01-29,2008,US 24847306 F,2006-08-17,US 24847306 F,2006-08-17,Electrical connector,,AIRBORN INC,MCEVOY HERBERT J;;CUFF MICHAEL P;;GRANT JOHN L,AIRBORN INC (2006-08-07),https://lens.org/178-954-147-274-181,Design Right,no,0,9,1,1,0,,,1303;;D13/147,0,0,,,,EXPIRED
27,NZ,A,NZ 601082 A,037-963-261-690-156,2013-03-28,2013,NZ 60108207 A,2007-11-20,NZ 60108207 A,2007-11-20,Anthelmintic Formulations and Treatments Comprising Separate Marcolactone and Levamisole Containing Formulations,"601082 Disclosed herein is a method of controlling parasites in ruminants and extending the time between treatment to minimise drench use, by treating the animal with at least (a) a long acting macrocylic lactone anthelmintic formulation A capable of providing a persistent anthelmintic activity of from 3-14 days so that it is capable of removing or killing incoming larvae for a sufficiently long period to allow the host to recognise incoming larvae as foreign and mount an immune response/self-treatment effect to reduce the effect of the parasite including reduce egg output and incoming larvae, and (b) treating the ruminant with a short acting levamisole anthelmintic formulation B to substantially eliminate the initial adult and immature parasite population present in the animal. More particularly wherein formulation A comprises ivermectin.",VIRBAC NEW ZEALAND LTD,VICKERS MARK COLIN;;PULFORD PETER NORMAN;;CUFF NICOLA JANE;;MARTIN PAUL JOHN,,https://lens.org/037-963-261-690-156,Patent Application,no,0,0,1,1,0,,A01N25/02;;A01N43/90;;A61K31/365;;A61K31/41;;A61K31/4188;;A61K31/429,,0,0,,,,PENDING
28,US,A,US 4302990 A,029-376-235-050-722,1981-12-01,1981,US 9150079 A,1979-11-05,US 9150079 A,1979-11-05,Socket wrench,A socket wrench comprises a ratchet head which is removably held in an aperture in the forward end of a ratchet handle. A knurled drive ring allows the ratchet head to be used when detached from the handle and the handle itself is hollow and receives a tray which is dimensioned to hold a plurality of sockets. Access to the sockets is obtained by withdrawing the tray from the handle.,LITTON INDUSTRIAL PRODUCTS,CHRICHTON JOHN P;;TREBEL JOHN M;;CUFF GEORGE W;;GOODWIN DAVID H;;LEVY EDWARD D,NATIONAL HAND TOOL CORPORATION A CORP. OF DE (1987-05-27);;STANLEY WORKS THE 1000 STANLEY DR. NEW BRITAIN CT 06050 A CORP. OF CT (1986-12-30),https://lens.org/029-376-235-050-722,Granted Patent,yes,19,77,3,3,0,B25G1/085;;B25G1/085,B25B13/46;;B25B13/56;;B25G1/08,81/60,0,0,,,,EXPIRED
29,EC,A,EC SP014078 A,102-970-777-962-109,2002-02-25,2002,EC SP014078 A,2001-05-18,US 20600300 P,2000-05-19,DERIVADOS DE SULFONAMIDA,"La presente invención se refiere a un compuesto de fórmula I (gráfico), o una sal farmacéuticamente aceptable del mismo, que es útil para el tratamiento de defencias asociadas con la hipofusión como trastornos psiquiátricos y neurológicos.",LILLY CO ELI,CUFF GEORGE WILLIAM;;BLEISCH THOMAS JOHN;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL;;ARNOLD MACKLIN BRIAN,,https://lens.org/102-970-777-962-109,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K9/48;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,PENDING
30,BR,A,BR 0110874 A,145-375-882-898-456,2003-02-11,2003,BR 0110874 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,Derivados de sulfonamida,"""DERIVADOS DE SULFONAMIDA"". A presente invenção refere-se a um composto de fórmula (I) ou um sal farmaceuticamente aceitável do mesmo que é utilizável para o tratamento de condições associadas com hipofunção de glutamato, como distúrbios psiquiátricos e neurológicos.",LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEOGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/145-375-882-898-456,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K9/48;;A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
31,AU,A,AU 2001/059053 A,036-627-826-782-754,2001-12-03,2001,AU 2001/059053 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,Sulfonamide derivatives,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/036-627-826-782-754,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K9/48;;A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
32,ZA,B,ZA 200208749 B,025-127-858-144-917,2004-01-30,2004,ZA 200208749 A,2002-10-29,US 20600300 P,2000-05-19,Sulfonamide derivatives.,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;CUFF GEORGE WILLIAM;;ZIMMERMAN DENNIS MICHAEL;;BLEISCH THOMAS JOHN;;ORNSTEIN PAUL LESLIE,,https://lens.org/025-127-858-144-917,Granted Patent,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,EXPIRED
33,HU,A2,HU P0302255 A2,120-090-976-619-79X,2003-11-28,2003,HU P0302255 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,"SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE","A találmány tárgya valamely (I) képletű vegyületre vagy ennekgyógyszerészetileg elfogadható sójára vonatkozik, amely csökkentglutamát-receptor működéshez társuló állapotok, úgymint pszichiátriaiés neurológiai rendellenességek kezelésére alkalmas. A találmánykiterjed a vegyületet tartalmazó gyógyszerkészítményekre is. Ó",LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/120-090-976-619-79X,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
34,DZ,A1,DZ 3343 A1,002-578-866-595-230,2001-11-29,2001,DZ 013343 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,DERIVES DE SULFONAMIDE,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ZIMMERMAN DENNIS MICHAEL;;ORNSTEIN PAUL LESLIE,,https://lens.org/002-578-866-595-230,Granted Patent,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K9/48;;A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,EXPIRED
35,SK,A3,SK 16312002 A3,097-732-917-647-061,2003-05-02,2003,SK 16312002 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,Sulfonamide derivatives,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/097-732-917-647-061,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,PENDING
36,SV,A,SV 2002000459 A,051-019-861-305-19X,2002-07-03,2002,SV 2001000459 A,2001-05-18,US 20600300 P,2000-05-19,DERIVADOS DE SULFONAMIDAS REF. X-13840,"LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE FORMULA I, VER FORMULA, O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, QUE SON UTILES PARA EL TRATAMIENTO DE DOLENCIAS ASOCIADAS CON HIPOFUNCION DE GLUTAMATO, COMO TRASTORNOS PSIQUIATRICOS Y NEUROLOGICOS.",LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/051-019-861-305-19X,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/10;;A61K9/48;;A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
37,NO,D0,NO 20025459 D0,093-014-922-080-520,2002-11-14,2002,NO 20025459 A,2002-11-14,US 20600300 P;;US 0111747 W,2000-05-19,Sulfonamidderivater,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/093-014-922-080-520,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K9/48;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
38,PL,A1,PL 358180 A1,139-531-322-892-851,2004-08-09,2004,PL 35818001 A,2001-05-04,US 0111747 W;;US 20600300 P,2000-05-19,SULFONAMIDE DERIVATIVES,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/139-531-322-892-851,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61P25/00;;A61K9/48;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
39,EP,A1,EP 1311474 A1,025-901-556-833-514,2003-05-21,2003,EP 01932536 A,2001-05-04,US 0111747 W;;US 20600300 P,2000-05-19,SULFONAMIDE DERIVATIVES,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/025-901-556-833-514,Patent Application,yes,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
40,HR,A2,HR P20020918 A2,036-127-895-484-805,2004-02-29,2004,HR P20020918 A,2002-11-19,US 20600300 P;;US 0111747 W,2000-05-19,SULFONAMIDE DERIVATIVES,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF WILLIAM GEORGE;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/036-127-895-484-805,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
41,CZ,A3,CZ 20023797 A3,063-627-858-554-405,2003-04-16,2003,CZ 20023797 A,2001-05-04,US 20600300 P,2000-05-19,Sulfonamide derivatives,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/063-627-858-554-405,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;A61K9/48;;C07C311/05,,0,0,,,,PENDING
42,CA,A1,CA 2409830 A1,088-105-366-418-895,2001-11-29,2001,CA 2409830 A,2001-05-04,US 20600300 P;;US 0111747 W,2000-05-19,SULFONAMIDE DERIVATIVES,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ZIMMERMAN DENNIS MICHAEL;;ORNSTEIN PAUL LESLIE,,https://lens.org/088-105-366-418-895,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K9/48;;A61K31/18;;A61K47/32;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
43,WO,A1,WO 2001/090057 A1,063-276-041-101-119,2001-11-29,2001,US 0111747 W,2001-05-04,US 20600300 P,2000-05-19,SULFONAMIDE DERIVATIVES,"The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.",LILLY CO ELI;;ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/063-276-041-101-119,Patent Application,yes,1,11,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,PENDING
44,AU,A,AU 2000/026375 A,141-887-113-921-598,2001-06-18,2001,AU 2000/026375 A,2000-02-03,US 16998599 P;;US 0002657 W,1999-12-10,Cationic amphiphiles for intracellular delivery of therapeutic molecules,,GENZYME CORP,MARSHALL JOHN;;HARRIS DAVID J;;SIEGEL CRAIG S;;LEE EDWARD R;;LANE MATHIEU;;CUFF LISA,,https://lens.org/141-887-113-921-598,Patent Application,no,0,0,2,2,0,A61K9/0019;;A61K47/18;;C07C271/10,A61K47/18;;C07C271/10,,0,0,,,,DISCONTINUED
45,WO,A1,WO 2001/042200 A1,107-923-470-464-391,2001-06-14,2001,US 0002657 W,2000-02-03,US 16998599 P,1999-12-10,CATIONIC AMPHIPHILES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES,"Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically bycontacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.",GENZYME CORP;;MARSHALL JOHN;;HARRIS DAVID J;;SIEGEL CRAIG S;;LEE EDWARD R;;LANE MATHIEU;;CUFF LISA,MARSHALL JOHN;;HARRIS DAVID J;;SIEGEL CRAIG S;;LEE EDWARD R;;LANE MATHIEU;;CUFF LISA,,https://lens.org/107-923-470-464-391,Patent Application,yes,9,9,2,2,0,A61K9/0019;;A61K47/18;;C07C271/10,A61K47/18;;C07C271/10,,1,0,,,"KALALOVA, ELISKA ET AL: ""Copper(II) complexes with the monosubstituted ethylenediamine. I. Preparation of the ligands"", SB. VYS. SK. CHEM.-TECHNOL. PRAZE, ANORG. CHEM. TECHNOL. (1976), B21, 51-8, XP000980181",PENDING
46,US,A1,US 2003/0225163 A1,184-198-520-135-355,2003-12-04,2003,US 25815902 A,2002-10-17,US 25815902 A;;US 0111747 W;;US 20600300 P,2000-05-19,Sulfonamide derivatives,"
    The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders. 
",ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,ELI LILLY AND COMPANY (2001-04-09),https://lens.org/184-198-520-135-355,Patent Application,yes,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,514/601;;564/97,0,0,,,,DISCONTINUED
47,PE,A1,PE 20020052 A1,116-576-388-601-599,2002-02-02,2002,PE 2001000451 A,2001-05-18,US 20600300 P,2000-05-19,DERIVADOS DE SULFONAMIDAS UTIL PARA POTENCIAR LA FUNCION DEL RECEPTOR DE GLUTAMATO,"SE REFIERE A UN COMPUESTO {(2R)-2-[4-(4-{2-[(METILSULFONIL)AMINO]ETIL}FENIL)FENIL]PROPIL}[(METILETIL)SULFONIL]AMINA DE FORMULA I EL CUAL POTENCIA LA FUNCION DE RECEPTORES DE GLUTAMATO Y PUEDE SER UTIL PARA TRATAR LA DEPRESION, ESQUIZOFRENIA",LILLY CO ELI,BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL;;ARNOLD MACKLIN BRIAN,,https://lens.org/116-576-388-601-599,Patent Application,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
48,CA,A1,CA 2944047 A1,160-531-113-371-09X,2014-11-06,2014,CA 2944047 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/160-531-113-371-09X,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,DISCONTINUED
49,WO,A1,WO 2014/176645 A1,095-954-420-910-750,2014-11-06,2014,AU 2014/050024 W,2014-04-30,AU 2013/901504 A,2013-04-30,USER AUTHENTICATION,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/095-954-420-910-750,Patent Application,yes,7,3,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,1,0,,,See also references of EP 2992472A4,PENDING
50,KR,A,KR 20160003796 A,111-675-005-441-666,2016-01-11,2016,KR 20157033769 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,"안전한 환경을 액세스하려고 시도하는 사용자를 인증하는 방법, 시스템, 서버 프로세싱 시스템 및 컴퓨터 판독가능 매체가 개시된다. 일 형태에서, 서버 프로세싱 시스템은, 인증 요청을 수신하여 안전한 환경을 액세스하려고 시도하는 사용자를 인증하고, 키맵으로부터의 선택 키에 대응하는 인덱스를 사용자 또는 사용자와 연관된 사용자 장치로 전송하고, 사용자 장치에 의해 제시된 선택 키 및 개인 식별자에 기초한 코드를 나타내는 데이터를 수신하고, 코드를 이용하여 사용자가 인증되었는지를 결정하도록 구성된다. 유리하게, 서버 프로세싱 시스템은 개인 식별자를 직접 나타내는 데이터를 저장하거나 수신하지 않아, 어느 누구도, 심지어 사용자가 액세스를 시도하려는 안전한 환경의 고용인조차도, 개인 식별자를 결정할 수 없다.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/111-675-005-441-666,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,DISCONTINUED
51,NO,L,NO 20025459 L,159-209-720-971-301,2002-11-14,2002,NO 20025459 A,2002-11-14,US 20600300 P;;US 0111747 W,2000-05-19,Sulfonamidderivater,,LILLY CO ELI,ARNOLD MACKLIN BRIAN;;BLEISCH THOMAS JOHN;;CUFF GEORGE WILLIAM;;ORNSTEIN PAUL LESLIE;;ZIMMERMAN DENNIS MICHAEL,,https://lens.org/159-209-720-971-301,Abstract,no,0,0,26,26,0,C07C311/05;;A61P25/00;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/36;;A61P43/00;;C07C311/05;;C07C311/05,A61K31/18;;A61K47/32;;A61K9/48;;A61P25/00;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07C311/05,,0,0,,,,DISCONTINUED
52,US,B2,US 9871805 B2,034-085-716-522-760,2018-01-16,2018,US 201414767720 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,User authentication,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier, and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,TOKEN ONE PTY LTD (2015-09-21),https://lens.org/034-085-716-522-760,Granted Patent,yes,11,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,H04L29/06;;G06F21/00;;G06F21/36;;G06Q20/40,,2,0,,,International Search Report corresponding to International Application No. PCT/AU2014/050024.;;Written Opinion of the International Preliminary Examining Authority corresponding to International Application No. PCT/AU2014/050024.,ACTIVE
53,US,B2,US 7541466 B2,087-226-265-903-503,2009-06-02,2009,US 604204 A,2004-12-07,US 604204 A;;US 53187303 P,2003-12-23,Tetrahydroisoquinoline derivatives for treating protein trafficking diseases,"Tetrahydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.",GENZYME CORP,PREGEL MARKO J;;HIRTH BRADFORD H;;KANE JR JOHN L;;QIAO SHUANG;;GREGORY JILL;;CUFF LISA,,https://lens.org/087-226-265-903-503,Granted Patent,yes,9,1,2,2,0,A61K31/47;;A61K31/4709;;A61K31/4709;;A61K31/47,C07D215/12;;A61K31/47;;A61K31/4709,546/168;;546/169;;546/153,28,27,096-426-184-078-786;;013-359-888-948-999;;056-543-168-732-76X;;013-169-581-749-832;;048-679-529-931-637;;019-448-450-005-032;;016-405-943-021-496;;019-448-450-005-032;;015-780-613-037-012;;041-190-392-268-003;;011-365-997-419-779;;024-905-115-732-517;;058-413-528-007-092;;084-082-661-785-511;;027-164-329-355-941;;028-133-757-872-704;;038-322-195-774-250;;030-443-300-324-615;;076-663-959-659-716;;031-606-791-526-296;;002-148-436-243-921;;087-053-081-180-117;;002-876-403-681-859;;053-918-853-962-124;;068-610-214-464-341;;097-123-625-583-402;;067-212-222-914-357,11677132;;10.1016/s0960-894x(01)00585-6;;11937331;;10.1016/s0968-0896(02)00035-4;;12008052;;10.1016/s0223-5234(02)01351-x;;12767230;;10.1021/bi034138g;;16127463;;10.1172/jci24898;;pmc1190372;;16443646;;10.1152/ajplung.00169.2005;;10.1177/1087057103256153;;14567795;;16443646;;10.1152/ajplung.00169.2005;;15808474;;10.1016/j.bmcl.2005.02.041;;11208074;;10.1034/j.1600-0854.2000.011104.x;;9488705;;10.1074/jbc.273.10.5727;;9222597;;pmc248464;;10.1379/1466-1268(1996)001<0117:ccctmp>2.3.co;2;;10.1152/ajplung.1995.268.4.l615;;7733303;;10.1038/358761a0;;1380673;;10.1242/jcs.114.22.4073;;11739639;;10.1038/nm0502-485;;11984593;;10.1152/ajplung.2001.281.1.l52;;11404245;;10.1152/ajpcell.1997.273.3.c988;;9316420;;10.1152/ajpcell.1998.275.1.c171;;9688848;;15992174;;10.1517/14728222.5.2.165;;10.1146/annurev.ph.55.030193.003141;;7682047;;9457113;;10.1016/s0140-6736(97)09174-5;;10.1172/jci119788;;9366560;;pmc508446;;10.1152/ajpcell.1990.259.3.c375;;2205105;;10.1016/0092-8674(93)90353-r;;7686820;;10.1152/ajpcell.1993.264.5.c1219;;7684560;;12095312;;10.1006/mthe.2002.0639,"Su, Bioorganic & Med Chem Lett, vol. 11(22), pp. 2974-2950, 2001.;;Vendeville, Bioorg & Med Chem, vol. 10(6), pp. 1719-1729, 2002.;;Gibson, Eu J of Med Chem, vol. 37(5), pp. 379-389, 2002.;;Hyde, Biochemistry, VOI 42(21), pp. 6475-6483, 2003.;;Pedemonte, J Clin inventigation, vol. 115(9), pp. 2564-2571, 2005.;;VanGoor, Am J pyysiol Lung Cell Mol Physiol, vol. 290, pp. L1117-L1130, 2006.;;Lobell J of Biomol Screening, VOI 8(4), pp. 430-438, 2003.;;Van Goor, F., et al., ""Rescue of DeltaF508 CFTR Trafficking and Gating in Human Cystic Fibrosis Airway Primary Cultures by Small Molecules,"" Am. J. Physiol. Lung Cell Mol. Physiol., doi: 10.1152/ajplung.00169.2005, pp. 1-57 (2006).;;Hirth, B. H., et al., ""Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport,"" Bioorg. Med. Chem. Lett., 15: 2087-2091(2005). Available online at www.sciencedirect.com.;;Aridor, M. , et al., ""Traffic Jam: A Compendium of Human Diseases that Affect Intracellular Transport Processes,"" Traffic, 1: 836-851 (2000).;;Arispe, N., et al. ""Direct Activation of Cystic Fibrosis Transmembrane Conductance Regulator Channels by 8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-Diallyl-8-cyclohexylxanthine (DAX),"" J. Biol. Chem., 273(10): 5727-5734 (1998).;;Brown, C.R., et al., ""Chemical Chaperones Correct the Mutant Phenotype of the ▴F508 Cystic Fibrosis Transmembrane Conductance Regulator Protein,"" Cell Stress and Chaperones, 1(2): 117-125 (1996).;;Cheng, S.H., et al., ""Functional Activation of the Cystic Fibrosis Trafficking Mutant ▴F508-CFTR by Overexpression,"" Am. J. Physiol., 268: L615-L624 (1995).;;Denning, et al., ""Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator is Temperature-Sensitive,"" Nature, 358: 761-764 (1992).;;Dormer, R.L., et al., ""Correction of delF508-CFTR Activity with Benzo(c)quinolizinium Compounds Through Facilitation of its Processing in Cystic Fibrosis Airway Cells,"" J. Cell Science, 114: 4073-4081 (2001).;;Egan, M.E., et al., ""Calcium-Pump Inhibitors Induce Functional Surface Expression of ▴F508-CFTR Protein in Cystic Fibrosis Epithelial Cells,"" Nature Medicine, 8(5): 485-492 (2002).;;Fischer, H., et al., ""Partial Restoration of Defective Chloride Conductance in ▴F508 CF Mice by Trimethylamine Oxide,"" Am. J. Physiol. Lung Cell. Mol. Physiol., 281: L52-L57 (2001).;;Hwang, T.C., et al., ""Genistein Potentiates Wild-Type and ▴F508-CFTR Channel Activity,"" Am. J. Physiol., 273: C988-C998 (1997).;;Jiang, C., et al., ""Partial Restoration of cAMP-Stimulated CFTR Chloride Channel Activity in ▴F508 Cells by Deoxyspergualin,"" Am. J. Physiol., 275: C171-C178 (1998).;;Moyer, B.D., et al., ""A New Frontier in Pharmacology: The Endoplasmic Reticulum as a Regulated Export Pathway in Health and Disease,"" Emerging Therapeutic Targets, 5: 165-176 (2001).;;Riordan, J.R., ""The Cystic Fibrosis Transmembrane Conductance Regulator,"" Ann. Rev. Physiol., 55: 609-630 (1993).;;Rosenstein, B.R., et al., ""Cystic Fibrosis,"" Lancet, 351: 277-282 (1998).;;Rubinstein, et al., ""In Vitro Pharmacologic Restoration of CFTR-Mediated Chloride Transport with Sodium-4-Phenylbutyrate in Cystic Firbrosis Epithelial Cells Containing ▴F508-CFTR,"" J. Clin. Invest., 100: 2457-2465 (1997).;;Verkman, A.S., ""Development and Biological Applications of Chloride-Sensitive Fluoroscent Indicators,"" Am. J. Physiol, 259: C375-C388 (1990).;;Welsh, M.J., et al., ""Molecular Mechanisms of CFTR Chloride Channel Dysfunction in Cystic Fibrosis,"" Cell, 73: 1251-1254 (1993).;;Yankaskas, et al., ""Papilloma Virus Immortalized Tracheal Epithelial Cells Retain a Well-Differentiated Phenotype,"" Am. J. Physiol., 264: C1219-C1230 (1993).;;Zeitlin, P.L., et al., ""Evidence of CFTR Function in Cystic Fibrosis After Systemic Administration of 4-Phenylbutyrate,"" Molecular Therapy, 6: 119-126 (2002).;;Welsh, M.J., et al., Ch. 201: ""Cystic Fibrosis."" In The Metabolic and Molecular Bases of Inherited Disease, 8th Edition, online, Ed by Scriver, C.L., et al., (McGraw Hill) (2001).",INACTIVE
54,EP,A1,EP 2992472 A1,139-980-030-431-256,2016-03-09,2016,EP 14791894 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,,TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/139-980-030-431-256,Patent Application,yes,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06F21/36;;G06Q20/40;;H04L29/06,,0,0,,,,ACTIVE
55,EP,A4,EP 2992472 A4,044-350-836-764-913,2016-10-26,2016,EP 14791894 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,,TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/044-350-836-764-913,Search Report,no,4,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06F21/36;;G06Q20/40;;H04L29/06,,1,0,,,See also references of WO 2014176645A1,ACTIVE
56,AU,A1,AU 2014/262138 A1,048-269-185-290-837,2015-11-05,2015,AU 2014/262138 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W;;AU 2014/262138 A,2013-04-30,User authentication,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/048-269-185-290-837,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,INACTIVE
57,CN,A,CN 105164689 A,080-088-931-336-890,2015-12-16,2015,CN 201480024591 A,2014-04-30,AU 2014/050024 W;;AU 2013/901504 A,2013-04-30,User authentication,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, by using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/080-088-931-336-890,Patent Application,no,5,4,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/36,,0,0,,,,ACTIVE
58,SG,A,SG 11201506484P A,120-537-650-859-345,2015-11-27,2015,SG 11201506484P A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,,TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/120-537-650-859-345,Unknown,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,PENDING
59,MX,B,MX 355189 B,021-119-414-789-700,2018-04-09,2018,MX 2015015140 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION.,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;DAVID ROBERT GRIEVE,,https://lens.org/021-119-414-789-700,Granted Patent,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/36;;G06F21/00;;G06Q20/40;;H04L29/06,,0,0,,,,ACTIVE
60,MX,A,MX 2015015140 A,165-234-162-338-641,2016-07-05,2016,MX 2015015140 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION.,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/165-234-162-338-641,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06F21/36;;G06Q20/40,,0,0,,,,ACTIVE
61,EP,B1,EP 2992472 B1,169-789-196-718-372,2017-12-06,2017,EP 14791894 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,,TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/169-789-196-718-372,Granted Patent,yes,11,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06F21/36;;G06Q20/40;;H04L29/06,,0,0,,,,ACTIVE
62,US,A1,US 2016/0099950 A1,175-496-551-551-959,2016-04-07,2016,US 201414767720 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W,2013-04-30,USER AUTHENTICATION,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier, and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,TOKEN ONE PTY LTD (2015-09-21),https://lens.org/175-496-551-551-959,Patent Application,yes,3,12,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,H04L29/06,,0,0,,,,ACTIVE
63,US,A1,US 2005/0176761 A1,190-998-075-881-159,2005-08-11,2005,US 604204 A,2004-12-07,US 604204 A;;US 53187303 P,2003-12-23,Tetrahydroisoquinoline derivatives for treating protein trafficking diseases,"Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.",GENZYME CORP,PREGEL MARKO J;;HIRTH BRADFORD H;;KANE JOHN L JR;;QIAO SHUANG;;GREGORY JILL;;CUFF LISA,,https://lens.org/190-998-075-881-159,Patent Application,yes,7,21,2,2,0,A61K31/47;;A61K31/4709;;A61K31/4709;;A61K31/47,A61K31/47;;A61K31/4709,514/310,0,0,,,,INACTIVE
64,BR,A2,BR 112015027633 A2,185-724-248-421-494,2017-08-22,2017,BR 112015027633 A,2013-04-30,AU 2014/050024 W;;AU 2013/901504 A,2013-04-30,AUTENTICAÇÃO DE USUÁRIO,"AUTENTICAÇÃO DE USUÁRIO. Trata-se de um método, um sistema, um sistema de processamento de servidor e um meio legível por computador para autenticar um usuário que tenta acessar um ambiente seguro. Em um aspecto, o sistema de processamento de servidor é configurado para: receber uma solicitação de autenticação para autenticar o usuário que tenta acessar o ambiente seguro; transferir, para o usuário ou um dispositivo de usuário associado ao usuário, um índice que corresponde a uma tecla selecionada a partir de um mapa de teclas; receber dados indicativos de um código que é baseado na tecla selecionada apresentada pelo dispositivo de usuário e um identificador pessoal; e determinar, com o uso do código se o usuário é autenticado. Vantajosa-mente, o sistema de processamento de servidor nunca armazena ou recebe dados diretamente indicativos do identificador pessoal de tal modo que ninguém seja capaz determinar o identificador pessoal, nem mesmo um funcionário do ambiente seguro que o usuário está tentando acessar.",TOKEN ONE PTY LTD,PHILIP ANTHONY FREDERICK CUFF;;KAMIL KREISER;;DAVID ROBERT GRIEVE;;SEBASTIEN JOHN ECKERSLEY-MASLIN;;JEREMY WAYNE PADDISON,,https://lens.org/185-724-248-421-494,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,DISCONTINUED
65,AU,B2,AU 2014/262138 B2,049-554-865-529-011,2019-07-04,2019,AU 2014/262138 A,2014-04-30,AU 2013/901504 A;;AU 2014/050024 W;;AU 2014/262138 A,2013-04-30,User authentication,"A method, system, server processing system and computer readable medium for authenticating a user attempting to access a secure environment is disclosed. In one aspect, the server processing system is configured to: receive an authentication request to authenticate the user attempting to access the secure environment; transfer, to the user or a user device associated with the user, an index corresponding to a selected key from a keymap; receive data indicative of a code which is based on the selected key presented by the user device and a personal identifier; and determine, using the code whether the user is authenticated. Advantageously, the server processing system never stores nor receives data directly indicative of the personal identifier such that no one else is able to determine the personal identifier, not even an employee of the secure environment which the user is attempting to access.",TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/049-554-865-529-011,Granted Patent,no,4,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F21/00;;G06Q20/40,,0,0,,,,INACTIVE
66,HK,A1,HK 1222002 A1,118-410-819-464-235,2017-06-16,2017,HK 16110001 A,2016-08-22,AU 2014/050024 W;;AU 2013/901504 A,2013-04-30,USER AUTHENTICATION,,TOKEN ONE PTY LTD,CUFF PHILIP ANTHONY FREDERICK;;ECKERSLEY-MASLIN SEBASTIEN JOHN;;KREISER KAMIL;;PADDISON JEREMY WAYNE;;GRIEVE DAVID ROBERT,,https://lens.org/118-410-819-464-235,Patent Application,no,0,0,19,19,0,G06F21/00;;G06Q20/40;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06Q20/4014;;G06F21/00;;G06F21/36;;G06Q20/40;;H04L63/06;;H04L63/10;;G06F21/36;;G06F2221/2149;;H04L63/0838;;G06F21/00;;G06Q20/40;;G06Q20/4014;;H04L63/06;;H04L63/10;;H04L63/12,G06F/;;G06Q/,,0,0,,,,DISCONTINUED
67,CN,A,CN 114630628 A,100-828-862-150-113,2022-06-14,2022,CN 202080076055 A,2020-09-02,US 201916560221 A;;EP 2020074504 W,2019-09-04,Test radial head implant,"The present invention provides an orthopedic trial implant having a plurality of bearing component reinforcements of different heights, where each reinforcement is releasably, slidably connected to the trial implant.",NEW TESS LTD RESPONSIBILITY COMPANY,HODOREK BRANDON C;;PURDY MICHAEL J;;WAIATT JAMES M;;MURTY ASHOK MAHESH;;SMITH MATTHEW JAMES;;CUFF DAVID JOHN;;GAVA AMIR,,https://lens.org/100-828-862-150-113,Patent Application,no,0,0,7,13,0,A61F2/4684;;A61F2/3804;;A61B17/1662;;A61F2002/30401;;A61F2002/30841;;A61F2002/30112;;A61F2002/30233;;A61F2002/30398;;A61F2002/30326;;A61F2002/3809;;A61F2002/30616;;A61F2002/30604;;A61F2002/30934;;A61F2002/3818;;A61F2002/304;;A61F2002/4658;;A61F2002/3827;;A61F2002/3055;;A61F2002/4661;;A61F2002/3021;;A61F2002/30383;;A61F2002/30403;;A61F2002/30233;;A61F2002/30326;;A61F2002/3055;;A61F2002/4658;;A61F2/4684;;A61F2/3804;;A61F2002/3827;;A61F2002/3809;;A61F2002/30616;;A61F2002/3818;;A61F2002/3021;;A61F2002/30383;;A61F2002/30398;;A61F2002/304;;A61F2002/30401;;A61F2002/30604;;A61F2002/30841;;A61F2002/4661;;A61B17/1662,A61B17/16;;A61F2/38;;A61F2/46,,0,0,,,,PENDING
68,EP,A3,EP 2594565 A3,064-289-099-773-304,2013-08-07,2013,EP 13154970 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YABIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/064-289-099-773-304,Search Report,yes,4,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,2,1,025-913-184-941-642,10.1093/oxfordjournals.jbchem.a022631;;10731721,"DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ALBERTI, CARLO GIUSEPPE: ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", XP002495477, retrieved from STN Database accession no. 1957:17088;;JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X",ACTIVE
69,WO,A2,WO 2008/150486 A2,062-397-685-857-995,2008-12-11,2008,US 2008/0006906 W,2008-05-30,US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",GENZYME CORP;;SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/062-397-685-857-995,Patent Application,yes,0,54,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,0,0,,,,PENDING
70,EP,A2,EP 2594565 A2,029-466-698-871-630,2013-05-22,2013,EP 13154970 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YABIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/029-466-698-871-630,Patent Application,yes,12,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,15,8,009-542-128-522-566;;102-509-495-349-845;;100-005-886-323-421;;047-458-832-757-760;;018-291-712-488-427;;096-617-488-485-139;;024-919-860-416-474;;074-979-551-686-305,11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;1820092;;2145065;;1281244;;12529488;;10.1038/oby.2003.12;;10.1111/j.1464-5491.2004.01225.x;;15209770,"NOJRI ET AL., PROC. NATL. ACAD. SCL USA, vol. 83, 1986, pages 782;;YAMASHITA ET AL., PROC. NATL. ACAD. SCL USA, vol. 100, no. 6, 2003, pages 3445;;TAGAMI ET AL., J BIOL CHEM., vol. 277, no. 5, 2002, pages 3085;;YAMASHITA ET AL., PROC. NATL. ACAD. SC. USA, vol. 100, 2003, pages 3445 - 3449;;SVENSSON, M. ET AL.: ""Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production"", INFECT. AND IMMUN., vol. 62, 1994, pages 4404 - 4410;;INOKUCHI, J. ET AL.: ""Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis"", CANCER LETT., vol. 38, 1987, pages 23 - 30;;HAKOMORI, S.: ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy"", CANCER CELLS, vol. 3, 1991, pages 461 - 470;;INOKUCHI, J. ET AL.: ""Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action"", CANCER RES., vol. 50, 1990, pages 6731 - 6737, XP008103809;;ZICHE, M. ET AL.: ""Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio"", LAB. INVEST., vol. 67, 1992, pages 711 - 715, XP002918640;;COMUZZIE, OBES. RES., vol. 11 I, no. 1, 2003, pages 75;;RUBINO ET AL., ANN. SURG., vol. 240, no. 2, 2004, pages 389;;GILL-RANDALL ET AL., DIABET. MED., vol. 21, no. 7, 2004, pages 759;;FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1996, pages 219;;""Handbook of Pharmaceutical Excipients 5'th Ed.,"", 2005, PHARMACEUTICAL PRESS;;GENNARO: ""Remington's Pharmaceutical Sciences, 18th ed."", 1990",ACTIVE
71,EP,B1,EP 2594563 B1,034-376-445-762-833,2018-07-18,2018,EP 13154955 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/034-376-445-762-833,Granted Patent,yes,2,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
72,HK,A1,HK 1185076 A1,181-967-549-975-731,2014-02-07,2014,HK 13112541 A,2013-11-07,US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS 2-,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/181-967-549-975-731,Patent Application,no,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
73,EP,A2,EP 2594563 A2,190-113-770-627-477,2013-05-22,2013,EP 13154955 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/190-113-770-627-477,Patent Application,yes,12,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,14,8,009-542-128-522-566;;102-509-495-349-845;;100-005-886-323-421;;047-458-832-757-760;;018-291-712-488-427;;096-617-488-485-139;;024-919-860-416-474;;074-979-551-686-305,11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;1820092;;2145065;;1281244;;12529488;;10.1038/oby.2003.12;;10.1111/j.1464-5491.2004.01225.x;;15209770,"YAMASHITA ET AL., PROC. NATL. ACAD. SCL USA, vol. 100, no. 6, 2003, pages 3445;;TAGAMI ET AL., J BIOL CHEM., vol. 277, no. 5, 2002, pages 3085;;YAMASHITA ET AL., PROC. NATL. ACAD. SC. USA, vol. 100, 2003, pages 3445 - 3449;;SVENSSON, M. ET AL.: ""Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production"", INFECT. AND IMMUN., vol. 62, 1994, pages 4404 - 4410;;INOKUCHI, J. ET AL.: ""Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis"", CANCER LETT., vol. 38, 1987, pages 23 - 30;;HAKOMORI, S.: ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy"", CANCER CELLS, vol. 3, 1991, pages 461 - 470;;INOKUCHI, J. ET AL.: ""Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action"", CANCER RES., vol. 50, 1990, pages 6731 - 6737, XP008103809;;ZICHE, M. ET AL.: ""Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio"", LAB. INVEST., vol. 67, 1992, pages 711 - 715, XP002918640;;COMUZZIE, OBES. RES., vol. 11 I, no. 1, 2003, pages 75;;RUBINO ET AL., ANN. SURG., vol. 240, no. 2, 2004, pages 389;;GILL-RANDALL ET AL., DIABET. MED., vol. 21, no. 7, 2004, pages 759;;FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1996, pages 219;;""Handbook of Pharmaceutical Excipients 5'h Ed.,"", 2005, PHARMACEUTICAL PRESS;;GENNARO: ""Remington's Pharmaceutical Sciences, 18th ed."", 1990",ACTIVE
74,EP,B1,EP 2594564 B1,146-972-705-782-964,2016-09-28,2016,EP 13154967 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/146-972-705-782-964,Granted Patent,yes,8,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,2,0,,,"KOGA K. ET AL.: ""Stereochemical Studies. X. Effects of Neighboring Functional Groups on 1, 2-Asymmetric Induction in the Reduction of Propiophenone Derivatives with Sodium Borohydride"", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 20, no. 3, 1972, pages 526-538, XP002699865, ISSN: 0009-2363;;JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485-491, XP002372070, ISSN: 0021-924X",ACTIVE
75,EP,A3,EP 2594563 A3,149-361-745-603-146,2013-08-07,2013,EP 13154955 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/149-361-745-603-146,Search Report,yes,4,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,2,2,000-981-111-711-659;;025-913-184-941-642,10.1016/s0040-4039(02)02096-8;;10.1093/oxfordjournals.jbchem.a022631;;10731721,"HUSAIN A ET AL: ""syn-Selective additions to Garner aldehyde: synthesis of a potent glucosylceramide synthase inhibitor"", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 47, 18 November 2002 (2002-11-18), pages 8621 - 8623, XP027281685, ISSN: 0040-4039, [retrieved on 20021118];;JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X",ACTIVE
76,EP,A3,EP 2594564 A3,045-124-745-670-162,2013-08-21,2013,EP 13154967 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/045-124-745-670-162,Search Report,yes,8,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,2,2,094-645-762-447-043;;025-913-184-941-642,10.1248/cpb.20.526;;10.1093/oxfordjournals.jbchem.a022631;;10731721,"KOGA K. ET AL.: ""Stereochemical Studies. X. Effects of Neighboring Functional Groups on 1, 2-Asymmetric Induction in the Reduction of Propiophenone Derivatives with Sodium Borohydride"", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 20, no. 3, 1972, pages 526 - 538, XP002699865, ISSN: 0009-2363;;JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X",ACTIVE
77,EP,A3,EP 2594562 A3,130-813-548-486-483,2013-08-14,2013,EP 13154949 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;DIOS ANGELES;;LIAO JUNKAI,,https://lens.org/130-813-548-486-483,Search Report,yes,5,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,1,1,025-913-184-941-642,10.1093/oxfordjournals.jbchem.a022631;;10731721,"JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X",ACTIVE
78,EP,A2,EP 2594564 A2,086-620-720-471-386,2013-05-22,2013,EP 13154967 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/086-620-720-471-386,Patent Application,yes,12,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,15,8,009-542-128-522-566;;102-509-495-349-845;;100-005-886-323-421;;047-458-832-757-760;;018-291-712-488-427;;096-617-488-485-139;;024-919-860-416-474;;074-979-551-686-305,11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;1820092;;2145065;;1281244;;12529488;;10.1038/oby.2003.12;;10.1111/j.1464-5491.2004.01225.x;;15209770,"NOJRI ET AL., PROC. NATL. ACAD. SCL USA, vol. 83, 1986, pages 782;;YAMASHITA ET AL., PROC. NATL. ACAD. SCL USA, vol. 100, no. 6, 2003, pages 3445;;TAGAMI ET AL., J BIOL CHEM., vol. 277, no. 5, 2002, pages 3085;;YAMASHITA ET AL., PROC. NATL. ACAD. SC. USA, vol. 100, 2003, pages 3445 - 3449;;SVENSSON, M. ET AL.: ""Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production"", INFECT. AND IMMUN., vol. 62, 1994, pages 4404 - 4410;;INOKUCHI, J. ET AL.: ""Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis"", CANCER LETT, vol. 38, 1987, pages 23 - 30;;HAKOMORI, S.: ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy"", CANCER CELLS, vol. 3, 1991, pages 461 - 470;;INOKUCHI, J. ET AL.: ""Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action"", CANCER RES., vol. 50, 1990, pages 6731 - 6737, XP008103809;;ZICHE, M. ET AL.: ""Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio"", LAB. INVEST., vol. 67, 1992, pages 711 - 715, XP002918640;;COMUZZIE, OBES. RES., vol. 11 I, no. 1, 2003, pages 75;;RUBINO ET AL., ANN. SURG., vol. 240, no. 2, 2004, pages 389;;GILL-RANDALL ET AL., DIABET. MED., vol. 21, no. 7, 2004, pages 759;;FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1996, pages 219;;""Handbook of Pharmaceutical Excipients 5 'h Ed.,"", 2005, PHARMACEUTICAL PRESS;;GENNARO: ""Remington's Pharmaceutical Sciences, 18th ed. ,"", 1990",ACTIVE
79,HK,A1,HK 1185341 A1,022-326-684-591-583,2014-02-14,2014,HK 13112578 A,2013-11-08,US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS 2-,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;DIOS ANGELES;;LIAO JUNKAI,,https://lens.org/022-326-684-591-583,Patent Application,no,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
80,WO,A3,WO 2008/150486 A3,033-383-931-347-52X,2009-02-05,2009,US 2008/0006906 W,2008-05-30,US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",GENZYME CORP;;SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/033-383-931-347-52X,Search Report,yes,7,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,3,1,025-913-184-941-642,10.1093/oxfordjournals.jbchem.a022631;;10731721,"JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; INOKUCHI, KIMIKAZU ET AL: ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"", XP002495476, retrieved from STN Database accession no. 1998:816280;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ALBERTI, CARLO GIUSEPPE: ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", XP002495477, retrieved from STN Database accession no. 1957:17088",PENDING
81,EP,A2,EP 2594562 A2,175-613-744-761-24X,2013-05-22,2013,EP 13154949 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;DIOS ANGELES;;LIAO JUNKAI,,https://lens.org/175-613-744-761-24X,Patent Application,yes,18,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,15,8,009-542-128-522-566;;102-509-495-349-845;;100-005-886-323-421;;047-458-832-757-760;;018-291-712-488-427;;096-617-488-485-139;;024-919-860-416-474;;074-979-551-686-305,11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;1820092;;2145065;;1281244;;12529488;;10.1038/oby.2003.12;;10.1111/j.1464-5491.2004.01225.x;;15209770,"NOJRI ET AL., PROC. NATL. ACAD. SCL USA, vol. 83, 1986, pages 782;;YAMASHITA ET AL., PROC. NATL. ACAD. SCL USA, vol. 100, no. 6, 2003, pages 3445;;TAGAMI ET AL., J BIOL CHEM., vol. 277, no. 5, 2002, pages 3085;;YAMASHITA ET AL., PROC. NATL. ACAD. SC. USA, vol. 100, 2003, pages 3445 - 3449;;SVENSSON, M. ET AL.: ""Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production"", INFECT. AND IMMUN., vol. 62, 1994, pages 4404 - 4410;;INOKUCHI, J. ET AL.: ""Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis"", CANCER LETT., vol. 38, 1987, pages 23 - 30;;HAKOMORI, S.: ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy"", CANCER CELLS, vol. 3, 1991, pages 461 - 470;;INOKUCHI, J. ET AL.: ""Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action"", CANCER RES., vol. 50, 1990, pages 6731 - 6737, XP008103809;;ZICHE, M. ET AL.: ""Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio"", LAB. INVEST., vol. 67, 1992, pages 711 - 715, XP002918640;;COMUZZIE, OBES. RES., vol. 11 I, no. 1, 2003, pages 75;;RUBINO ET AL., ANN. SURG., vol. 240, no. 2, 2004, pages 389;;GILL-RANDALL ET AL., DIABET. MED., vol. 21, no. 7, 2004, pages 759;;FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1996, pages 219;;""Handbook of Pharmaceutical Excipients (5'h Ed.,"", 2005, PHARMACEUTICAL PRESS;;GENNARO: ""Remington's Pharmaceutical Sciences, 18th ed."", 1990",ACTIVE
82,HK,A1,HK 1138282 A1,196-664-867-614-858,2010-08-20,2010,HK 10105161 A,2010-05-26,US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS 2-,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/196-664-867-614-858,Patent Application,no,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
83,EP,B1,EP 2594562 B1,111-750-024-587-203,2016-07-20,2016,EP 13154949 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;DIOS ANGELES;;LIAO JUNKAI,,https://lens.org/111-750-024-587-203,Granted Patent,yes,5,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,1,0,,,"JIMBO ET AL: ""Development of a new inhibitor of glucosylceramide synthase"", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485-491, XP002372070, ISSN: 0021-924X",ACTIVE
84,EP,A2,EP 2167485 A2,076-438-820-971-130,2010-03-31,2010,EP 08768008 A,2008-05-30,US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/076-438-820-971-130,Patent Application,yes,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,1,0,,,See references of WO 2008150486A3,ACTIVE
85,EP,B1,EP 2594565 B1,067-094-242-800-117,2018-10-24,2018,EP 13154970 A,2008-05-30,US 93237007 P;;US 99784607 P;;EP 08768008 A;;US 2008/0006906 W,2007-05-31,2-acylaminopropanol-type glucosylceramide synthase inhibitors,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YABIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2018-07-18),https://lens.org/067-094-242-800-117,Granted Patent,yes,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,1,1,020-114-708-399-776,10.1016/0009-3084(80)90057-2;;6445239,"R. R. VUNNAM ET AL.: ""Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain"", CHEMISTRY AND PHYSICS OF LIPIDS, vol. 26, 1980, pages 265 - 278",ACTIVE
86,EP,B1,EP 2167485 B1,035-298-379-858-700,2015-09-30,2015,EP 08768008 A,2008-05-30,US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA;;VINICK FREDERIC;;JOZEFIAK THOMAS;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/035-298-379-858-700,Granted Patent,yes,1,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D319/18;;A61K31/357;;A61P3/10;;C07D295/125;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,1,1,010-215-744-161-837,10329660;;10.1074/jbc.274.21.14662,"LEE LIHSUEH ET AL: ""Improved inhibitors of glucosylceramide synthase"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 21, 21 May 1999 (1999-05-21), pages 14662 - 14669, ISSN: 0021-9258",ACTIVE
87,JP,A,JP 2015129186 A,155-425-482-049-717,2015-07-16,2015,JP 2015075248 A,2015-04-01,US 10254108 P,2008-10-03,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,PROBLEM TO BE SOLVED: To provide 2-acylaminopropanol-type glucosylceramide synthase inhibitors.SOLUTION: There is provided a compound for use in treating polycystic kidney disease represented by a prescribed structural formula or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;DAVID J HARRIS;;ANGELES DIOS;;EDWARD LEE;;RICHARD SILVA;;LISA M CUFF;;MIKAELA LEVINE;;CASSANDRA A CELATKA;;THOMAS H JOZAFIAK;;FREDERIC VINICK;;XIANG YIBIN;;JOHN KANE;;JUNKAI LIAO,,https://lens.org/155-425-482-049-717,Patent Application,no,11,1,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,C07D207/10;;A61K31/357;;A61K31/40;;A61K31/4025;;A61K31/4035;;A61K31/407;;A61K31/4192;;A61K31/42;;A61K31/422;;A61K31/4245;;A61K31/427;;A61K31/428;;A61K31/4402;;A61K31/4439;;A61K31/453;;A61K31/4709;;A61K31/4725;;A61K31/5377;;A61P13/12;;C07D207/12;;C07D213/40;;C07D217/16;;C07D263/06;;C07D271/06;;C07D277/64;;C07D295/12;;C07D317/58;;C07D319/18;;C07D319/20;;C07D333/20;;C07D333/28;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D413/04;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08,,6,5,022-861-665-824-921;;006-530-492-820-511;;094-645-762-447-043;;000-981-111-711-659;;127-453-640-205-029,11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;10.1016/s0022-2275(20)41159-9;;7806975;;10.1248/cpb.20.526;;10.1016/s0040-4039(02)02096-8;;18576636;;10.1021/ja801602q;;pmc2562865,"KIDNEY INT, VOL.59 P.2005-2022 (2001), JPN6014031143, ISSN: 0003248964;;DESHMUKH, G. D. ET AL., J. LIPID RES. 1994, VOL.35, NO.9, P.1611-8, JPN6015022418, ISSN: 0003248965;;ALBERTI, CARLO GIUSEPPE: ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", GAZZETTA CHIMICA ITALIANA, vol. 86, JPN6016004143, 1956, pages 240 - 249, ISSN: 0003248960;;KOGA, KENJI; YAMADA, SHUNICHI: ""Stereochemical studies. X. Effects of neighboring functional groups on 1,2-asymmetric induction in"", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 20, no. 3, JPN6016004145, 1972, pages 526 - 538, XP002699865, ISSN: 0003248961, DOI: 10.1248/cpb.20.526;;HUSAIN, ARIFA; GANEM, BRUCE: ""syn-Selective additions to Garner aldehyde: synthesis of a potent glucosylceramide synthase inhibito"", TETRAHEDRON LETTERS, vol. Vol. 43, Iss. 47, JPN6016004146, 2002, pages 8621 - 8623, ISSN: 0003248962;;CELLITTI, SUSAN E.; JONES, DAVID H.; LAGPACAN, LEANNA; HAO, XUESHI; ZHANG, QIONG; HU, HUIYONG; BRITT: ""In vivo Incorporation of Unnatural Amino Acids to Probe Structure, Dynamics, and Ligand Binding in a"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. Vol. 130, Iss. 29, JPN6016004149, 2008, pages 9268 - 9281, ISSN: 0003248963",INACTIVE
88,US,B2,US 8304447 B2,169-478-593-161-813,2012-11-06,2012,US 60187108 A,2008-05-30,US 60187108 A;;US 99784607 P;;US 93237007 P;;US 2008/0006906 W,2007-05-31,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/169-478-593-161-813,Granted Patent,yes,100,16,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,A61K31/40;;A61K31/4025;;C07D207/04;;C07D405/02,514/408;;514/422;;548/400;;548/526,100,74,087-720-399-410-986;;025-913-184-941-642;;024-919-860-416-474;;018-291-712-488-427;;084-596-711-500-19X;;100-005-886-323-421;;009-542-128-522-566;;102-509-495-349-845;;101-441-717-112-268;;013-186-690-689-175;;027-757-703-898-799;;005-316-633-999-516;;013-129-766-729-356;;074-979-551-686-305;;047-458-832-757-760;;082-544-376-300-192;;036-669-847-776-367;;010-215-744-161-837;;095-564-866-172-621;;037-256-760-224-384;;096-617-488-485-139;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;099-417-575-155-106;;019-168-888-620-949;;127-620-706-386-56X;;007-195-876-506-733;;036-519-046-514-216;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;008-960-930-558-465;;003-994-644-386-459;;103-843-422-810-071;;061-607-931-932-732;;080-009-135-438-214;;111-509-011-354-346;;078-712-681-777-54X;;058-392-587-867-500;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;012-374-430-412-462;;069-903-420-503-60X;;006-912-262-242-73X;;038-420-412-060-975;;048-359-395-870-441;;032-507-877-332-372;;145-399-125-974-761;;120-463-739-961-857;;056-300-053-225-737;;089-212-206-875-704;;019-772-803-841-699;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;047-142-399-168-373;;003-652-677-788-251;;078-857-409-314-797;;005-002-282-762-215;;013-092-512-192-775;;038-253-278-873-477;;013-863-667-338-436;;010-213-588-950-017;;050-936-181-578-778;;015-233-440-103-014;;002-423-422-743-881;;020-114-708-399-776;;006-772-308-047-402;;009-735-754-008-354,10.1172/jci9711;;10841515;;pmc300859;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;12529488;;10.1038/oby.2003.12;;2145065;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1016/s0022-2275(20)39163-x;;8808768;;8724138;;10.1093/glycob/6.3.303;;10.1016/0042-6822(91)90759-5;;1926769;;13428781;;10.1016/s0021-9258(18)64849-5;;4957125;;10.1111/j.1464-5491.2004.01225.x;;15209770;;1820092;;3690511;;10.1016/0304-3835(87)90196-0;;10.1016/s0026-265x(01)00097-2;;10329660;;10.1074/jbc.274.21.14662;;pmc288030;;10.1172/jci116299;;8450061;;17470562;;10.2337/db06-0719;;1281244;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;7775872;;10.1016/s0022-2275(20)39895-3;;10.1021/ja00275a054;;10.1016/s0040-4020(98)00302-0;;7537307;;10.1016/0076-6879(66)08014-5;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;10.1021/jo00277a032;;10.1002/jps.2600570510;;5657533;;10.1021/ja00401a031;;10.1021/bi00478a028;;2207076;;6273689;;10.1016/s0076-6879(81)72026-3;;10.1039/a807471b;;10.1016/s0957-4166(00)82093-5;;10.1007/bf02535381;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/0005-2760(92)90160-w;;1567913;;10.1016/s0022-2275(20)39651-6;;14280461;;10.1002/(sici)1099-1344(199603)38:3<285::aid-jlcr836>3.0.co;2-p;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;10.1016/0003-2697(84)90484-6;;6084960;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1016/s0960-894x(97)00341-7;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;10.1016/s0022-2275(20)39966-1;;7964184;;1567816;;10.1021/bi00129a005;;10.1016/s0021-9258(19)38320-6;;2142685;;1744091;;10.1016/s0021-9258(18)54449-5;;10.1016/s0022-2275(20)42059-0;;1856614;;2148864;;10.1016/0003-9861(90)90657-k;;10.1016/0005-2760(91)90130-a;;1827738;;10.1093/jnci/82.13.1107;;2359136;;10.1016/s0021-9258(17)40706-x;;8195192;;10.1002/cbf.290090306;;1661208;;2149853;;10.1093/oxfordjournals.jbchem.a123236;;10.1016/0009-3084(80)90057-2;;6445239;;10.1021/jo00111a007;;15795412;;10.1503/cmaj.045232;;pmc554876,"""Tay-Sachs."" URL: http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm. National Institute of Neurological Disorders and Stroke. Accessed online Sep. 9, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450 dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773 dated Sep. 21, 2010.;;Abe, A., et al., ""Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation"", J. Clin Invest. 105(11): 1563-1571, (2000).;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/006906, dated Apr. 12, 2008.;;Jimbo, M., et al., ""Development of a New Inhibitor of Glucosylceramide Synthase"", J. Biochem, 127: 485-491 (2000).;;Inokuchi, K., et al, ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"", Chemical Abstracts Service, XP002495476 retrieved from CAPLUS Database accession No. 1998:816280 (abstract).;;Alberti, C., et al., ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", Chemical Abstracts Service, XP002495477 retrieved from CAPLUS Database accession No. 1957:17088 (abstract).;;Comuzzie, A.G., et al., ""The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity"", Obesity Research, 11(1):75-80 (Jan. 2003).;;Inokuchi, J., et al., ""Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action"", Cancer Research, 50:6731-6737 (Oct. 15, 1990).;;Nojiri, H., et al., ""Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937"", Proc. Natl. Acad. Sci., 83:782-786 (Feb. 1986).;;Rubino, MD., F., et al., ""Letter to the Editor"", Annals of Surgery, 240(2):389-390 (Aug. 2004).;;Svensson, M., et al., ""Epithelial Glucosphingolipid Express as a Determinant of Bacterial Adherence and Cytokine Production"", Infection and Immunity, 62:10 pp. 4404-4410 (Oct. 1994).;;Tagami, S., et al., ""Ganglioside GM3 Participates in the Pathological Conditions of Insulin Resistance"", The Journal of Biological Chemistry, 227(5):3085-3092 (Feb. 1, 2002).;;Yamashita, T., et al., ""Enhanced insulin sensitivity in mice lacking ganglioside GM3"", Proc. Natl. Acad. Scl., 100(6): 3445-3449 (Mar. 18, 2003).;;Chatterjee, S., et al.,""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Chatterjee, S., et al.,""Oxidized Low Density Lipoprotein Stimulates Aortic Smooth Muscle Cell Proliferation"", Glycobiology, 6(3): 303-311 (1996).;;Dickie, P., et al., ""HIV-Associated Nephropathy in Transgenic Mice Expressing HIV-1 Genes,"" Virology, 185:109-119, 1991.;;Folch, J., et al., ""A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues"", J. Biol. Chem., 226:497-509, 1957.;;Freireich, E., et al., ""Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hampster, Dog, Monkey, and Man"", Cancer Chemother. Reports 50(4):219 (1996).;;Gill-Randall, R.J., et al., ""Is human Type 2 diabetes maternally inherited? Insights from an animal model"", Diabet. Med. 21 (7):759 (2004).;;Hakomori, S. ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy,"" Cancer Cells 3:461-470 (1991).;;Inokuchi, J. et al., ""Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis,"" Cancer Lett., 38:23-30(1987).;;Jankowski, K., ""Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion"", Microchem. J., 70:41-49, 2001.;;Lee, L., et al. ""Improved Inhibitors of Glucosylceramide Synthase"", J. of Bio Chem., 274(21): 14662-14669 (1999).;;Zador, I., et al. ""A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus"", J. Clin. Invest., 91: 797-803 (1993).;;Zhao, H., et al., ""Inhibiting glycosphingolipid systhesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes."", Diabetes, 56(5): 1210-1218 (2007).;;Ziche, M. et al., ""Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3 :GD3 Ganglioside Ratio,"" Lab. Invest., 67:711-715 (1992).;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2008/006906 Dated Dec. 10, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/011450, dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2009/001773, dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2009/051864, dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2009/005435, dated Feb. 12, 2010.;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/005435 dated Apr. 5, 2011.;;Abe, A., et al., ""Improved Inhibitors of Glucosylceramide Synthase,"" J. Biochem., 111:191-196 (1992).;;Abe, A., et al., ""Induction of Glucosylceramide Synthase by Synthase Inhibitors and Ceramide,"" Biochim. Biophys. Acta, 1299: 333-341 (1996).;;Abe, A., et al., ""Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C,"" Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., ""Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,"" J. of Lipid Research, 36:611-621 (1995).;;Abdel-Magid, A., et al., ""Metal-Assisted Aldol Condensation of Chiral alpha-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Syntheses,""J. Am. Chem Soc., 108: 4595-4602 (1986).;;Alker, D., et al., ""Application of Enantiopure Templated Azomethine Ylids to beta-Hydroxy-alpha-amino Acid Syntheses,"" Tetrahedron: 54: 6089-6098 (1998).;;Alon, R., et al., ""Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,"" J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., ""Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,"" Methods Enzymol., 8: 115-118 (1996).;;Bielawska, A., et al.., ""Ceramide-Mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,"" J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., ""Modulation of Cell Growth and Differentiation by Ceramide,"" FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., ""Regulation of Protein Kinase C and its Role in Cancer Biology,"" Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al., ""Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,"" Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No. 1985:221199, Keith McCullagh, et al., ""Carboxyalkyl peptide derivatives."";;Carson, K.G., et al., ""Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,"" Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Dellaria, Jr., J.F., et al., ""Enantioselective Synthesis of alpha-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon,"" J. Org. Chem., 54: 3916-3926 (1989).;;Dittert, L.W., et al., ""Acetaminophen Prodrugs I-Synthesis, Physicochemical Properties and Analgesic Activity"", J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Evans, D.A., et al., ""Stereoselective Aldol Condensations Via Boron Enolates,"" J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Felding-Habermann, B., et al., ""A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosins Synthesis,"" Biochemistry, 29: 6314-6322 (1990).;;Gatt, S., et al., ""Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids,"" Meth. Enzymol., 72: 351-375 (1981).;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., ""Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,"" Chem. Commun., 2641-2642 (1998).;;Harwood, L.M., et al., ""Asymmetric Cycloadditions of Aldehydes to Stabilized Azomethine Ylids: Enantiocontrolled Construction of beta-Hydroxy-alpha-amino acid Derivitives,"" Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;International Search Report for PCT/US2000/018935 dated Nov. 28, 2000.;;Hospattankar, A.V., et al., ""Changes in Liver Lipids After Administration of 2-Decanoylamino-3-morpholinopropiophenone and Chlorpromazine,"" Lipids, 17(8): 538-543 (1982).;;Inokuchi, et al., ""Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,"" Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;Inokuchi, J., et al., ""Preparation of the Active Isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, Inhibitor of Murine Clucocerebroside Synthetase,"" Journal of Lipid Research, 28:565-571 (1987).;;Inokuchi, J., et al., ""Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action"", Cancer Research, 50:6731-6737 (1990).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;Jaffrézou, Jr., et al., ""Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance,"" Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Kalén, A., et al., ""Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,"" Biochim. Biophys. Acta, 1125: 90-96 (1992).;;Kopaczyk, K., C., et al., ""In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,"" J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., ""C14-Labeling of Novel Atypical beta-Adrenoceptor Agonist, SM-11044,"" Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Högberg, T. and Ulf Norinder, ""Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists"" Textbook of Drug Design and Development, pp. 55-91 (1991).;;Mitchell, S., et al., ""Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,"" J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., ""Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase"", Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Nakamura, K., et al., ""Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,"" Anal. Biochem., 142: 406-410 (1984).;;Nicolaou, K., et al., ""A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),"" J. Am. Chem., Soc., 110: 7910-7912 (1988).;;Nishida, A., et al., ""Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) from L-Serine,"" Synlett, 389-390(1998).;;Ogawa, S., et al., ""Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)beta-Valienamine, and Related Compounds,"" Bioorganic & Medicinal Chemistry Letters, 7(14):1915-1920 (1997).;;Overkleeft, H.S., et al., ""Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,"" The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al., ""Quantitative Measurement of sn-1,2-Diaclglycerols Present in Platelets, Hepatocytes, and ras-and sis- Transformed Normal Rat Kidney Cells,"" J. Biol.Chem., 261(19): 8597-8600 (1986).;;Radin, N.S., ""Killing Cancer Cells by Poly-drug Elevation of Ceramide Levels, A Hypothesis Whose Time has Come:,"" Eur. J. Biochem. 268(2): 193-204 (2001).;;Radin, N.S., et al., ""Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances."" Advances in Lipid Research: Sphingolipids, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., ""Ultrasonic Baths as Substitutes for Shaking Incubator Baths,"" Enzyme, 45: 867-70(1991).;;Radin, N.S., et al., ""Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,"" In NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenweld, A.G., et al., ""Effects of the Glucosphingolipid Synthesis Inhibitor, PDMP, on Lysosomes in Cultured Cells,"" J. Lipid Res., 35: 1232-1240 (1994).;;Rosenweld, A.G., et al., ""Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,"" Biochemistry, 31: 3581-3590 (1992).;;Shayman, J.A., et al., ""Glucosphingolipid Dependence of Hormone-Stimulated Inositol Trisphophate Formation,"" J. Biol. Chem., 265(21): 12135-12138 (1990).;;Shayman, J.A., et al., ""Modulation of Renal Epithelial Cell Growth by Glucosylceramide,"" the Journal of Biological Chemistry, 266(34):22968-22974 (1991).;;Shukla, A., et al., ""Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis and the synergistic action of an inhibitor of microsomal momooxygenase,"" J. of Lipid Research, 32: 713-722 (1991).;;Shukla, G.S., et al., ""Glucosylceramide Synthase of Mouse Kidney: Further Characterization with an Improved Assay Method,"" Arch. Biochem. Biophys., 283(2): 372-378 (1990).;;Shukla, G., et al., ""Rapid Kidney Changes Resulting From Glycosphingolipid Depletion by Treatment with a Glucosyltransferase Inhibitor,"" Biochim. Biophys. Acta, 1083: 101-108 (1991).;;Skehan, P., et al., ""New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,"" N. Natl. Cancer Inst., 82(13): 1107-1112 (1990).;;Strum, J.C., et al.,""1-beta-D-Arabinofuranosylcytosine Stimulates Ceramide and Diglyceride Formation in HL-60- Cells,"" J. Biol. Chem., 269(22): 15493-15497 (1994).;;Tang, W., et al., ""Phorbol Ester Inhibits 13-Cis-Retinoic Acid-Induced Hydrolysis of Phosphatidylinositol 4,5-Biophosphate in cultured Murine Keratinocytes: A Possible Negative Feedback Via Protein Kinase C-Activation,"" Cell Bioch. Funct., 9: 183-191 (1991).;;Uemura, K., et al., ""Effect of an Inhibitor of Glucosylceramide Synthesis on Cultured Rabbit Skin Fibroblasts,"" J. Biochem., (Tokyo) 108(4): 525-530 (1990).;;Vunnum, R.,R., et al.., ""Analogs of Ceramide That Inhibit Glucocerebroside Synthetase in Mouse Brain,"" Chemistry and Physics of Lipids, LD. Bergelson, et al., eds. (Elsevier/North-Holland Scientific Publishers Ltd.), 26: 265-278 (1980).;;Wermuth, C.G., et al.., ""Designing Prodrug and Bioprecursors I: Carrier Prodrug"", The Practice of Medicinal Chemistry, C.G., Wermuth, ed.(CA: Academic Press Limited), pp. 671-696 (1996).;;Wong, C-H., et al.., ""Synthesis and Evaluation of Homoazasugars as Glycosidase Inhibitors,"" J. Org. Chem., 60: 1492-1501, (1995).;;International Search Report for PCT/US2002/00808 dated Oct. 1, 2002.;;International Preliminary Report on Patentability, issued in International Application PCT/US2002/00808, dated Jan. 10, 2003.;;International Preliminary Examination Report on Patentability, issued in International Application PCT/US2000/18935 (WO 01/04108) dated Jul. 20, 2001.;;European Search Report, European Application No. 09003291.3 dated Apr. 29, 2009.;;International Preliminary Report on Patentability for International Application No. PCT/US2002/022659 dated Jul. 24, 2003.;;International Search Report for PCT/US2002/022659 dated Nov. 5, 2002.;;Adams, L.A., et al., ""Nonalcoholic Fatty Liver Disease,"" CMAJ, 172(7):899-905 (2005).",INACTIVE
89,US,B2,US 8940776 B2,057-123-169-226-530,2015-01-27,2015,US 201213595349 A,2012-08-27,US 201213595349 A;;US 60187110 A;;US 2008/0006906 W;;US 99784607 P;;US 93237007 P,2007-05-31,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/057-123-169-226-530,Granted Patent,yes,99,9,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,A61K31/42;;A61K31/40;;A61K31/4025;;A61K31/4245;;A61K31/427;;A61K31/428;;C07D207/04;;C07D261/06;;C07D271/06;;C07D277/20;;C07D277/62;;C07D295/125;;C07D319/18;;C07D405/02;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,514/364;;514/365;;514/367;;514/380;;514/422;;514/424;;514/428;;548/131;;548/159;;548/204;;548/245;;548/518;;548/526;;548/527;;548/541;;548/571,99,66,022-861-665-824-921;;019-168-888-620-949;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;087-720-399-410-986;;099-417-575-155-106;;009-735-754-008-354;;127-620-706-386-56X;;007-195-876-506-733;;036-519-046-514-216;;060-285-756-774-11X;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;013-186-690-689-175;;101-441-717-112-268;;058-000-601-334-562;;024-919-860-416-474;;008-960-930-558-465;;027-757-703-898-799;;003-994-644-386-459;;004-197-046-964-508;;103-843-422-810-071;;061-607-931-932-732;;005-316-633-999-516;;013-129-766-729-356;;080-009-135-438-214;;074-979-551-686-305;;047-458-832-757-760;;078-712-681-777-54X;;111-509-011-354-346;;058-392-587-867-500;;082-544-376-300-192;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;036-669-847-776-367;;025-913-184-941-642;;011-301-633-602-65X;;012-374-430-412-462;;069-903-420-503-60X;;006-912-262-242-73X;;010-215-744-161-837;;131-172-531-021-398;;038-420-412-060-975;;048-359-395-870-441;;032-507-877-332-372;;145-399-125-974-761;;120-463-739-961-857;;084-596-711-500-19X;;056-300-053-225-737;;089-212-206-875-704;;019-772-803-841-699;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;003-652-677-788-251;;047-142-399-168-373;;057-382-993-877-418;;011-812-030-137-650;;078-857-409-314-797;;005-002-282-762-215,11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;10.1021/ja00275a054;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;10.1172/jci9711;;10841515;;pmc300859;;7775872;;10.1016/s0022-2275(20)39895-3;;15795412;;10.1503/cmaj.045232;;pmc554876;;10.1016/s0040-4020(98)00302-0;;7537307;;10.1016/0076-6879(66)08014-5;;12851286;;10.1093/glycob/cwg090;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;8724138;;10.1093/glycob/6.3.303;;10.1016/s0022-2275(20)39163-x;;8808768;;10.1001/jama.289.22.3000;;12799409;;12529488;;10.1038/oby.2003.12;;10.1021/jo00277a032;;10.1016/0042-6822(91)90759-5;;1926769;;10.1002/jps.2600570510;;5657533;;1743438;;10.1096/fasebj.5.15.1743438;;10.1021/ja00401a031;;10.1021/bi00478a028;;2207076;;13428781;;10.1016/s0021-9258(18)64849-5;;4957125;;6273689;;10.1016/s0076-6879(81)72026-3;;10.1111/j.1464-5491.2004.01225.x;;15209770;;1820092;;10.1016/s0957-4166(00)82093-5;;10.1039/a807471b;;10.1007/bf02535381;;3690511;;10.1016/0304-3835(87)90196-0;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/s0026-265x(01)00097-2;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;15306563;;10.1093/glycob/cwh135;;10.1016/0005-2760(92)90160-w;;1567913;;10.1016/s0022-2275(20)39651-6;;14280461;;10.1002/(sici)1099-1344(199603)38:3<285::aid-jlcr836>3.0.co;2-p;;10329660;;10.1074/jbc.274.21.14662;;10.2337/diabetes.54.1.220;;15616032;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;10.1016/0003-2697(84)90484-6;;6084960;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.1016/s0960-894x(97)00341-7;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;1567816;;10.1021/bi00129a005;;10.1016/s0022-2275(20)39966-1;;7964184;;10.1098/rstb.2003.1265;;pmc1693173;;12803917;;12730204;;10.1074/jbc.m212200200;;10.1016/s0021-9258(19)38320-6;;2142685;;1744091;;10.1016/s0021-9258(18)54449-5,"Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/055,036; titled: ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease"" Date Mailed: Oct. 31, 2012.;;Qian, Q., et al., ""Treatment prospects for autosomal-dominant polysystic kidney disease"", Kidney International, vol. 59, pp. 2005-2002 (2001).;;Non-Final Office Action for U.S. Appl. No. 12/681,291 dated Dec. 10, 2012, ""Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives"".;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/601,871; ""2- Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" Date Mailed: Aug. 9, 2012.;;Final Office Action for U.S. Appl. No. 12/227,076 dated Mar. 20, 2012.;;Non-Final Office Action for U.S. Appl. No. 13/122,135 mailed on Apr. 27, 2012.;;Abdel-Magid, A., et al., ""Metal-Assisted Aldol Condensation of Chiral alpha-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Syntheses,""J. Am. Chem Soc., 108: 4595-4602 (1986).;;Abe, A., et al., ""Improved Inhibitors of Glucosylceramide Synthase,"" J. Biochem., 111:191-196 (1992).;;Abe, A., et al., ""Induction of Glucosylceramide Synthase by Synthase Inhibitors and Ceramide,"" Biochim. Biophys. Acta, 1299: 333-341 (1996).;;Abe, A., et al., ""Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C,"" Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., ""Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation"", J. Clin Invest. 105(11): 1563-1571, (2000).;;Abe, A., et al., ""Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,"" J. Lipid Research, 36:611-621 (1995).;;Adams, L.A., et al., ""Nonalcoholic Fatty Liver Disease,"" CMAJ, 172(7):899-905 (2005).;;Alberti, C., et al., ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", Chemical Abstracts Service, XP002495477 retrieved from CAPLUS Database accession No. 1957:17088 (abstract).;;Alker, D., et al., ""Application of Enantiopure Templated Azomethine Ylids to beta-Hydroxy-alpha-amino Acid Syntheses,"" Tetrahedron, 54: 6089-6098 (1998).;;Alon, R., et al., ""Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,"" J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., ""Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,"" Methods Enzymol., 8: 115-118 (1996).;;Asano, N., ""Glycosidase Inhibitors: Update and Perspectives on Practical Use,"" Glycobiology, 13(10):93R-104R (2003).;;Bielawska, A., et al., ""Ceramide-Mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,"" J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., ""Modulation of Cell Growth and Differentiation by Ceramide,"" FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., ""Regulation of Protein Kinase C and its Role in Cancer Biology,"" Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al., ""Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,"" Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No. 1985:221199, Keith McCullagh, et al., ""Carboxyalkyl peptide derivatives."";;Carson, K.G., et al., ""Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,"" Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Chatterjee, S., et al.,""Oxidized Low Density Lipoprotein Stimulates Aortic Smooth Muscle Cell Proliferation"", Glycobiology, 6(3): 303-311 (1996).;;Chatterjee, S., et al.,""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Clark, J.M., et al., ""Nonalcoholic Fatty Liver Disease, An Underrecognized Cause of Cryptogenic Cirrhosis,"" JAMA, 289(22):3000-3004 (2003).;;Comuzzie, A.G., et al., ""The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity"", Obesity Research, 11(1):75-80 (2003).;;Dellaria, Jr., J.F., et al., ""Enantioselective Synthesis of alpha-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon,"" J. Org. Chem., 54: 3916-3926 (1989).;;Dickie, P., et al., ""HIV-Associated Nephropathy in Transgenic Mice Expressing HIV-1 Genes,"" Virology, 185:109-119, 1991.;;Dittert, L.W., et al., ""Acetaminophen Prodrugs I-Synthesis, Physicochemical Properties and Analgesic Activity"", J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Elbein, A.D., ""Glycosidase Inhibitors: Inhibitors of N-linked Oligosaccharide Processing,"" The FASEB Journal, 5:3055-3063 (1991).;;European Search Report, European Application No. 09003291.3 dated Apr. 29, 2009.;;Evans, D.A., et al., ""Stereoselective Aldol Condensations Via Boron Enolates,"" J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Fan, J-G., et al., ""Preventie Effects of Metformin on Rats with Nonalcoholic Steatohepatitis,"" Hepatology, 34(4)(1), p. 501A (2003).;;Felding-Habermann, B., et al., ""A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosins Synthesis,"" Biochemistry, 29: 6314-6322 (1990).;;Folch, J., et al., ""A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues"", J. Biol. Chem., 226:497-509, 1956.;;Freireich, E., et al., ""Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hampster, Dog, Monkey, and Man"", Cancer Chemother. Reports 50(4):219 (1996).;;Gatt, S., et al., ""Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids,"" Meth. Enzymol., 72: 351-375 (1981).;;Gill-Randall, R.J., et al., ""Is human Type 2 diabetes maternally inherited? Insights from an animal model"", Diabet. Med. 21 (7):759 (2004).;;Hakomori, S. ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy,"" Cancer Cells 3(12): 461-470 (1991).;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., ""Asymmetric Cycloadditions of Aldehydes to Stabilized Azomethine Ylids: Enantiocontrolled Construction of beta-Hydroxy-alpha-amino acid Derivitives,"" Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;Harwood, L.M., et al., ""Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,"" Chem. Commun., 2641-2642 (1998).;;Högberg, T. and ULF Norinder, ""Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists"" Textbook of Drug Design and Development, pp. 55-91 (1991).;;Hospattankar, A.V., et al., ""Changes in Liver Lipids After Administration of 2-Decanoylamino-3-morpholinopropiophenone and Chlorpromazine,"" Lipids, 17(8): 538-543 (1982).;;Inokuchi, et al., ""Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,"" Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;Inokuchi, J. et al., ""Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis,"" Cancer Lett., 38:23-30(1987).;;Inokuchi, J., et al., ""Preparation of the Active Isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, Inhibitor of Murine Clucocerebroside Synthetase,"" Journal of Lipid Research, 28:565-571 (1987).;;Inokuchi, J., et al., ""Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action"", Cancer Research, 50:6731-6737 (1990).;;Inokuchi, et al., ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"", Chemical Abstracts Service, XP002495476 retrieved from CAPLUS Database accession No. 1998:816280 (abstract).;;International Preliminary Examination Report issued in International Application PCT/US2000/18935, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"" (WO 01/04108) dated Jul. 20, 2001.;;International Preliminary Examination Report for International Application No. PCT/US2002/022659, titled: ""Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors"" dated Jul. 24, 2003.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450, titled: ""Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives"" dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773, titled: Method of Treating Lupus with Ceramide Derivatives: dated Sep. 21, 2010.;;International Preliminary Report on Patentability issued in International Application PCT/US2007/068521, titled: ""Methods of Treating Fatty Liver Disease"" dated Nov. 11, 2008.;;International Preliminary Report on Patentability issued in International Application PCT/US2005/040596, titled: ""Methods of Treating Diabetes Mellitus"" dated May 15, 2007.;;International Preliminary Examination Report issued in International Application PCT/US2002/00808, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"", dated Jan. 10, 2003.;;International Search Report for PCT/US2000/018935, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"" dated Nov. 28, 2000.;;International Search Report for PCT/US2002/00808, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"", dated Oct. 1, 2002.;;International Search Report for PCT/US2002/022659, titled: ""Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors"" dated Nov. 5, 2002.;;Jaffrézou, Jr., et al, ""Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance,"" Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Jankowski, K., ""Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion"", Microchem. J., 70:41-49, 2001.;;Jimbo, M., et al., ""Development of a New Inhibitor of Glucosylceramide Synthase"", J. Biochem, 127: 485-491 (2000).;;Kabayama, K., et al., ""TNFalpha-induced Insulin Resistance in Adipocytes as a Membrane Microdomain Disorder: Involvement of Ganglioside GM3,"" Glycobiology, 15(1): 21-29 (2005).;;Kalén, A., et al., ""Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,"" Biochim. Biophys. Acta, 1125: 90-96 (1992).;;Kopaczyk, K., C., et al., ""In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,"" J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., ""C14-Labeling of Novel Atypical beta-Adrenoceptor Agonist, SM-11044,"" Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Lee, L., et al. ""Improved Inhibitors of Glucosylceramide Synthase"", J. Bio Chem., 274(21): 14662-14669 (1999).;;Masson, E., et al., ""a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation-A Common Mediator for Retinal and Renal Microangiopathy?,"" Diabetes, 54:220-227 (2005).;;Mitchell, S., et al., ""Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo- PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,"" J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., ""Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase"", Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Nakamura, K., et al., ""Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,"" Anal. Biochem., 142: 406-410 (1984).;;Nicolaou, K., et al., ""A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),"" J. Am. Chem., Soc., 110: 7910-7912 (1988).;;Nishida, A., et al., ""Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl- 2-palmitoylamino-3-morpholino-l-propanol (PPMP) from L-Serine,""Synlett, 389-390(1998).;;Nojiri, H., et al., ""Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937"", Proc. Natl. Acad. Sci., 83:782-786 (1986).;;International Preliminary Report on Patentability for International Application No. PCT/US2008/006906, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" Dated Dec. 1, 2009.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/051864, titled ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases"" dated Feb. 1, 2011.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2008/006906, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" dated Dec. 4, 2008.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2008/011450, titled ""Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives"" dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2009/001773, titled ""Method of Treating Lupus with Ceramide Derivatives"", dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2009/051864, titled ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases"" dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2009/005435, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"", dated Feb. 12, 2010.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2007/068521, titled: ""Methods of Treating Fatty Liver Disease"" dated Nov. 21, 2007.;;Ogawa, S., et al., ""Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)-beta-Valienamine, and Related Compounds,"" Bioorganic & Medicinal Chemistry Letters, 7(14):1915-1920 (1997).;;Overkleeft, H.S., et al., ""Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,"" The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al., ""Quantitative Measurement of sn-1,2-Diaclglycerols Present in Platelets, Hepatocytes, and ras-and sis- Transformed Normal Rat Kidney Cells,"" J. Biol.Chem., 261(19): 8597-8600 (1986).;;Radin, N.S., ""Killing Cancer Cells by Poly-drug Elevation of Ceramide Levels, A Hypothesis Whose Time has Come:,"" Eur. I Biochem. 268(2): 193-204 (2001).;;Radin, N.S., et al., ""Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances.""Advances in Lipid Research: Sphingolipid, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., ""Ultrasonic Baths as Substitutes for Shaking Incubator Baths,"" Enzyme, 45: 867-70(1991).;;Radin, N.S., et al., ""Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,"" In NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenwald, A.G., et al., ""Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,"" Biochemistry, 31: 3581-3590 (1992).;;Rosenwald, A.G., et al., ""Effects of the Glucosphingolipid Synthesis Inhibitor, PDMP, on Lysosomes in Cultured Cells,"" J. Lipid Res., 35: 1232-1240 (1994).;;Rubino, Md., F., et al., ""Letter to the Editor,"" Annals of Surgery, 240(2):389-390 (2004).;;Sandhoff, K., et al., ""Biosynthesis and Degradation of Mammalian Glycosphingolipids,"" Phil. Trans. R. Soc. Lond, B 358:847-861 (2003).;;Sasaki, A., et al., ""Overexpression of Plasma Membrane-Associated Sialidase Attenuates Insulin Signaling in Transgenic Mice,"" The Journal of Biological Chemistry, 278(30):27896-27902 (2003).;;Shayman, J.A., et al., ""Glucosphingolipid Dependence of Hormone-Stimulated Inositol Trisphophate Formation,"" J. Biol. Chem., 265(21): 12135-12138 (1990).;;Shayman, J.A., et al., ""Modulation of Renal Epithelial Cell Growth by Glucosylceramide,"" The Journal of Biological Chemistry, 266(34):22968-22974 (1991).",INACTIVE
90,US,B2,US 9272996 B2,177-729-609-431-798,2016-03-01,2016,US 201213595251 A,2012-08-27,US 201213595251 A;;US 201113122135 A;;US 2009/0005435 W;;US 10254108 P,2008-10-03,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/177-729-609-431-798,Granted Patent,yes,101,6,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/397;;A61K31/325;;A61K31/40;;A61K31/42;;A61K31/44;;A61K31/5377;;C07C271/12;;C07D207/12;;C07D271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12,,100,65,022-861-665-824-921;;022-861-665-824-921;;053-135-256-880-410;;019-168-888-620-949;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;087-720-399-410-986;;099-417-575-155-106;;009-735-754-008-354;;127-620-706-386-56X;;007-195-876-506-733;;036-519-046-514-216;;060-285-756-774-11X;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;013-186-690-689-175;;101-441-717-112-268;;058-000-601-334-562;;024-919-860-416-474;;008-960-930-558-465;;027-757-703-898-799;;003-994-644-386-459;;004-197-046-964-508;;103-843-422-810-071;;061-607-931-932-732;;005-316-633-999-516;;013-129-766-729-356;;080-009-135-438-214;;074-979-551-686-305;;047-458-832-757-760;;078-712-681-777-54X;;111-509-011-354-346;;058-392-587-867-500;;082-544-376-300-192;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;036-669-847-776-367;;025-913-184-941-642;;011-301-633-602-65X;;012-374-430-412-462;;069-903-420-503-60X;;006-912-262-242-73X;;010-215-744-161-837;;131-172-531-021-398;;038-420-412-060-975;;048-359-395-870-441;;032-507-877-332-372;;145-399-125-974-761;;120-463-739-961-857;;084-596-711-500-19X;;056-300-053-225-737;;089-212-206-875-704;;019-772-803-841-699;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;003-652-677-788-251;;047-142-399-168-373;;057-382-993-877-418,11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;pmc3660226;;10.1038/nm.2171;;20562878;;10.1021/ja00275a054;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;10.1172/jci9711;;10841515;;pmc300859;;7775872;;10.1016/s0022-2275(20)39895-3;;15795412;;10.1503/cmaj.045232;;pmc554876;;10.1016/s0040-4020(98)00302-0;;7537307;;10.1016/0076-6879(66)08014-5;;12851286;;10.1093/glycob/cwg090;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;8724138;;10.1093/glycob/6.3.303;;10.1016/s0022-2275(20)39163-x;;8808768;;10.1001/jama.289.22.3000;;12799409;;12529488;;10.1038/oby.2003.12;;10.1021/jo00277a032;;10.1016/0042-6822(91)90759-5;;1926769;;10.1002/jps.2600570510;;5657533;;1743438;;10.1096/fasebj.5.15.1743438;;10.1021/ja00401a031;;10.1021/bi00478a028;;2207076;;13428781;;10.1016/s0021-9258(18)64849-5;;4957125;;6273689;;10.1016/s0076-6879(81)72026-3;;10.1111/j.1464-5491.2004.01225.x;;15209770;;1820092;;10.1016/s0957-4166(00)82093-5;;10.1039/a807471b;;10.1007/bf02535381;;3690511;;10.1016/0304-3835(87)90196-0;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/s0026-265x(01)00097-2;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;15306563;;10.1093/glycob/cwh135;;10.1016/0005-2760(92)90160-w;;1567913;;10.1016/s0022-2275(20)39651-6;;14280461;;10.1002/(sici)1099-1344(199603)38:3<285::aid-jlcr836>3.0.co;2-p;;10329660;;10.1074/jbc.274.21.14662;;10.2337/diabetes.54.1.220;;15616032;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;10.1016/0003-2697(84)90484-6;;6084960;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.1016/s0960-894x(97)00341-7;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;1567816;;10.1021/bi00129a005;;10.1016/s0022-2275(20)39966-1;;7964184;;10.1098/rstb.2003.1265;;pmc1693173;;12803917,"Qi Qian et al. (Kidney International (2001) 59, 2005-2022; doi:10.1046/j.1523 1755.2001.00716).;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: ""Methods of Treating Fatty Liver Disease"" Date Mailed: Oct. 9, 2012.;;Belikov., V.G., ""Pharmaceutical Chemistry, Moscow"", Vysshaya Shkola Publishers, pp. 43-47 (1993).;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/055,036; titled: ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease"" Date Mailed: Oct. 31, 2012.;;Qian, Q., et al., ""Treatment prospects for autosomal-dominant polysystic kidney disease"", Kidney International, vol. 59, pp. 2005-2002 (2001).;;Non-Final Office Action for U.S. Appl. No. 12/681,291 dated Dec. 10, 2012, ""Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives"".;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/601,871; ""2- Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" Date Mailed: Aug. 9, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/122,135; ""2- Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" Date Mailed: Aug. 1, 2012.;;Non-Final Office Action for U.S. Appl. No. 13/122,135 mailed on Apr. 27, 2012.;;Natoli, T.A., et al., ""Inhibition of glucosylceramide accumulation results in effective blockade of polysystic kidney disease in mouse models"" and supplemental information, Nature Medicine, 16(7): 788-792 (Jul. 2010).;;Abdel-Magid, A., et al., ""Metal-Assisted Aldol Condensation of Chiral alpha-Halogenated Imide Enolatcs: A Stereocontrolled Chiral Epoxide Syntheses, ""J. Am. Chem Soc., 108: 4595-4602 (1986).;;Abe, A., et al., ""Improved Inhibitors of Glucosylceramide Synthase,"" J. Biochem., 111:191-196 (1992).;;Abe, A., et al., ""Induction of Glucosylceramide Synthase by Synthase Inhibitors and Ceramide,"" Biochim. Biophys. Acta, 1299: 333-341 (1996).;;Abe, A., et al., ""Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C,"" Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., ""Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation"", J. Clin Invest. 105(11): 1563-1571, (2000).;;Abe, A., et al., ""Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,"" J. Lipid Research, 36:611-621 (1995).;;Adams, L.A., et al., ""Nonalcoholic Fatty Liver Disease,"" CMAJ, 172(7):899-905 (2005).;;Alberti, C., et al., ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", Chemical Abstracts Service,. XP002495477 retrieved from CAPLUS Database accession No. 1957:17088 (abstract).;;Alker, D., et al., ""Application of Enantiopure Templated Azomethine Ylids to beta-Hydroxy-alpha-amino Acid Syntheses,"" Tetrahedron, 54: 6089-6098 (1998).;;Alon, R., et al., ""Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,"" J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., ""Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,"" Methods Enzymol., 8: 115-118 (1996).;;Asano, N., ""Glycosidase Inhibitors: Update and Perspectives on Practical Use,"" Glycobiology, 13(10):93R-104R (2003).;;Bielawska, A., et al., ""Ceramide-Mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,"" J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., ""Modulation of Cell Growth and Differentiation by Ceramide,"" FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., ""Regulation of Protein Kinase C and its Role in Cancer Biology,"" Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al., ""Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,"" Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No: 1985:221199, Keith McCullagh, et al.,""Carboxyalkyl peptide derivatives."".;;Carson, K.G., et al., ""Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,"" Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Chatterjee, S., et al., ""Oxidized Low Density Lipoprotein Stimulates Aortic Smooth Muscle Cell Proliferation"", Glycobiology, 6(3): 303-311 (1996).;;Chatterjee, S., et al., ""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Clark, J.M., et al., ""Nonalcoholic Fatty Liver Disease, An Underrecognized Cause of Cryptogenic Cirrhosis,"" JAMA, 289(22):3000-3004 (2003).;;Comuzzie, A.G., et al., ""The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity"", Obesity Research, 11(1):75-80 (2003).;;Dellaria, Jr., J.F., et al., ""Enantioselective Synthesis of alpha-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon,"" J. Org. Chem., 54: 3916-3926 (1989).;;Dickie, P., et al., ""HIV-Associated Nephropathy in Transgenic Mice Expressing HIV-1 Genes,"" Virology, 185:109-119, 1991.;;Dittert, L.W., et al.,"" Acetaminophen Prodrugs I-Synthesis, Physicochemical Properties and Analgesic Activity"", J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Elbein, A.D., ""Glycosidase Inhibitors: Inhibitors of N-linked Oligosaccharide Processing,"" The FASEB Journal, 5:3055-3063 (1991).;;European Search Report, European Application No. 09003291.3 dated Apr. 29, 2009.;;Evans, D.A., et al., ""Stereoselective Aldol Condensations Via Boron Enolates,"" J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Fan, J-G., et al., ""Preventie Effects of Metformin on Rats with Nonalcoholic Steatohepatitis,"" Hepatology, 34(4)(1), p. 501A (2003).;;Felding-Habermann, B., et al., ""A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosins Synthesis,"" Biochemistry, 29: 6314-6322 (1990).;;Folch, J., et al., ""A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues"", J. Biol. Chem., 226:497-509, 1956.;;Freircich, E., et al., ""Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hampster, Dog, Monkey, and Man"", Cancer Chemother. Reports 50(4):219 (1996).;;Gatt, S., et al., ""Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids,"" Meth. Enzymol., 72: 351-375 (1981).;;Gill-Randall, R.J., et al., ""Is human Type 2 diabetes maternally inherited? Insights from an animal model"", Diabet. Med. 21 (7):759 (2004).;;Hakomori, S. ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy,"" Cancer Cells 3(12): 461-470 (1991).;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., ""Asymmetric Cycloadditions of Aldehydes to Stabilized Azomethine Ylids: Enantiocontrolled Construction of beta-Hydroxy-alpha-amino acid Derivitives,"" Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;Harwood, L.M., et al., ""Double diastereocontrol in the synthesis of enantiomerieally pure polyoxamic acid,"" Chem. Commun., 2641-2642 (1998).;;Högberg, T. and Ulf Norinder, ""Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists"" Textbook of Drug Design and Development, pp. 55-91 (1991).;;Hospattankar, A.V., et al., ""Changes in Liver Lipids After Administration of 2-Decanoylamino-3-morpholinopropiophenone and Chlorpromazine,"" Lipids, 17(8): 538-543 (1982).;;Inokuchi, et al., ""Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,"" Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;Inokuchi, J. et al., ""Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis,"" Cancer Lett., 38:23-30(1987).;;Inokuchi, J., et al., ""Preparation of the Active Isomer of 1-pheny1-2-decanoylamino-3-morpholino-1-propanol, inhibitor of Murine Clucocerebroside Synthetase,"" Journal of Lipid Research, 28:565-571 (1987).;;Inokuchi, J., et al., ""Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action"", Cancer Research, 50:6731-6737 (1990).;;Inokuchi, el al., ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"", Chemical Abstracts Service, XP002495476 retrieved from CAPLUS Database accession No. 1998:816280 (abstract).;;International Preliminary Examination Report issued in International Application PCT/US2000/18935, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"" (WO 01/04108) dated Jul. 20, 2001.;;International Preliminary Examination Report for International Application No. PCT/US2002/022659, titled: ""Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors"" dated Jul. 24, 2003.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450, titled: ""Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives"" dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773, titled: Method of Treating Lupus with Ceramide Derivatives: dated Sep. 21, 2010.;;International Preliminary Report on Patentability issued in International Application PCT/US2007/068521, titled: ""Methods of Treating Fatty Liver Disease"" dated Nov. 11, 2008.;;International Preliminary Report on Patentability issued in International Application PCT/US2005/040596, titled: ""Methods of Treating Diabetes Mellitus"" dated May 15, 2007.;;International Preliminary Examination Report issued in International Application PCT/US2002/00808, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"", dated Jan. 10, 2003.;;International Search Report for PCT/US2000/018935, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"" dated Nov. 28, 2000.;;International Search Report for PCT/US2002/00808, titled: ""Amino Ceramide-Like Compounds and Therapeutic Methods of Use"", dated Oct. 1, 2002.;;International Search Report for PCT/US2002/022659, titled: ""Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors"" dated Nov. 5, 2002.;;Jaffrézou, Jr., et al., ""Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance,"" Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Jankowski, K., ""Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion"", Microchem. J., 70:41-49, 2001.;;Jimbo, M., et al., ""Development of a New Inhibitor of Glucosylceramide Synthase"", J. Biochem, 127: 485-491 (2000).;;Kabayama, K., et al., ""TNFalpha-induced Insulin Resistance in Adipocytes as a Membrane Microdomain Disorder: Involvement of Ganglioside GM3,"" Glycobiology, 15(1): 21-29 (2005).;;Kalén, A., et al., ""Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,"" Biochim. Biophys. Acta, 1125: 90-96 (1992).;;Kopaczyk, K., C., et al., ""In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,"" J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., ""C14-Labeling of Novel Atypical beta-Adrenoceptor Agonist, SM-11044,"" Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Lee, L., et al. ""Improved Inhibitors of Glucosylceramide Synthase"", J. Bio Chem., 274(21): 14662-14669 (1999).;;Masson, E., et al., ""a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation-A Common Mediator for Retinal and Renal Microangiopathy?,"" Diabetes, 54:220-227 (2005).;;Mitchell, S., et al., ""Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,"" J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., ""Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase"", Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Nakamura, K., et al., ""Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,"" Anal. Biochem., 142: 406-410 (1984).;;Nicolaou, K., et al., ""A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),"" J. Am. Chem., Soc., 110: 7910-7912 (1988).;;Nishida, A., et al., ""Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl-2-palmitoylamino-3-morpholino-l-propanol (PPMP) from L-Serine, ""Synlett, 389390(1998).;;Nojiri, H., et al., ""Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937"", Proc. Natl. Acad. Sci., 83:782-786 (1986).;;International Preliminary Report on Patentability for International Application No. PCT/US2008/006906, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" Dated Dec. 1, 2009.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/051864, titled ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases"" dated Feb. 1, 2011.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2008/006906, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"" dated Dec. 4, 2008.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2008/011450, titled ""Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives"" dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2009/001773, titled ""Method of Treating Lupus with Ceramide Derivatives"", dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2009/051864, titled ""Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases"" dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2009/005435, titled: ""2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors"", dated Feb. 12, 2010.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2007/068521, titled: ""Methods of Treating Fatty Liver Disease"" dated Nov. 21, 2007.;;Ogawa, S., et al., ""Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)-beta-Valienamine, and Related Compounds,"" Bioorganic & Medicinal Chemistry Letters, 7(14):1915-1920 (1997).;;Overkleeft, H.S., et al., ""Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,"" The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al., ""Quantitative Measurement of sn-1,2-DiacIglycerols Present in Platelets, Hepatocytes, and ras-and sis- Transformed Normal Rat Kidney Cells,"" J. Biol. Chem., 261(19): 8597-8600 (1986).;;Radin, N.S.. ""Killing Cancer Cells by Poly-drug Elevation of Ceramide Levels, A Hypothesis Whose Time has Come:,"" Eur. J. Biochem. 268(2): 193-204 (2001).;;Radin, N.S., et al., ""Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances.""Advances in Lipid Research: Sphingolipids, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., ""Ultrasonic Baths as Substitutes for Shaking Incubator Baths,"" Enzyme, 45: 867-70(1991).;;Radin, N.S., et al., ""Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,"" In NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenwald, A.G., et al., ""Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,"" Biochemistry, 31: 3581-3590 (1992).;;Rosenwald, A.G., et al., ""Effects of the Glucosphingolipid Synthesis Inhibitor, PDMP, on Lysosomes in Cultured Cells,"" J. Lipid Res., 35: 1232-1240 (1994).;;Rubino, MD., F., et al., ""Letter to the Editor,"" Annals of Surgery, 240(2):389-390 (2004).;;Sandhoff, K., et al., ""Biosynthesis and Degradation of Mammalian Glycosphingolipids,"" Phil. Trans. R. Soc. Lond, B 358:847-861 (2003).",INACTIVE
91,US,A1,US 2012/0322786 A1,067-077-104-230-799,2012-12-20,2012,US 201213595251 A,2012-08-27,US 201213595251 A;;US 201113122135 A;;US 2009/0005435 W;;US 10254108 P,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/067-077-104-230-799,Patent Application,yes,2,13,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;A61K31/397;;A61K31/40;;A61K31/422;;A61K31/428;;A61K31/4439;;A61K31/5377,514/210.19;;514/422;;514/428;;514/338;;514/378;;514/367;;514/371;;514/374;;514/233.8,1,1,022-861-665-824-921,11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x,"Qi Qian et al. (Kidney International (2001) 59, 2005-2022; doi:10.1046/j.1523 1755.2001.00716).",INACTIVE
92,KR,A,KR 20110067055 A,162-607-481-854-037,2011-06-20,2011,KR 20117010056 A,2009-10-02,US 10254108 P;;US 2009/0005435 W,2008-10-03,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/162-607-481-854-037,Patent Application,no,2,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,C07D207/10;;A61K31/4025;;A61P13/12;;C07C271/12,,0,0,,,,ACTIVE
93,CA,C,CA 2738768 C,080-336-735-182-388,2017-10-31,2017,CA 2738768 A,2009-10-02,US 10254108 P;;US 2009/0005435 W,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/080-336-735-182-388,Granted Patent,no,0,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
94,CN,A,CN 107935983 A,108-632-255-183-112,2018-04-20,2018,CN 201710483611 A,2009-10-02,US 10254108 P;;CN 200980147488 A,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"The invention relates a 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR, and disclsoes a compound for use in treating polycystic kidney disease is represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The compound is aglucosylceramide synthesis inhibitor and can be used for treating various diseases related to GSL metabolism, including diabetes and lysosome storage diseases. The compound can effectively inhibit synthesis of the glucosylceramide and is high in metabolic stability in liver.",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/108-632-255-183-112,Patent Application,no,3,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,C07D319/18;;C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12,,0,0,,,,DISCONTINUED
95,US,A1,US 2018/0093981 A1,029-456-650-942-445,2018-04-05,2018,US 201715649128 A,2017-07-13,US 201715649128 A;;US 201414571922 A;;US 201213595349 A;;US 60187110 A;;US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/029-456-650-942-445,Patent Application,yes,0,2,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D417/14;;C07D295/125;;C07D319/18;;C07D405/06;;C07D405/12;;C07D405/14;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
96,EP,A1,EP 2349255 A1,031-174-953-299-959,2011-08-03,2011,EP 09741487 A,2009-10-02,US 2009/0005435 W;;US 10254108 P,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/031-174-953-299-959,Patent Application,yes,0,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
97,US,B2,US 9745294 B2,109-617-434-669-389,2017-08-29,2017,US 201414571922 A,2014-12-16,US 201414571922 A;;US 201213595349 A;;US 60187110 A;;US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/109-617-434-669-389,Granted Patent,yes,136,1,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,A61K31/42;;A61K31/40;;A61K31/4025;;A61K31/4245;;A61K31/427;;A61K31/428;;C07D295/125;;C07D319/18;;C07D405/06;;C07D405/12;;C07D405/14;;C07D407/12;;C07D409/12;;C07D409/14;;C07D411/12;;C07D413/12;;C07D413/14;;C07D417/14,,171,85,127-453-640-205-029;;006-530-492-820-511;;031-125-860-040-891;;035-017-124-510-530;;056-195-211-698-993;;029-165-542-494-403;;048-202-794-038-729;;019-168-888-620-949;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;087-720-399-410-986;;099-417-575-155-106;;009-735-754-008-354;;007-195-876-506-733;;036-519-046-514-216;;060-285-756-774-11X;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;013-186-690-689-175;;101-441-717-112-268;;058-000-601-334-562;;024-919-860-416-474;;008-960-930-558-465;;027-757-703-898-799;;003-994-644-386-459;;004-197-046-964-508;;103-843-422-810-071;;111-509-011-354-346;;058-392-587-867-500;;000-981-111-711-659;;082-544-376-300-192;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;036-669-847-776-367;;025-913-184-941-642;;011-301-633-602-65X;;012-374-430-412-462;;094-645-762-447-043;;069-903-420-503-60X;;010-215-744-161-837;;006-806-427-104-062;;131-172-531-021-398;;038-420-412-060-975;;048-359-395-870-441;;032-507-877-332-372;;053-135-256-880-410;;145-399-125-974-761;;120-463-739-961-857;;084-596-711-500-19X;;014-153-260-613-491;;089-212-206-875-704;;019-772-803-841-699;;022-861-665-824-921;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;003-652-677-788-251;;047-142-399-168-373;;057-382-993-877-418;;011-812-030-137-650;;009-082-755-322-366;;078-857-409-314-797;;005-002-282-762-215;;013-092-512-192-775;;013-863-667-338-436;;038-253-278-873-477;;010-213-588-950-017;;100-005-886-323-421;;009-542-128-522-566;;015-233-440-103-014;;002-423-422-743-881;;020-114-708-399-776;;006-772-308-047-402;;102-509-495-349-845;;113-967-182-481-72X;;095-564-866-172-621;;009-997-959-779-435;;037-256-760-224-384;;096-617-488-485-139,18576636;;10.1021/ja801602q;;pmc2562865;;10.1016/s0022-2275(20)41159-9;;7806975;;10.1007/s11560-006-0052-0;;16564783;;10.1016/j.amjmed.2005.08.045;;7126619;;10.1016/0005-2760(82)90272-7;;10.1098/rstb.2003.1266;;pmc1693184;;12803919;;pmc1501855;;5551302;;10.1021/ja00275a054;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;10.1172/jci9711;;10841515;;pmc300859;;7775872;;10.1016/s0022-2275(20)39895-3;;15795412;;10.1503/cmaj.045232;;pmc554876;;7537307;;10.1016/0076-6879(66)08014-5;;12851286;;10.1093/glycob/cwg090;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;8724138;;10.1093/glycob/6.3.303;;10.1016/s0022-2275(20)39163-x;;8808768;;10.1001/jama.289.22.3000;;12799409;;12529488;;10.1038/oby.2003.12;;10.1021/jo00277a032;;10.1016/0042-6822(91)90759-5;;1926769;;10.1002/jps.2600570510;;5657533;;1743438;;10.1096/fasebj.5.15.1743438;;10.1021/ja00401a031;;10.1039/a807471b;;10.1007/bf02535381;;10.1016/s0040-4039(02)02096-8;;3690511;;10.1016/0304-3835(87)90196-0;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/s0026-265x(01)00097-2;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;15306563;;10.1093/glycob/cwh135;;10.1016/0005-2760(92)90160-w;;1567913;;10.1248/cpb.20.526;;10.1016/s0022-2275(20)39651-6;;14280461;;10329660;;10.1074/jbc.274.21.14662;;12163162;;10.1016/s0014-5793(02)03067-3;;10.2337/diabetes.54.1.220;;15616032;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;10.1016/0003-2697(84)90484-6;;6084960;;pmc3660226;;10.1038/nm.2171;;20562878;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.3949/ccjm.71.8.657;;15449761;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;1567816;;10.1021/bi00129a005;;10.1016/s0022-2275(20)39966-1;;7964184;;10.1098/rstb.2003.1265;;pmc1693173;;12803917;;12730204;;10.1074/jbc.m212200200;;10.1067/s0022-3476(03)00325-1;;14571229;;10.1016/s0021-9258(19)38320-6;;2142685;;1744091;;10.1016/s0021-9258(18)54449-5;;10.1016/s0022-2275(20)42059-0;;1856614;;10.1016/0005-2760(91)90130-a;;1827738;;2148864;;10.1016/0003-9861(90)90657-k;;10.1093/jnci/82.13.1107;;2359136;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;11707432;;10.1074/jbc.m103705200;;10.1002/cbf.290090306;;1661208;;2149853;;10.1093/oxfordjournals.jbchem.a123236;;10.1016/0009-3084(80)90057-2;;6445239;;10.1021/jo00111a007;;pmc152312;;10.1073/pnas.0635898100;;12629211;;pmc2888613;;10.1371/journal.pone.0011239;;20574539;;pmc288030;;10.1172/jci116299;;8450061;;19444873;;10.1002/hep.22970;;17470562;;10.2337/db06-0719;;1281244,"Final Office Action for U.S. Appl. No. 14/595,251, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: May 5, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/464,432, titled: “Method of Treating Diabetes Mellitus” Date Mailed: Sep. 9, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/247,732, titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Jan. 25, 2016.;;Non-Final Office Action for U.S. Appl. No. 14/255,634, titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Aug. 11, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/532,432, titled: “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” Date Mailed: Jan. 5, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/595,251; titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Oct. 21, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/255,634; titled:.“Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Mar. 1, 2016.;;Notice of Allowance for U.S. Appl. No. 14/464,432, “Method of Lowering Blood Glucose”, dated May 16, 2016.;;Cellitti, Susan E., et al., “In vivo incorporation of Unnatural Amino Acids to Probe Structure, Dynamics, and Ligand Binding in a Large Protein by Nuclear Magnetic Resonance Spectroscopy”, J. Am. Chem. 130: 9266-9281 (2008).;;Deshmukh, G.D., et al., “Abnormalities of glycosphingolipid, sulfatide, and ceramide in the Polycystic (cpk/cpk) mouse”, Journal of Lipid Research, 35: 1611-1618 (1994).;;Extended European Search Report for European Application No. EP 15 16 2842, “Methods of Treating Fatty Liver Disease”, Date of completion: Jul. 24, 2015.;;Gennaro, et al., Remington, The Science and Practice of Pharmacy, Chapter 38, 20th Edition, 2000, pp. 703-712.;;GRCEVSKA L, POLENAKOVIC M, PETRUSEVSKA G: ""TREATMENT WITH STEROIDS AND CYCLOPHOSPHAMIDE IN COLLAPSING GLOMERULOPATHY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS-COMPARATIVE STUDY"", NEPHROLOGY DIALYSIS TRANSPLANTATION., OXFORD UNIVERSITY PRESS., GB, vol. 15, no. 09, 1 September 2000 (2000-09-01), GB, pages A89, XP008047905, ISSN: 0931-0509;;Huynh-Do, U., “Membranuous nephropathy: Pathogenesis, diagnostics and current treatment”, Der Nephrologe; Zeitschrift Für Nephrologie Und Hypertensiologie, Springer, Berlin, DE, 2(1): 20-26 (Jan. 1, 2007).;;Klein, M., et al., “Cyclosporine Treatment of Glomerular Diseases”, Annu. Rev. Med, 17 pgs. (Feb. 1, 1999).;;Mok, C., et al., “Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide”, American Journal of Medicine, 119(4):355e.25-355e33 (Apr. 1, 2006).;;Nilsson, O., et al., “The Occurrence of Psychosing and Other Glycolipids in Spleen and Liver From the Three Major Types of Gaucher's Disease”, Biochimica et Biophysica Acta, 712 (1982) 453-463.;;van Meer, G., et al., “The fate and function of glycosphingolipid glucosylceramide”, Phil. Trans. R. Soc. Lond. B (2003) 358, 869-873.;;Yatsu, F..M., “Sphingolipidoses”, California Medicine, The Western Journal of Medicine, pp. 1-6 (Apr. 1971).;;Final Office Action for U.S. Appl. No. 12/227,076, dated Mar. 20, 2012, “Methods of Treating Fatty Liver Disease”.;;Non-Final Office Action for U.S. Appl. No. 12/227,076 mailed on Nov. 23, 2011, “Methods of Treating Fatty Liver Disease”.;;Non-Final Office Action for U.S. Appl. No. 12/681,291 dated Dec. 10, 2012, “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives”.;;Non-Final Office Action for U.S. Appl. No. 13/122,135, titled “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” mailed on Apr. 27, 2012.;;Non-Final Office Action for U.S. Appl. No. 13/595,251, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Nov. 19, 2014.;;Non-Final Office for U.S. Appl. No. 12/681,291, titled “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives”, dated: Oct. 18, 2013.;;Non-Final Office for U.S. Appl. No. 13/193,990, titled “Method of Treating Diabetes Mellitus”, dated: Feb. 20, 2014.;;Non-Final Office for U.S. Appl. No. 13/595,349, titled “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated: Dec. 19, 2013.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 11/667,224, “Method of Treating Diabetes Mellitus”; Date Mailed: Apr. 22, 2011.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Oct. 9, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Jun. 4, 2013.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Dec. 23, 2013.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/601,871; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Aug. 9, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/681,291; titled: “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” Date Mailed: Aug. 4, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/055,036; titled: “Glucosylccramidc Synthasc Inhibition for the Trcatmcnt of Collapsing Glomcrulopathy and Other Glomerular Disease” Date Mailed: Oct. 31, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/122,135; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Aug. 1, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/595,349; titled: 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors Date Mailed: Sep. 10, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/762,102; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Jan. 9, 2014.;;Office Action dated Mar. 29, 2012 for U.S. Appl. No. 12/601,871, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”.;;Office Action dated May 28, 2013 for U.S. Appl. No. 13/762,102; titled: “Glucosylccramidc Synthasc Inhibition for the Trcatmcnt of Collapsing Glomcrulopathy and Other Glomerular Disease”.;;Office Action for U.S. Appl. No. 12/601,871 dated Sep. 21, 2011, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”.;;Abdel-Magid, A., et al., “Metal-Assisted Aldol Condensation of Chiral a-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Synthesis1,”J. Am. Chem Soc., 108: 4595-4602 (1986).;;Abe, A., et al., “Improved Inhibitors of Glucosylceramide Synthasel,” J. Biochem., 111: 191-196 (1992).;;Abe, A., et al., “Induction of glucosylceramide synthase by synthase inhibitors and ccramidc,” Biochimics Biophysica Acta, 1299: 333-341 (1996).;;Abe, A., et al., “Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C,” Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., “Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation”, J. Clin Invest. 105(11): 1563-1571, Jun. 2000.;;Abe, A., et al., “Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,” J. Lipid Research, 36: 611-621 (1995).;;Abe, A., et al., “Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for d-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthasc Inhibitors”, Analytical Biochemistry, vol. 287, pp. 344-347 (2000).;;Adams, L.A., et al. “Nonalcoholic fatty liver disease”, CMAJ, 172(7):899-905 (2005).;;CHEMICAL ABSTRACTS, 1 January 1956, Columbus, Ohio, US; ALBERTI CARLO GIUSEPPE: ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"" XP002495477;;Alker, D., et al., “Application of Enantiopure Templated Azomethine Ylids to β-Hydroxyaa-amino Acid Synthesis,” Tetrahedron: Asymmetry, 54: 6089-6098 (1998).;;Alon, R., et al., “Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions1,” J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., “Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,” Methods Enzymol., 8: 115-118 (1996).;;Asano, N., “Glycosidase Inhibitors: update and perspectives on practical use”, Glycobiology, 13(10):93R-104R (2003).;;Belikov, V.G., “Pharmaceutical Chemistry, Moscow”, Vysshaya Shkola Publishers, pp. 43-47 (1993).;;Bielawska, A., et al.., “Ceramide-mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,” J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., “Modulation of cell growth and differentiation by ceramide,” FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., “Regulation of protein kinase C and its role in cancer biology,” Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al., “Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,” Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No. 1985:221199, Keith McCullagh, et al., “Carboxyalkyl peptide derivatives.”;;Carson, K.G., et al., “Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,” Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Chatterjee, S., et al.,“ Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation”, Glycobiology, 6(3): 303-311, 1996.;;Chatterjee, S., et al.,“Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease”, Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Clark, J.M., et al., “Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogcnic Cirrhosis”, JAMA 289(22): 3000-3004 (2003).;;Comuzzie, A.G., et al., “The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity”, Obesity Research, 11(1):75-80 (2003).;;Dellaria, Jr., J.F., et al., “Enantioselective Synthesis of a-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycinc Enolatc Synthon1,” J. Org. Chem., 54: 3916-3926 (1989).;;Dickic, P., ct al., “HIV-Associatcd Ncphropathy in Transgcnic Micc Expressing HIV-1 Genes,” Virology, 185:109-119, 1991.;;Dittert, L.W., et al., “Acetaminophen Prodrugs I—Synthesis, Physicochemical Properties and Analgesic Activity”, J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Elbein, A.D., “Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing” The FASEB Journal, 5: 3055-3063 (1991).;;European Search Report for EP Patent Application No. 12007327.5, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” dated Apr. 11, 2013.;;European Search Report, European Application No. 09003291.3 Apr. 29, 2009.;;European Search Report, European Application No. 13154949.5, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 12, 2013.;;European Search Report, European Application No. 13154955.2, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 10, 2013.;;European Search Report, European Application No. 13154967.7, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 18, 2013.;;European Search Report, European Application No. 13154970.1, “2-Acylaminopropoanol-Type Glucosylceramide Synthesis Inhibitors” dated Jul. 10, 2013.;;Evans, D.A., et al., “Stereoselective Aldol Condensations Via Boron Enolates1,” J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Fan, J-G., et al., “Preventie Effects of Metformin on Rats with nonalcoholic steatohepatitis”, Hepatology, 34(4)(1), p. 501A (2003).;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., “Asymmetric Cycloadditions of Aldehydes to Stabilised Azomcthinc Ylids: Enantiocontrollcd Construction of β-Hydroxy-a-amino acid Derivitives,” Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;Harwood, L.M., et al., “Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,” Chem. Commun., 2641-2642 (1998).;;Högberg, T., et al., “Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists.” In Textbook of Drug Design and Development, pp. 55-91 (1991).;;Hospattankar, A.V., et al., “Changes in Liver Lipids After Administration of 2-Decanoylamino-3-Morpholinopropiophcnonc and Chlorpromazinc,” Lipids, 17(8): 538-543 (1982).;;Husain, A., and Gancm, B., “syn-Selective additions to Garncr aldchydc: synthcsis of a potent glucosylceramide synthase inhibitor”, Tetrahedron Letters, 43: 8621-8623 (2002).;;Inokuchi, et al., “Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,” Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;CHEMICAL ABSTRACTS, 22 December 1998, Columbus, Ohio, US; INOKUCHI KIMIKAZU ET AL: ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"" XP002495476;;Inokuchi, J. et al., “Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis,” Cancer Lett., 38:23-30(1987).;;Inokuchi, J., et al., “Preparation of the Active Isomer of 1-pheny1-2-decanoylamino-3-morpholino-1-propanol, Inhibitor of Murine Clucocerebroside Synthetase,” Journal of Lipid Research, 28: 565-571 (1987).;;Inokuchi, J., et al., “Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action1”, Cancer Research, 50: 6731-6737 (Oct. 15, 1990).;;International Preliminary Examination Report for International Application No. PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransfcrasc Inhibitors” dated Jul. 24, 2003.;;International Preliminary Examination Report on Patentability, issued in International Application PCT/US2000/18935, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Jul. 20, 2001.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/006906, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Dec. 10, 2009.;;International Preliminary Report on Patentability for International Application No. PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors” dated Jul. 24, 2003.;;International Preliminary Report on Patentability for International Application No. PCT//US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 11, 2008.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773, “Method of Trcating Lupus With Ccramidc Dcrivativcs” datcd Sep. 21, 2010.;;Intcrnational Prcliminary Rcport on Patcntability for Intcrnational Application No. PCT/US2009/051864, “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases” dated Feb. 1, 2011.;;International Preliminary Report on Patentability, issued in International Application PCT/US2005/040596, “Methods of Treating Diabetes Mellitus”, dated May 15, 2007 (14 pages).;;International Preliminary Report on Patentability, issued in International Application PCT/US2002/00808, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Jan. 10, 2003.;;International Report on Patentability for International Application PCT/US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 11, 2008 with Written Opinion.;;International Search Report for International Application No. PCT/US2000/18935, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Nov. 28, 2000.;;International Search Report for PCT/US2002/00808, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Oct. 1, 2002.;;International Search Report for PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors” dated Nov. 5, 2002.;;Jaffrézou, Jr., et al., “Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance,” Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Jankowski, K., “Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion”, Microchem. J., 70:41-49, 2001.;;Jimbo, M., et al., “Development of a New Inhibitor of Glucosylceramide Synthase”, J. Biochem, 127: 485-491 (2000).;;Kabayama, K., et al., “TNFa-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement in ganglioside GM3”, Glycobiology, 15(1): 21-29 (2005).;;Kalén, A., et al., “Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,” Biochimica et Biophysica Acta, 1125: 90-96 (1992).;;Kharkevich, D.A., “Pharmacology”, M., Medicament, 47-48 (1987).;;Koga, K., and Yamada, S., “Stereochemical Studies. X. Effects of Neighboring Functional Groups on 1,2-Asymmctric Induction in the Rcduction of Propiophcnonc Dcrivativcs with Sodium Borohydride”, Chemical and Pharmaceutical Bulletin, 20(3): 526-538 (1972).;;Kopaczyk, K., C., et al., “In Vivo Convcrsions of Ccrcbrosidc and Ccramidc in Rat Brain,” J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., “C-Labeling of novel Atypical β-Adrenoceptor Agonist, SM-11044,” Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Lee, L., et al.“Improved inhibitors of glucosylceramide synthase”, J. Bio Chem., 274(21): 14662-14669, 1999.;;Levery, S.B., et al., “Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc:ceramide glucosyltransfcrasc strongly affccts sporc gcrmination, ccll cyclc, and hyphal growth”, FEBS Letters, vol. 525, pp. 59-64 (2002).;;Masson, E., et al.“a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation: A Common Mediator for Retinol and Renal Microangiopathy?” Diabetes, 54: 220-227 (2005).;;Mitchell, S., et al., “Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,” J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., “Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase”, Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Nakamura, K., et al., “Coomassic Brilliant Bluc Staining of Lipids on Thin-Layer Platcs,” Anal. Biochem., 142: 406-410 (1984).;;Natoli, T.A., et al., “Inhibition of glucosylceramide accumulation results in effective blockade of polysystic kidney disease in mouse models” and supplemental information, Nature Medicine, 16(7): 788-792 (Jul. 2010).;;Nicolaou, K., et al., “A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),” J. Am. Chem., Soc., 110: 7910-7912 (1988).;;NICOLAUS B J R: ""SYMBIOTIC APPROACH TO DRUG DESIGN"", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), XX, pages 173 - 186, XP001111439;;Nishida, A., et al., “Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl-2-palmitoylamino-3-morpholino-l-propanol (PPMP) from L-Serine,” Synlett, 389-390(1998).;;Nojiri, H., et al., “Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937”, Proc. Natl. Acad. Sci., 83: 782-786 (1986).;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/005435, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Apr. 14, 2011.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/006906 “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated Dec. 4, 2008.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration of International Application No. PCT/US2008/011450, “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives”, dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/001773, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/051864, “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases” dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/005435, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Feb. 12, 2010.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 21, 2007.;;Ogawa, S., et al., “Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)-β-Valienamine, and Related Compounds,” Bioorganic & Mcdicinal Chcmistry Lcttcrs, 7(14): 1915-1920 (1997).;;Ong, et al., “Nonalcoholic Fatty Liver Disease and the epidemic of Obesity”, Cleveland Clinic Journal of Medicine, 71(8): 657-664 (Aug. 2004).;;Overkleeft, H.S., et al., “Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,” The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al., “Quantitative Measurement of sn-1,2-Diacylglycerols Present in Platelets, Hepatocytes, and ras- and sis-Transformcd Normal Rat Kidncy Cclls,” J. Biol.Chcm., 261(19): 8597-8600 (1986).;;Qian, Q., ct al., “Trcatmcnt prospccts for autosomal-dominant polysystic kidncy discasc”, Kidney International, vol. 59, pp. 2005-2002 (2001).;;Radin, N.S., “Killing Cancer Cells by Poly-drug elevation of ceramide levels, a hypothesis whose time has come?,” Eur. J. Biochem. (268(2): 193-204 (2001).;;Radin, N.S., et al., “Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances.” Advances in Lipid Research: Sphingolipids, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., “Ultrasonic Baths as Substitutes for Shaking Incubator Baths,” Enzyme, 45: 567-70(1991).;;Radin, N.S., et al., “Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,” in NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenwald, A.G., et al., “Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,” Biochemistry, 31: 3581-3590 (1992).;;Rosenwald, A.G., et al., “Effects of the glucosphingolipid synthesis inhibitor, PDMP, on lysosomes in cultured cells,” J. Lipid Res., 35: 1232-1240 (1994).;;Rubino, MD., F., et al., “Letter to the Editor”, Annals of Surgery, 240(2):389-390 (2004).;;Sandhoff, K., et al., “Biosynthesis and degradation of mammalian glycosphingolipids” Phil. Trans. R. Soc. Lond, B 358 :847-861 (2003).;;Sasaki, A., et al., “Overexpression of Plasma Membrane-associated Sialidase Attentuates Insulin Signaling in Transgenic Mice”, The Journal of Biological Chemistry, 278(30):27896-27902 (2003).;;Schwimmer, J.B., et al., “Obesity, Insulin Resistance, and and Other Clinicopathological Correlates of Pediatric Nonalcoholic Fatty Liver Disease”, Journal of Pediatrics, 143(4): 500-505 (2003).;;Shayman, J.A., et al., “Glucosphingolipid Dependence of Hormone-Stimulated Inositol Trisphophate Formation,” J. Biol. Chem., 265(21): 12135-12138 (1990).;;Shayman, J.A., et al., “Modulation of Renal Epithelial Cell Growth by Glucosylceramide,” The Journal of Biological Chemistry, 266(34):22968-22974 (1991).;;Shukla, A., et al., “Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis and the synergistic action of an inhibitor of microsomal monooxygenase,” J. of Lipid Research, 32: 713-722 (1991).;;Shukla, G., et al., “Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor,” Biochimica et Biophysica Acta, 1083: 101-108 (1991).;;Shukla, G.S., et al., “Glucosylceramide Synthase of Mouse Kidney: Further Charactcrization with an Improved Assay Mcthod1,” Arch. Biochem. Biophys., 283(2): 372-378 (1990).;;Skchan, P., ct al., “New Colorimctric Cytotoxicity Assay for Anticanccr-Drug Scrccning,” J. Natl. Cancer Inst., 82(13): 1107-1112 (1990).;;Strum, J.C., et al., “1-β-D-Arabinofuranosylcytosine Stimulates Ceramide and Diglyceride Formation in HL-60-Cells,” J. Biol. Chem., 269(22): 15493-15497 (1994).;;Svensson, M., et al., “Epithelial Glucosphingolipid Express as a Determinant of Bacterial Adherence and Cytokine Production”, Infection and Immunity, 62(10): 4404-4410 (1994).;;Tagami, S., et al., “Ganglioside GM3 Participates in the Pathological Conditions of Insulin Resistance”, The Journal of Biological Chemistry, 227(5): 3085-3092 (2002).;;Tang, W., et al., “Phorbol Ester Inhibits 13-Cis-Retinoic Acid-Induced Hydrolysis of Phosphatidylinositol 4,5-Biophosphate in Cultured Murine Keratinocytes: A Possible Negative Feedback Via Protein Kinase C-Activation,” Cell Bioch. Funct., 9: 183-191 (1991).;;Tay-Sachs, URL: http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm. National Institute of Health of Neurological Disorders and Stroke. Accessed online Sep. 9, 2011.;;Uemura, K., et al., “Effect of an Inhibitor of Glucosylceramide Synthesis on Cultured Rabbit Skin Fibroblasts,” J. Biochem., (Tokyo) 108(4): 525-530 (1990).;;Vunnum, R.,R., et al., “Analogs of Ceramide That Inhibit Glucocerebroside Synthetase in Mouse Brain,” Chemistry and Physics of Lipids, LD. Bergelson, et al., Eds. (Elsevier/North-Holland Scientific Publishers Ltd.), 26: 265-278 (1980).;;Wermuth, C.G., et al.., “Designing Prodrug and Bioprecursors I: Carrier Prodrug”, The Practice of Medicinal Chemistry, C.G., Wermuth, Ed.(CA: Academic Press Limited), pp. 671-696 (1996).;;Wong, C-H., et al., “Synthesis and Evaluation of Homoazasugars as Glycosidase Inhibitors,” J. Org. Chem., 60: 1492-1501, (1995).;;Yamashita, T., et al., “Enhanced insulin sensitivity in mice lacking ganglioside GM3”, Proc. Natl. Acad. Scl., 100(6): 3445-3449 (2003).;;Yew, N.S., et al., “Increased Hepatic Insulin Action in Diet-Induced Obese Mice Following Inhibition of Glucosylceramide Synthase” PLoS one, 5(6): 1-9 (Jun. 2010).;;Zador, I., et al. “A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus”, J. Clin. Invest., 91: 797-803 (1993).;;Zhao, H., et al., “Inhibiting Glycosphingolipid Synthesis Ameliorates Hepatic Steatosis in Obese Mice” Hepatology, pp. 85-93 (Jul. 2009)).;;Zhao, H., et al., “Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.” Diabetes, 56(5): 1210-1218 (2007).;;Ziche, M. et al., “Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3 :GD3 Ganglioside Ratio,” Lab. Invest., 67:711-715 (1992).;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/255,634; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Jun. 7, 2016.;;Notice of Allowance for U.S. Appl. No. 14/464,432, “Method of Lowering Blood Glucose”, dated Aug. 15, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/247,732; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Sep. 20, 2016.;;EP Search Report for EP Application No. EP 16 16 2074; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, Date of Mailing: Sep. 12, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,432; titled: “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives” Date Mailed: Oct. 25, 2016.;;Non-Final Office Action for U.S. Appl. No. 15/003,207, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Nov. 1, 2016.",INACTIVE
98,AR,A1,AR 066817 A1,138-780-735-349-09X,2009-09-16,2009,AR P080102322 A,2008-06-02,US 99784607 P;;US 93237007 P,2007-05-31,INHIBIDORES DE LA GLUCOSILCERAMIDA SINTASA DEL TIPO 2-ACILAMINOPROPANOL,"Un compuesto representado por la formula estructural (1), o una sal farmacéuticamente aceptable de ésta. Una composicion farmacéutica comprende un compuesto representado por la formula estructural (1) o una sal farmacéuticamente aceptable de ésta. Un método para tratar a un sujeto que lo necesita comprende suministrar al sujeto una cantidad terapéuticamente efectiva de un compuesto representado por la formula estructural (1) o una sal farmacéuticamente aceptable de ésta. El sujeto tiene diabetes tipo 2; hipertrofia renal o hiperplasia asociada con neuropatía diabética; enfermedades Tay-Sachs; de Gaucher; y de Fabry. Los métodos para disminuir TNF-alfa de plasma, reducir niveles de glucosa en la sangre, disminuir niveles de hemoglobina glicosilada, inhibir la glucosilceramida sintasa y reducir concentraciones de glicoesfingolípidos en un sujeto que lo necesita comprenden respectivamente suministrar al sujeto una cantidad terapéuticamente efectiva de un compuesto representado por la formula estructural (1) o una sal farmacéuticamente aceptable de ésta. Reivindicacion 1: Un compuesto representado por la siguiente formula estructural (1), o una de sus sales aceptables desde el punto de vista farmacéutico, en los cuales: R1 es un grupo arilo sustituido o no sustituido; Y es -H, un grupo hidrolizable, o un grupo alquilo sustituido o no suslituido; R2 y R3 son, cada uno en forma independiente, H, un grupo alifático sustituido o no sustituido, o un grupo arilo sustituido o no sustituido, o R2 y R3 tomados junto con el átomo de nitrogeno de N(R2R3) forman un anillo heterocíclico no aromático sustituido o no sustituido; y X es -(CR5R6)n-Q-; Q es-O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, o -NR7SO3-; y R4 es -H, un grupo alifático sustituido o no sustituido, o un grupo arilo sustituido o no sustituido; o X es -O-, -S- o -NR7-; y R4 es un grupo alifático sustituido o no sustituido, o grupo arilo sustituido o no sustituido; o X es -(CR5R6)n-; y R4 es un grupo alquilo cíclico sustituido o no sustituido, o un grupo alquenilo cíclico sustituido o no sustituido, un grupo arilo sustituido o no sustituido, -CN, -NCS, -NO2, o un halogeno; o X es un enlace covalente; y R4 es un grupo arilo sustituido o no sustituido; y R5 y R6 son, cada uno en forma independiente, -H, -OH, -SH, un halogeno, un grupo alcoxi inferior sustituido o no sustituido, un grupo alquiltio inferior sustituido o no sustituido, o un grupo alifático inferior sustituido o no sustituido; n es 1, 2, 3, 4, 5 o 6; y cada R7 es, en forma independiente, -H, un grupo alifático sustituido o no sustituido, o un grupo arilo sustituido o no sustituido, o R7 y R4 tomados junto con el átomo de nitrogeno de NR7R4 forman un grupo heterocíclico no aromático sustituido o no sustituido.",GENZYME CORP,LEVINE MIKAELA;;KANE JOHN;;SIEGEL CRAIG;;HARRIS DAVID J;;BASTOS CECILIA M;;VINICK FREDERIC;;CUFF LISA M;;LEE THOMAS;;DIOS ANGELES;;SILVA FILHO LUIZ ROSA;;CELATKA CASSANDRA;;JOZEEFLAK THOMAS;;XIANG YIBIN;;LIAO JUNKAI,,https://lens.org/138-780-735-349-09X,Patent Application,no,0,0,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,,,0,0,,,,ACTIVE
99,US,A1,US 2011/0184021 A1,180-831-873-143-76X,2011-07-28,2011,US 200913122135 A,2009-10-02,US 200913122135 A;;US 10254108 P;;US 2009/0005435 W,2008-10-03,2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/180-831-873-143-76X,Patent Application,yes,64,22,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/453;;A61K31/40;;A61K31/4025;;A61K31/422;;A61K31/428;;A61K31/4439;;A61P13/12,514/321;;514/428;;514/422;;514/338;;514/378;;514/367,0,0,,,,INACTIVE
100,EP,A1,EP 3078373 A1,011-624-252-329-633,2016-10-12,2016,EP 16162074 A,2009-10-02,US 10254108 P;;EP 09741487 A,2008-10-03,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR,"A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
 ",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILLA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/011-624-252-329-633,Patent Application,yes,16,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;A61P13/12;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,18,11,101-441-717-112-268;;013-186-690-689-175;;037-256-760-224-384;;009-542-128-522-566;;102-509-495-349-845;;100-005-886-323-421;;047-458-832-757-760;;018-291-712-488-427;;096-617-488-485-139;;024-919-860-416-474;;074-979-551-686-305,10.1016/s0022-2275(20)39163-x;;8808768;;8724138;;10.1093/glycob/6.3.303;;17470562;;10.2337/db06-0719;;11707432;;10.1074/jbc.m103705200;;pmc152312;;10.1073/pnas.0635898100;;12629211;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;1820092;;2145065;;1281244;;12529488;;10.1038/oby.2003.12;;10.1111/j.1464-5491.2004.01225.x;;15209770,"CHATTERJEE, S.; SHI, W.Y.; WILSON, P.; MAZUMDAR,A.: ""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", JOURNAL OF LIPID RESEARCH, vol. 37, 1996, pages 1334 - 1344, XP002562795;;CHATTERJEE S ET AL: ""OXIDIZED LOW DENSITY LIPOPROTEIN STIMULATES AORTIC SMOOTH MUSCLE CELL PROLIFERATION"", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 6, no. 3, 1 January 1996 (1996-01-01), pages 303 - 311, XP009028471, ISSN: 0959-6658;;ZHAO HONGMEI ET AL: ""Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes"", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 56, no. 5, 1 May 2007 (2007-05-01), pages 1210 - 1218, XP002508439, ISSN: 0012-1797;;NOJRI ET AL., PROC. NATL. ACAD. SCL USA, vol. 83, 1986, pages 782;;YAMASHITA ET AL., PROC. NATL. ACAD. SCL USA, vol. 100, no. 6, 2003, pages 3445;;TAGAMI, J. BIOL. CHEM., vol. 277, no. 5, 2002, pages 3085;;YAMASHITA ET AL., PROC. NATL. ACAD. SC. USA, vol. 100, 2003, pages 3445 - 3449;;SVENSSON, M ET AL.: ""Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production"", INFECT, AND IMMUN., vol. 62, 1994, pages 4404 - 4410;;INOKUCHI, J. ET AL.: ""Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis"", CANCER LETT., vol. 38, 1987, pages 23 - 30;;HAKOMORI, S: ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy"", CANCER CELLS, vol. 3, 1991, pages 461 - 470;;INOKUCHI, J. ET AL.: ""Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action"", CANCER RES., vol. 50, 1990, pages 6731 - 6737, XP008103809;;ZICHE, M. ET AL.: ""Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio"", LAB. INVEST., vol. 67, 1992, pages 711 - 715, XP002918640;;COMUZZIE ET AL., OBES. RES., vol. 11, no. 1, 2003, pages 75;;RUBINO ET AL., ANN. SURG., vol. 240, no. 2, 2004, pages 389;;GILL-RANDALL ET AL., DIABET. MED., vol. 21, no. 7, 2004, pages 759;;FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, vol. 50, no. 4, 1996, pages 219;;""Handbook of Pharmaceutical Excipients 5th Ed.,"", 2005, PHARMACEUTICAL PRESS;;GENNARO: ""Remington's Pharmaceutical Sciences, 18th ed."", 1990",DISCONTINUED
101,US,B2,US 9744153 B2,149-010-487-074-266,2017-08-29,2017,US 201615003207 A,2016-01-21,US 201615003207 A;;US 201213595251 A;;US 201113122135 A;;US 2009/0005435 W;;US 10254108 P,2008-10-03,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/149-010-487-074-266,Granted Patent,yes,139,1,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12,,175,88,087-720-399-410-986;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;099-417-575-155-106;;019-168-888-620-949;;009-735-754-008-354;;007-195-876-506-733;;036-519-046-514-216;;060-285-756-774-11X;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;101-441-717-112-268;;013-186-690-689-175;;058-000-601-334-562;;024-919-860-416-474;;008-960-930-558-465;;027-757-703-898-799;;003-994-644-386-459;;006-530-492-820-511;;004-197-046-964-508;;103-843-422-810-071;;061-607-931-932-732;;005-316-633-999-516;;013-129-766-729-356;;111-509-011-354-346;;058-392-587-867-500;;000-981-111-711-659;;031-125-860-040-891;;082-544-376-300-192;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;036-669-847-776-367;;025-913-184-941-642;;011-301-633-602-65X;;012-374-430-412-462;;094-645-762-447-043;;069-903-420-503-60X;;010-215-744-161-837;;006-806-427-104-062;;131-172-531-021-398;;038-420-412-060-975;;048-359-395-870-441;;035-017-124-510-530;;032-507-877-332-372;;053-135-256-880-410;;145-399-125-974-761;;120-463-739-961-857;;084-596-711-500-19X;;014-153-260-613-491;;089-212-206-875-704;;019-772-803-841-699;;022-861-665-824-921;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;047-142-399-168-373;;003-652-677-788-251;;057-382-993-877-418;;011-812-030-137-650;;009-082-755-322-366;;078-857-409-314-797;;005-002-282-762-215;;013-092-512-192-775;;038-253-278-873-477;;013-863-667-338-436;;010-213-588-950-017;;100-005-886-323-421;;009-542-128-522-566;;015-233-440-103-014;;102-509-495-349-845;;002-423-422-743-881;;020-114-708-399-776;;006-772-308-047-402;;113-967-182-481-72X;;095-564-866-172-621;;009-997-959-779-435;;037-256-760-224-384;;096-617-488-485-139;;127-453-640-205-029;;056-195-211-698-993;;029-165-542-494-403;;048-202-794-038-729,10.1172/jci9711;;10841515;;pmc300859;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;7775872;;10.1016/s0022-2275(20)39895-3;;10.1021/ja00275a054;;15795412;;10.1503/cmaj.045232;;pmc554876;;7537307;;10.1016/0076-6879(66)08014-5;;12851286;;10.1093/glycob/cwg090;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;10.1016/s0022-2275(20)39163-x;;8808768;;8724138;;10.1093/glycob/6.3.303;;10.1001/jama.289.22.3000;;12799409;;12529488;;10.1038/oby.2003.12;;10.1021/jo00277a032;;10.1016/0042-6822(91)90759-5;;1926769;;10.1002/jps.2600570510;;5657533;;10.1016/s0022-2275(20)41159-9;;7806975;;1743438;;10.1096/fasebj.5.15.1743438;;10.1021/ja00401a031;;10.1021/bi00478a028;;2207076;;13428781;;10.1016/s0021-9258(18)64849-5;;4957125;;10.1039/a807471b;;10.1007/bf02535381;;10.1016/s0040-4039(02)02096-8;;10.1007/s11560-006-0052-0;;3690511;;10.1016/0304-3835(87)90196-0;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/s0026-265x(01)00097-2;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;15306563;;10.1093/glycob/cwh135;;10.1016/0005-2760(92)90160-w;;1567913;;10.1248/cpb.20.526;;10.1016/s0022-2275(20)39651-6;;14280461;;10329660;;10.1074/jbc.274.21.14662;;12163162;;10.1016/s0014-5793(02)03067-3;;10.2337/diabetes.54.1.220;;15616032;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;16564783;;10.1016/j.amjmed.2005.08.045;;10.1016/0003-2697(84)90484-6;;6084960;;pmc3660226;;10.1038/nm.2171;;20562878;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.3949/ccjm.71.8.657;;15449761;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;10.1016/s0022-2275(20)39966-1;;7964184;;1567816;;10.1021/bi00129a005;;10.1098/rstb.2003.1265;;pmc1693173;;12803917;;12730204;;10.1074/jbc.m212200200;;10.1067/s0022-3476(03)00325-1;;14571229;;10.1016/s0021-9258(19)38320-6;;2142685;;1744091;;10.1016/s0021-9258(18)54449-5;;10.1016/s0022-2275(20)42059-0;;1856614;;2148864;;10.1016/0003-9861(90)90657-k;;10.1016/0005-2760(91)90130-a;;1827738;;10.1093/jnci/82.13.1107;;2359136;;10.1128/iai.62.10.4404-4410.1994;;pmc303123;;7927702;;11707432;;10.1074/jbc.m103705200;;10.1002/cbf.290090306;;1661208;;pmc152312;;10.1073/pnas.0635898100;;12629211;;2149853;;10.1093/oxfordjournals.jbchem.a123236;;10.1016/0009-3084(80)90057-2;;6445239;;10.1021/jo00111a007;;pmc2888613;;10.1371/journal.pone.0011239;;20574539;;pmc288030;;10.1172/jci116299;;8450061;;19444873;;10.1002/hep.22970;;17470562;;10.2337/db06-0719;;1281244;;18576636;;10.1021/ja801602q;;pmc2562865;;7126619;;10.1016/0005-2760(82)90272-7;;10.1098/rstb.2003.1266;;pmc1693184;;12803919;;pmc1501855;;5551302,"Abe, A., et al., “Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation”, J. Clin Invest. 105(11): 1563-1571, Jun. 2000.;;Abe, A., et al., “Improved Inhibitors of Glucosylceramide Synthase1,” J. Biochem., 111: 191-196 (1992).;;Abe, A., et al., “Induction of glucosylceramide synthase by synthase inhibitors and ceramide,” Biochimics Biophysica Acta, 1299: 333-341 (1996).;;Abe, A., et al., “Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C,” Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., “Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,” J. Lipid Research, 36: 611-621 (1995).;;Abe, A., et al., “Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for d-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors”, Analytical Biochemistry, vol. 287, pp. 344-347 (2000).;;Abdel-Magid, A., et al., “Metal-Assisted Aldol Condensation of Chiral a-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Synthesis,” J. Am. Chem Soc., 108: 4595-4602 (1986).;;Adams, L.A., et al. “Nonalcoholic fatty liver disease”, CMAJ, 172(7):899-905 (2005).;;CHEMICAL ABSTRACTS, 1 January 1956, Columbus, Ohio, US; ALBERTI CARLO GIUSEPPE: ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"" XP002495477;;Alker, D., et al., “Application of Enantiopure Templated Azomethine Ylids to β-Hydroxy-a-amino Acid Synthesis,” Tetrahedron: Asymmetry, 54: 6089-6098 (1998).;;Alon, R., et al., “Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,” J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., “Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,” Methods Enzymol., 8: 115-118 (1996).;;Asano, N., “Glycosidase Inhibitors: update and perspectives on practical use”, Glycobiology, 13(10):93R-104R (2003).;;Bielawska, A., et al.., “Ceramide-mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,” J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., “Modulation of cell growth and differentiation by ceramide,” FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., “Regulation of protein kinase C and its role in cancer biology,” Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al.,“Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,” Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No: 1985:221199, Keith McCullagh, et al., “Carboxyalkyl peptide derivatives.”.;;Carson, K.G., et al., “Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,” Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Chatterjee, S., et al.,“Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease”, Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Chatterjee, S., et al.,“Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation”, Glycobiology, 6(3): 303-311, 1996.;;Clark, J.M., et al., “Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis”, JAMA 289(22): 3000-3004 (2003).;;Comuzzie, A.G., et al., “The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity”, Obesity Research, 11(1):75-80 (2003).;;Dellaria, Jr., J.F., et al., “Enantioselective Synthesis of a-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon1,” J. Org. Chem., 54:3916-3926 (1989).;;Dickie, P., et al., “HIV-Associated Nephropathy in Transgenic Mice Expressing HIV-1 Genes,” Virology, 185:109-119, 1991.;;Dittert, L.W., et al., “Acetaminophen Prodrugs I-Synthesis, Physicochemical Properties and Analgesic Activity”, J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Deshmukh, G.D., et al., “Abnormalities of glycosphingolipid, sulfatide, and ceramide in the Polycystic (cpk/cpk)mouse”, Journal of Lipid Research, 35: 1611-1618 1994).;;Elbein, A.D., “Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing” The FASEB Journal, 5: 3055-3063 (1991).;;Evans, D.A., et al., “Stereoselective Aldol Condensations Via Boron Enolates1,” J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Fan, J-G., et al., “Preventie Effects of Metformin on Rats with nonalcoholic steatohepatitis”, Hepatology, 34(4)(1), p. 501A (2003).;;Felding-Habermann, B., et al., “A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosins Synthesis,” Biochemistry, 29: 6314-6322 (1990).;;Folch, J., et al., “A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues”, J. Biol. Chem., 226:497-509, 1956.;;Freireich, E., et al.,“Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hampster, Dog, Monkey, and Man”, Cancer Chemother. Reports 50(4):219 (1996).;;GRCEVSKA L, POLENAKOVIC M, PETRUSEVSKA G: ""TREATMENT WITH STEROIDS AND CYCLOPHOSPHAMIDE IN COLLAPSING GLOMERULOPATHY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS-COMPARATIVE STUDY"", NEPHROLOGY DIALYSIS TRANSPLANTATION., OXFORD UNIVERSITY PRESS., GB, vol. 15, no. 09, 1 September 2000 (2000-09-01), GB, pages A89, XP008047905, ISSN: 0931-0509;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., “Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,” Chem. Commun., 2641-2642 (1998).;;Harwood, L.M., et al., “Asymmetric Cycloadditions of Aldehydes to Stabilised Azomethine Ylids: Enantiocontrolled Construction of β-Hydroxy-a-amino acid Derivitives,” Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;Högberg, T., et al., “Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists.” In Textbook of Drug Design and Development, pp. 55-91 (1991).;;Hospattankar, A.V., et al.,“Changes in Liver Lipids After Administration of 2- Decanoylamino-3-Morpholinopropiophenone and Chlorpromazine,” Lipids, 17(8): 538-543 (1982).;;Husain, A., and Ganem, B., “syn-Selective additions to Garner aldehyde: synthesis of a potent glucosylceramide synthase inhibitor”, Tetrahedron Letters, 43: 8621-8623 (2002).;;Huynh-Do, U., “Membranuous nephropathy: Pathogenesis, diagnostics and current treatment”, Der Nephrologe; Zeitschrift Für Nephrologie Und Hypertensiologie, Springer, Berlin, De, 2(1): 20-26 (Jan. 1, 2007).;;Inokuchi, et al.,“Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,” Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;CHEMICAL ABSTRACTS, 22 December 1998, Columbus, Ohio, US; INOKUCHI KIMIKAZU ET AL: ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"" XP002495476;;Inokuchi, J. et al., “Antitumor Activity via Inhibition of Glycosphingolipid Biosynthesis,” Cancer Lett., 38:23-30(1987).;;Inokuchi, J., et al., “Preparation of the Active Isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, Inhibitor of Murine Clucocerebroside Synthetase,” Journal of Lipid Research, 28: 565-571 (1987).;;Inokuchi, J., et al .,“Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Actions1”, Cancer Research, 50: 6731-6737 (Oct. 15, 1990).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;Jaffrézou, Jr., et al., “Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance,” Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Jankowski, K., “Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion”, Microchem. J., 70:41-49, 2001.;;Jimbo, M., et al., “Development of a New Inhibitor of Glucosylceramide Synthase”, J. Biochem, 127: 485-491 (2000).;;Kabayama, K., et al., “TNFa-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement in ganglioside GM3”, Glycobiology, 15(1): 21-29 (2005).;;Kalén, A., et al., “Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,” Biochimica et Biophysica Acta, 1125: 90-96 (1992).;;Kharkevich, D.A., “Pharmacology”, M., Medicament, 47-48 (1987).;;Klein, M., et al., “Cyclosporine Treatment of Glomerular Diseases”, Annu. Rev. Med, 17 pgs. (Feb. 1, 1999).;;Koga, K., and Yamada, S., “Stereochemical Studies. X. Effects of Neighboring Functional Groups on 1,2-Asymmetric Induction in the Reduction of Propiophenone Derivatives with Sodium Borohydride”, Chemical and Pharmaceutical Bulletin, 20(3): 526-538 (1972).;;Kopaczyk, K., C., et al., “In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,” J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., “C-Labeling of novel Atypical β-Adrenoceptor Agonist, SM-11044,” Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Lee, L., et al. “Improved inhibitors of glucosylceramide synthase”, J. Bio Chem., 274(21): 14662-14669, 1999.;;Levery, S.B., et al., “Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc:ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth”, FEBS Letters, vol. 525, pp. 59-64 (2002).;;Masson, E., et al. “a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation: A Common Mediator for Retinol and Renal Microangiopathy?” Diabetes, 54: 220-227 (2005).;;Mitchell, S., et al., “Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,” J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., “Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase”, Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Mok, C., et al., “Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide”, American Journal of Medicine, 119(4):355e.25-355e33 (Apr. 1, 2006).;;Nakamura, K., et al., “Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,” Anal. Biochem., 142: 406-410 (1984).;;Natoli, T.A., et al., “Inhibition of glucosylceramide accumulation results in effective blockade of polysystic kidney disease in mouse models” and supplemental information, Nature Medicine, 16(7): 788-792 (Jul. 2010).;;Nicolaou, K., et al., “A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),” J. Am. Chem., Soc., 110: 7910-7912 (1988).;;NICOLAUS B J R: ""SYMBIOTIC APPROACH TO DRUG DESIGN"", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), XX, pages 173 - 186, XP001111439;;Nishida, A., et al ., “Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) from L-Serine,” Synlett, 389-390(1998).;;Nojiri, H., et al., “Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937”, Proc. Natl. Acad. Sci., 83: 782-786 (1986).;;Non-Final Office Action for U.S. Appl. No. 12/227,076 mailed on Nov. 23, 2011.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/601,871; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Aug. 9, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/122,135; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Aug. 1, 2012.;;Office Action dated Mar. 29, 2012 for U.S. Appl. No. 12/601,871.;;Ogawa, S., et al., “Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)-β-Valienamine, and Related Compounds,” Bioorganic & Medicinal Chemistry Letters, 7(14): 1915-1920 (1997).;;Ong, et al., “Nonalcoholic Fatty Liver Disease and the epidemic of Obesity”, Cleveland Clinic Journal of Medicine, 71(8): 657-664 (Aug. 2004).;;Overkleeft, H.S., et al., “Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,” The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al.,“Quantitative Measurement of sn-1,2-Diacylglycerols Present in Platelets, Hepatocytes, and ras-and sis-Transformed Normal Rat Kidney Cells,” J. Biol.Chem., 261(19): 8597-8600 (1986).;;Qian, Q., et al., “Treatment prospects for autosomal-dominant polysystic kidney disease”, Kidney International, vol. 59, pp. 2005-2022 (2001).;;Radin, N.S., “Killing Cancer Cells by Poly-drug elevation of ceramide levels, a hypothesis whose time has come?,” Eur. J. Biochem. (268(2): 193-204 (2001).;;Radin, N.S., et al., “Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances.” Advances in Lipid Research: Sphingolipids, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., “Ultrasonic Baths as Substitutes for Shaking Incubator Baths,” Enzyme, 45: 567-70(1991).;;Radin, N.S., et al., “Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,” In NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenwald, A.G., et al., “Effects of the glucosphingolipid synthesis inhibitor, PDMP, on lysosomes in cultured cells,” J. Lipid Res., 35: 1232-1240 (1994).;;Rosenwald, A.G., et al., “Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,” Biochemistry, 31: 3581-3590 (1992).;;Rubino, MD., F., et al., “Letter to the Editor”, Annals of Surgery, 240(2):389-390 (2004).;;Sandhoff, K., et al., “Biosynthesis and degradation of mammalian glycosphingolipids” Phil. Trans. R. Soc. Lond, B 358 :847-861 (2003).;;Sasaki, A., et al., “Overexpression of Plasma Membrane-associated Sialidase Attentuates Insulin Signaling in Transgenic Mice”, The Journal of Biological Chemistry, 278(30):27896-27902 (2003).;;Schwimmer, J.B., et al., “Obesity, Insulin Resistance, and and Other Clinicopathological Correlates of Pediatric Nonalcoholic Fatty Liver Disease”, Journal of Pediatrics, 143(4): 500-505 (2003).;;Shayman, J.A., et al., “Glucosphingolipid Dependence of Hormone-Stimulated Inositol Trisphophate Formation,” J. Biol. Chem., 265(21): 12135-12138 (1990).;;Shayman, J.A., et al., “Modulation of Renal Epithelial Cell Growth by Glucosylceramide,” The Journal of Biological Chemistry, 266(34):22968-22974 (1991).;;Shukla, A., et al., “Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-propanol, an inhibitor of glucosylceramide synthesis and the synergistic action of an inhibitor of microsomal monooxygenase,” J. of Lipid Research, 32: 713-722 (1991).;;Shukla, G.S., et al., “Glucosylceramide Synthase of Mouse Kidney: Further Characterization with an Improved Assay Method1,” Arch. Biochem. Biophys., 283(2): 372-378 (1990).;;Shukla, G., et al., “Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor,” Biochimica et Biophysica Acta, 1083: 101-108 (1991).;;Skehan, P., et al., “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,” J. Natl. Cancer Inst., 82(13): 1107-1112 (1990).;;Strum, J.C., et al.,“1-β-D-Arabinofuranosylcytosine Stimulates Ceramide and Diglyceride Formation in HL-60- Cells,” J. Biol. Chem., 269(22): 15493-15497 (1994).;;Svensson, M., et al., “Epithelial Glucosphingolipid Express as a Determinant of Bacterial Adherence and Cytokine Production”, Infection and Immunity, 62(10): 4404-4410 (1994).;;Tagami, S., et al., “Ganglioside GM3 Participates in the Pathological Conditions of Insulin Resistance”, The Journal of Biological Chemistry, 227(5): 3085-3092 (2002).;;Tang, W., et al., “Phorbol Ester Inhibits 13-Cis-Retinoic Acid-Induced Hydrolysis of Phosphatidylinositol 4,5-Biophosphate in Cultured Murine Keratinocytes: A Possible Negative Feedback via Protein Kinase C-Activation,”Cell Bioch. Funct., 9: 183-191 (1991).;;Tay-Sachs, URL: http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm. National Institute of Health of Neurological Disorders and Stroke. Accessed online Sep. 9, 2011.;;Yamashita, T., et al., “Enhanced insulin sensitivity in mice lacking ganglioside GM3”, Proc. Natl. Acad. Scl, 100(6): 3445-3449 (2003).;;Uemura, K., et al., “Effect of an Inhibitor of Glucosylceramide Synthesis on Cultured Rabbit Skin Fibroblasts,” J. Biochem., (Tokyo) 108(4): 525-530 (1990).;;Vunnum, R.,R., et al., “Analogs of Ceramide That Inhibit Glucocerebroside Synthetase in Mouse Brain,” Chemistry and Physics of Lipids, LD. Bergelson, et al., Eds. (Elsevier/North-Holland Scientific Publishers Ltd.), 26: 265-278 (1980).;;Wermuth, C.G., et al.., “Designing Prodrug and Bioprecursors I: Carrier Prodrug”, The Practice of Medicinal Chemistry, C.G., Wermuth, Ed.(CA: Academic Press Limited), pp. 671-696 (1996).;;Wong, C-H., et al.,“Synthesis and Evaluation of Homoazasugars as Glycosidase Inhibitors,” J. Org. Chem., 60: 1492-1501, (1995).;;Yew, N. S., et al., “Increased Hepatic Insulin Action in Diet-Induced Obese Mice Following Inhibition of Glucosylceramide Synthase” PLoS one, 5(6): 1-9 (Jun. 2010).;;Zador, I., et al. “A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus”, J. Clin. Invest., 91: 797-803 (1993).;;Zhao, H., et al., “Inhibiting Glycosphingolipid Synthesis Ameliorates Hepatic Steatosis in Obese Mice” Hepatology, pp. 85-93 (Jul. 2009)).;;Zhao, H., et al., “Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.” Diabetes, 56(5): 1210-1218 (2007).;;Ziche, M. et al., “Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3 :GD3 Ganglioside Ratio,” Lab. Invest., 67:711-715 (1992).;;International Preliminary Report on Patentability, issued in International Application PCT/US2005/040596, “Methods of Treating Diabetes Mellitus” dated May 15, 2007 (14 pages).;;International Preliminary Report on Patentability for International Application No. PCT/US2008/006906, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated Dec. 10, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/006906, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated Dec. 4, 2008.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration of International Application No. PCT/US2008/011450, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives”, dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/001773, “Method of Treating Lupus With Ceramide Derivatives”, dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/051864, “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases”, dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration from counterpart International Application No. PCT/US2009/005435, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated Feb. 12, 2010.;;International Search Report for PCT/US2002/00808, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Oct. 1, 2002.;;International Preliminary Report on Patentability, issued in International Application PCT/US2002/00808, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Jan. 10, 2003.;;International Preliminary Examination Report on Patentability, issue in International Application PCT/US2000/18935, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” (WO 01/04108) dated Jul. 20, 2001.;;European Search Report, European Application No. 09003291.3, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyl-Transferase Inhibitors” Apr. 29, 2009 (2478.2001-016).;;International Preliminary Report on Patentability for International Application No. PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors” dated Jul. 24, 2003.;;International Search Report for PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors” dated Nov. 5, 2002.;;European Search Report for EP Patent Application No. 12007327.5, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” dated Apr. 11, 2013.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 21, 2007.;;International Preliminary Report on Patentability for International Application No. PCT//US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 11, 2008.;;International Search Report for International Application No. PCT/US2000/18935, “Amino Ceramide-Like Compounds and Therapeutic Methods of Use” dated Nov. 28, 2000.;;International Preliminary Examination Report for International Application No. PCT/US2002/022659, “Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors” dated Jul. 24, 2003.;;International Report on Patentability for International Application PCT/US2007/068521, “Methods of Treating Fatty Liver Disease” dated Nov. 11, 2008 with Written Opinion.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450, “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773, “Method of Treating Lupus With Ceramide Derivatives” dated Sep. 21, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/051864, “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Diseases” dated Feb. 1, 2011.;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/005435, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Apr. 14, 2011.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 11/667,224; Date Mailed: Apr. 22, 2011.;;Office Action for U.S. Appl. No. 12/601,871 dated Sep. 21, 2011.;;Final Office Action for U.S. Appl. No. 12/227,076 dated Mar. 20, 2012.;;Non-Final Office Action for U.S. Appl. No. 13/122,135, titled “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” mailed on Apr. 27, 2012.;;Non-Final Office Action for U.S. Appl. No. 12/681,291 dated Dec. 10, 2012, “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives”.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Oct. 9, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/055,036; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Oct. 31, 2012.;;Office Action dated May 28, 2013 for U.S. Appl. No. 13/762,102; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease”.;;International Search Report and Written Opinion for PCT/US2005/0405967, mailed Jun. 27, 2006 from the International Searching Authority of the European Patent Office.;;DATABASE WPI 1 January 1900 Derwent World Patents Index; AN 2003-820622, XP002372073, ""Insulin resistance releasing agent useful for treating type II diabetes, hypertension, hyperlipidemia and coronary artery disease, contains 2-acylamino-3-morpholino-1-propanol derivative or its salt"";;Belikov., V.G., “Pharmaceutical Chemistry, Moscow”, Vysshaya Shkola Publishers, pp. 43-47 (1993).;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Jun. 4, 2013.;;European Search Report, European Application No. 13154970.1, “2-Acylaminopropoanol-Type Glucosylceramide Synthesis Inhibitors” dated Jul. 10, 2013.;;European Search Report, European Application No. 13154967.7, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 18, 2013.;;European Search Report, European Application No. 13154949.5, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 12, 2013.;;European Search Report, European Application No. 13154955.2, “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” dated Jul. 10, 2013.;;Non-Final Office for U.S. Appl. No. 12/681,291, titled “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives”, dated: Oct. 18, 2013.;;Non-Final Office for U.S. Appl. No. 13/595,349, titled “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, dated: Dec. 19, 2013.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/227,076; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Dec. 23, 2013.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/762,102; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Jan. 9, 2014.;;Non-Final Office for U.S. Appl. No. 13/193,990, titled “Method of Treating Diabetes Mellitus”, dated: Feb. 20, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/681,291; titled: “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” Date Mailed: Aug. 4, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/595,349; titled: 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors Date Mailed: Sep. 10, 2014.;;Non-Final Office Action for U.S. Appl. No. 13/595,251, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Nov. 19, 2014.;;Final Office Action for U.S. Appl. No. 14/595,251, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Datd Mailed: May 5, 2015.;;Extended European Search Report for European Application No. EP 15 16 2842, “Methods of Treating Fatty Liver Disease”, Date of completion: Jul. 24, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/255,634, titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Aug. 11, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/464,432, titled: “Method of Treating Diabetes Mellitus” Date Mailed: Sep. 9, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/595,251; titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Oct. 21, 2015.;;Non-Final Office Action for U.S. Appl. No. 14/247,732, titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Jan. 25, 2016.;;Non-Final Office Action for U.S. Appl. No. 14/532,432, titled: “Method of Treating Polycystic Kidney Diseases With Ceramide Derivatives” Date Mailed: Jan. 5, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/255,634; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Mar. 1, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/255,634; titled: “Glucosylceramide Synthase Inhibition for the Treatment of Collapsing Glomerulopathy and Other Glomerular Disease” Date Mailed: Jun. 7, 2016.;;Notice of Allowance for U.S. Appl. No. 14/464,432, “Method of Lowering Blood Glucose”, dated May 16, 2016.;;Cellitti, Susan E., et al., “In vivo incorporation of Unnatural Amino Acids to Probe Structure, Dynamics, and Ligand Binding in a Large Protein by Nuclear Magnetic Resonance Spectroscopy”, J. Am. Chem. 130: 9266-9281 (2008).;;Gennaro, et al., Remington, The Science and Practice of Pharmacy, Chapter 38, 20th Edition, 2000, pp. 703-712.;;Nilsson, O., et al., “The Occurrence of Psychosing and Other Glycolipids in Spleen and Liver From the Three Major Types of Gaucher's Disease”, Biochimica et Biophysica Acta, 712 (1982) 453-463.;;van Meer, G., et al., “The fate and function of glycosphingolipid glucosylceramide”, Phil. Trans. R. Soc. Lond. B (2003) 358, 869-873.;;Yatsu, F..M., “Sphingolipidoses”, California Medicine, the Western Journal of Medicine, pp. 1-6 (Apr. 1971).;;EP Search Report for EP Application No. EP 16 16 2074; “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors”, Date of Mailing: Sep. 12, 2016.;;Non-Final Office Action for U.S. Appl. No. 14/571,922, titled: “2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors” Date Mailed: Sep. 20, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/247,732; titled: “Methods of Treating Fatty Liver Disease” Date Mailed: Sep. 20, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,432; titled: “Method of Treating Polycystic Kidney Diseases with Ceramide Derivatives” Date Mailed: Oct. 25, 2016.",INACTIVE
102,US,A1,US 2012/0322787 A1,010-906-099-398-462,2012-12-20,2012,US 201213595349 A,2012-08-27,US 201213595349 A;;US 60187110 A;;US 2008/0006906 W;;US 99784607 P;;US 93237007 P,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/010-906-099-398-462,Patent Application,yes,0,17,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,A61K31/4025;;A61K31/397;;A61K31/422;;A61K31/4245;;A61K31/428;;A61K31/4439;;A61K31/444;;A61K31/5377;;A61P3/10;;A61P13/12;;C07D405/10;;C07D409/14;;C07D413/14;;C07D417/14,514/210.19;;548/526;;514/422;;546/276.4;;514/338;;548/248;;514/378;;548/159;;514/367;;548/131;;514/364;;546/256;;514/333;;544/148;;514/233.8;;548/952,0,0,,,,INACTIVE
103,CA,A1,CA 2738768 A1,008-910-736-987-324,2010-04-08,2010,CA 2738768 A,2009-10-02,US 10254108 P;;US 2009/0005435 W,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/008-910-736-987-324,Patent Application,no,0,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
104,US,B2,US 8309593 B2,056-263-314-486-696,2012-11-13,2012,US 200913122135 A,2009-10-02,US 200913122135 A;;US 10254108 P;;US 2009/0005435 W,2008-10-03,2-acylaminopropoanol-type glucosylceramide synthase inhibitors,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI;;GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/056-263-314-486-696,Granted Patent,yes,99,15,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;A61K31/40,514/408;;514/422,99,68,014-153-260-613-491;;009-082-755-322-366;;019-168-888-620-949;;000-544-436-236-096;;056-218-927-077-884;;077-706-248-391-841;;087-720-399-410-986;;099-417-575-155-106;;009-735-754-008-354;;127-620-706-386-56X;;007-195-876-506-733;;036-519-046-514-216;;060-285-756-774-11X;;041-331-260-907-180;;090-946-420-987-502;;017-197-708-440-773;;061-252-862-655-312;;041-886-228-223-220;;013-186-690-689-175;;101-441-717-112-268;;058-000-601-334-562;;024-919-860-416-474;;008-960-930-558-465;;027-757-703-898-799;;003-994-644-386-459;;004-197-046-964-508;;103-843-422-810-071;;061-607-931-932-732;;005-316-633-999-516;;013-129-766-729-356;;080-009-135-438-214;;074-979-551-686-305;;047-458-832-757-760;;078-712-681-777-54X;;111-509-011-354-346;;058-392-587-867-500;;082-544-376-300-192;;027-026-579-404-886;;018-291-712-488-427;;130-519-703-181-499;;036-669-847-776-367;;025-913-184-941-642;;011-301-633-602-65X;;012-374-430-412-462;;069-903-420-503-60X;;006-912-262-242-73X;;010-215-744-161-837;;131-172-531-021-398;;038-420-412-060-975;;048-359-395-870-441;;032-507-877-332-372;;145-399-125-974-761;;120-463-739-961-857;;084-596-711-500-19X;;056-300-053-225-737;;089-212-206-875-704;;019-772-803-841-699;;093-900-568-861-709;;058-952-556-193-112;;092-792-696-843-968;;111-114-944-877-839;;003-652-677-788-251;;047-142-399-168-373;;057-382-993-877-418;;011-812-030-137-650;;078-857-409-314-797;;005-002-282-762-215;;013-092-512-192-775,10.3949/ccjm.71.8.657;;15449761;;10.1067/s0022-3476(03)00325-1;;14571229;;10.1021/ja00275a054;;10.1093/oxfordjournals.jbchem.a123736;;1533217;;10.1016/0005-2760(95)00217-0;;8597588;;10.1111/j.1432-1033.1992.tb17479.x;;1483461;;10.1172/jci9711;;10841515;;pmc300859;;7775872;;10.1016/s0022-2275(20)39895-3;;15795412;;10.1503/cmaj.045232;;pmc554876;;10.1016/s0040-4020(98)00302-0;;7537307;;10.1016/0076-6879(66)08014-5;;12851286;;10.1093/glycob/cwg090;;10.1016/s0021-9258(19)36989-3;;1526986;;1644175;;10.1016/0014-5793(92)80769-d;;7712599;;10.1007/bf00666107;;4257605;;10.1016/0006-8993(72)90774-3;;10.1016/s0040-4039(00)76999-1;;8724138;;10.1093/glycob/6.3.303;;10.1016/s0022-2275(20)39163-x;;8808768;;10.1001/jama.289.22.3000;;12799409;;12529488;;10.1038/oby.2003.12;;10.1021/jo00277a032;;10.1016/0042-6822(91)90759-5;;1926769;;10.1002/jps.2600570510;;5657533;;1743438;;10.1096/fasebj.5.15.1743438;;10.1021/ja00401a031;;10.1021/bi00478a028;;2207076;;13428781;;10.1016/s0021-9258(18)64849-5;;4957125;;6273689;;10.1016/s0076-6879(81)72026-3;;10.1111/j.1464-5491.2004.01225.x;;15209770;;1820092;;10.1016/s0957-4166(00)82093-5;;10.1039/a807471b;;10.1007/bf02535381;;3690511;;10.1016/0304-3835(87)90196-0;;2955067;;10.1007/bf03026693;;10.1016/s0022-2275(20)38673-9;;2145065;;10.1016/0167-4889(94)00219-5;;7718613;;10.1016/s0026-265x(01)00097-2;;10.1093/oxfordjournals.jbchem.a022631;;10731721;;15306563;;10.1093/glycob/cwh135;;10.1016/0005-2760(92)90160-w;;1567913;;10.1016/s0022-2275(20)39651-6;;14280461;;10.1002/(sici)1099-1344(199603)38:3<285::aid-jlcr836>3.0.co;2-p;;10329660;;10.1074/jbc.274.21.14662;;10.2337/diabetes.54.1.220;;15616032;;10.1021/jo980951j;;10.1016/s0968-0896(98)00077-7;;9801819;;10.1016/0003-2697(84)90484-6;;6084960;;10.1021/ja00231a071;;10.1055/s-1998-3132;;10.1073/pnas.83.3.782;;3456169;;pmc322949;;10.1016/s0960-894x(97)00341-7;;10.1074/jbc.273.41.26522;;9756888;;10.1016/s0021-9258(19)84420-4;;3013856;;11168352;;10.1046/j.1432-1033.2001.01845.x;;10.1046/j.1432-1327.2001.01845.x;;8379450;;1806368;;10.1159/000468867;;10.1006/ncmn.1993.1048;;1567816;;10.1021/bi00129a005;;10.1016/s0022-2275(20)39966-1;;7964184;;10.1098/rstb.2003.1265;;pmc1693173;;12803917;;12730204;;10.1074/jbc.m212200200;;10.1016/s0021-9258(19)38320-6;;2142685;;1744091;;10.1016/s0021-9258(18)54449-5;;10.1016/s0022-2275(20)42059-0;;1856614,"Non-Final Office Action for U.S. Appl. No. 12/227,076 mailed on Nov. 23, 2011.;;Ong, et al., ""Nonalcoholic Fatty Liver Disease and the epidemic of Obesity"", Cleveland Clinic Journal of Medicine, 71(8): 657-664 (Aug. 2004).;;Schwimmer, J.B., et al., ""Obesity, Insulin Resistance, and and Other Clinicopathological Correlates of Pediatric Nonalcoholic Fatty Liver Disease"", Journal of Pediatrics, 143(4): 500-505 (2003).;;Nicolaus, B.J.R., ""Symbiotic Approach to Drug Design"", Decision Making in Drug Research, XP-001111439, p. 1-14 (1983).;;Office Action for U.S. Appl. No. 12/227,076 dated Mar. 20, 2012.;;Abdel-Magid, A., et al., ""Metal-Assisted Aldol Condensation of Chiral alpha-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Syntheses,""J. Am. Chem Soc., 108: 4595-4602 (1986).;;Abe, A., et al., ""Improved Inhibitors of Glucosylceramide Synthase,"" J. Biochem., 111:191-196 (1992).;;Abe, A., et al., ""Induction of Glucosylceramide Synthase by Synthase Inhibitors and Ceramide,"" Biochim. Biophys. Acta, 1299: 333-341 (1996).;;Abe, A., et al., ""Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C,"" Eur. J. Biochem, 210: 765-773 (1992).;;Abe, A., et al., ""Reduction of Globotriasylceramide in Fabry Disease mice by substrate deprivation"", J. Clin Invest. 105(11): 1563-1571, (2000).;;Abe, A., et al., ""Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,"" J. Lipid Research, 36:611-621 (1995).;;Adams, L.A., et al., ""Nonalcoholic Fatty Liver Disease,"" CMAJ, 172(7):899-905 (2005).;;Alberti, C., et al., ""Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols"", Chemical Abstracts Service, XP002495477 retrieved from CAPLUS Database accession No. 1957:17088 (abstract).;;Alker, D., et al., ""Application of Enantiopure Templated Azomethine Ylids to beta-Hydroxy-alpha-amino Acid Syntheses,"" Tetrahedron, 54: 6089-6098 (1998).;;Alon, R., et al., ""Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,"" J. Immunol., 154: 5356-5366 (1995).;;Ames, Bruce N., ""Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,"" Methods Enzymol., 8: 115-118 (1996).;;Asano, N., ""Glycosidase Inhibitors: Update and Perspectives on Practical Use,"" Glycobiology, 13(10):93R-104R (2003).;;Bielawska, A., et al., ""Ceramide-Mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs,"" J. Biol. Chem., 267: 18493-18497 (1992).;;Bielawska, et al., ""Modulation of Cell Growth and Differentiation by Ceramide,"" FEBS Letters, 307(2): 211-214 (1992).;;Blobe, G.C., et al., ""Regulation of Protein Kinase C and its Role in Cancer Biology,"" Cancer Metastasis Rev., 13: 411-431 (1994).;;Brenkert, A., et al., ""Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,"" Brain Res., 36: 183-193 (1972).;;CAPLUS Listing of Accession No. 1985:221199, Keith McCullagh, et al., ""Carboxyalkyl peptide derivatives."";;Carson, K.G., et al., ""Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,"" Tetrahedron Letters, 35(17): 2659-2662 (1994).;;Chatterjee, S., et al.,""Oxidized Low Density Lipoprotein Stimulates Aortic Smooth Muscle Cell Proliferation"", Glycobiology, 6(3): 303-311 (1996).;;Chatterjee, S., et al.,""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", Journal of Lipid Research, 37(6): 1334-1344 (1996).;;Clark, J.M., et al., ""Nonalcoholic Fatty Liver Disease, An Underrecognized Cause of Cryptogenic Cirrhosis,"" JAMA, 289(22):3000-3004 (2003).;;Comuzzie, A.G., et al., ""The Baboon as a Nonhuman Primate Model for the Study of the Genetics of Obesity"", Obesity Research, 11(1):75-80 (2003).;;Dellaria, Jr., J.F., et al., ""Enantioselective Synthesis of alpha-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon,"" J. Org. Chem., 54: 3916-3926 (1989).;;Dickie, P., et al., ""HIV-Associated Nephropathy in Transgenic Mice Expressing HIV-1 Genes,"" Virology, 185:109-119, 1991.;;Dittert, L.W., et al., ""Acetaminophen Prodrugs I-Synthesis, Physicochemical Properties and Analgesic Activity"", J. Pharm. Sci. 57(5), pp. 774-780 (1968).;;Elbein, A.D., ""Glycosidase Inhibitors: Inhibitors of N-linked Oligosaccharide Processing,"" The FASEB Journal, 5:3055-3063 (1991).;;European Search Report, European Application No. 09003291.3 dated Apr. 29, 2009.;;Evans, D.A., et al., ""Stereoselective Aldol Condensations Via Boron Enolates,"" J. Am. Chem. Soc., 103: 3099-3111 (1981).;;Fan, J-G., et al., ""Preventie Effects of Metformin on Rats with Nonalcoholic Steatohepatitis,"" Hepatology, 34(4)(1), p. 501A (2003).;;Felding-Habermann, B., et al., ""A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosins Synthesis,"" Biochemistry, 29: 6314-6322 (1990).;;Folch, J., et al., ""A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues"", J. Biol. Chem., 226:497-509, 1956.;;Freireich, E., et al., ""Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hampster, Dog, Monkey, and Man"", Cancer Chemother. Reports 50(4):219 (1996).;;Gatt, S., et al., ""Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids,"" Meth. Enzymol., 72: 351-375 (1981).;;Gill-Randall, R.J., et al., ""Is human Type 2 diabetes maternally inherited? Insights from an animal model"", Diabet. Med. 21 (7):759 (2004).;;Hakomori, S. ""New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy,"" Cancer Cells 3(12): 461-470 (1991).;;Hammett, L.P. Physical Organic Chemistry, (NY: McGraw), (1940).;;Harwood, L.M., et al., ""Asymmetric Cycloadditions of Aldehydes to Stabilized Azomethine Ylids: Enantiocontrolled Construction of beta-Hydroxy-alpha-amino acid Derivitives,"" Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).;;Harwood, L.M., et al., ""Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,"" Chem. Commun., 2641-2642 (1998).;;Högberg, T. and ULF Norinder, ""Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists"" Textbook of Drug Design and Development, pp. 55-91 (1991).;;Hospattankar, A.V., et al., ""Changes in Liver Lipids After Administration of 2-Decanoylamino-3-morpholinopropiophenone and Chlorpromazine,"" Lipids, 17(8): 538-543 (1982).;;Inokuchi, et al., ""Amino Alcohol Esters as Ceramide Analogs and Pharmaceuticals Containing Them for Treatment of Nerve Diseases,"" Abstract of CAPLUS Accession No. 1998: 786189, JP 10324671 (1998).;;Inokuchi, et al., (1996): SNT International HCAPLUS database, Columbus (OH), accession No. 1996: 214749.;;Inokuchi, J. et al., ""Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis,"" Cancer Lett., 38:23-30(1987).;;Inokuchi, J., et al., ""Preparation of the Active Isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, Inhibitor of Murine Clucocerebroside Synthetase,"" Journal of Lipid Research, 28:565-571 (1987).;;Inokuchi, J., et al., ""Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action"", Cancer Research, 50:6731-6737 (1990).;;Inokuchi, et al., ""Aminoalcohol derivatives for treatment of abnormal proliferative diseases"", Chemical Abstracts Service, XP002495476 retrieved from CAPLUS Database accession No. 1998:816280 (abstract).;;International Preliminary Examination Report issued in International Application PCT/US2000/18935 (WO 01/04108) dated Jul. 20, 2001.;;International Preliminary Examination Report for International Application No. PCT/US2002/022659 dated Jul. 24, 2003.;;International Preliminary Report on Patentability for International Application No. PCT/US2008/011450 dated Apr. 7, 2010.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001773 dated Sep. 21, 2010.;;International Preliminary Report on Patentability issued in International Application PCT/US2007/068521 dated Nov. 11, 2008.;;International Preliminary Report on Patentability issued in International Application PCT/US2005/040596 dated May 15, 2007.;;International Preliminary Examination Report issued in International Application PCT/US2002/00808, dated Jan. 10, 2003.;;International Search Report for PCT/US2000/018935 dated Nov. 28, 2000.;;International Search Report for PCT/US2002/00808 dated Oct. 1, 2002.;;International Search Report for PCT/US2002/022659 dated Nov. 5, 2002.;;Jaffrézou, Jr., et al., ""Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance,"" Biochim. Biophys. Acta, 1266: 1-8 (1995).;;Jankowski, K., ""Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion"", Microchem. J., 70:41-49, 2001.;;Jimbo, M., et al., ""Development of a New Inhibitor of Glucosylceramide Synthase"", J. Biochem, 127: 485-491 (2000).;;Kabayama, K., et al., ""TNFalpha-induced Insulin Resistance in Adipocytes as a Membrane Microdomain Disorder: Involvement of Ganglioside GM3,"" Glycobiology, 15(1): 21-29 (2005).;;Kalén, A., et al., ""Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid,"" Biochim. Biophys. Acta, 1125: 90-96 (1992).;;Kopaczyk, K., C., et al., ""In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,"" J. Lipid Res., 6: 140-145 (1965).;;Kurosawa, M., et al., ""C14-Labeling of Novel Atypical beta-Adrenoceptor Agonist, SM-11044,"" Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).;;Lee, L., et al. ""Improved Inhibitors of Glucosylceramide Synthase"", J. Bio Chem., 274(21): 14662-14669 (1999).;;Masson, E., et al., ""a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation-A Common Mediator for Retinal and Renal Microangiopathy?,"" Diabetes, 54:220-227 (2005).;;Mitchell, S., et al., ""Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,"" J. Org. Chem., 63: 8837-8842 (1998).;;Miura, T., et al., ""Synthesis and Evaluation of Morpholino and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase"", Bioorganic and Medicinal Chemistry, (6) 1481-1489 (1998).;;Nakamura, K., et al., ""Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,"" Anal. Biochem., 142: 406-410 (1984).;;Nicolaou, K., et al., ""A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriasylceramide (Gb3),"" J. Am. Chem., Soc., 110: 7910-7912 (1988).;;Nishida, A., et al., ""Practical Synthesis of threo-(1S, 2S)- and erythro-(1R, 2S)-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) from L-Serine,""Synlett, 389-390(1998).;;Nojiri, H., et al., ""Ganglioside GM3: An acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monoctyoid leukemic cell lines HL-60 and U937"", Proc. Natl. Acad. Sci., 83:782-786 (1986).;;International Preliminary Report on Patentability for International Application No. PCT/US2008/006906 Dated Dec. 1, 2009.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/051864 dated Feb. 1, 2011.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/006906, dated Dec. 4, 2008.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2008/011450, dated Jan. 21, 2009.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority for counterpart International Application No. PCT/US2009/001773, dated Nov. 11, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for counterpart International Application No. PCT/US2009/051864, dated Nov. 3, 2009.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for counterpart International Application No. PCT/US2009/005435, dated Feb. 12, 2010.;;Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/US2007/068521 dated Nov. 21, 2007.;;Ogawa, S., et al., ""Synthesis and Biological Evaluation of Four Stereoisomers of PDMP-Analogue, N-(2-Decylamino-3-Hydroxy-3-Phenylprop-1-YL)-beta-Valienamine, and Related Compounds,"" Bioorganic & Medicinal Chemistry Letters, 7(14):1915-1920 (1997).;;Overkleeft, H.S., et al., ""Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase,"" The Journal of Biological Chemistry, 273(41):26522-26527 (1998).;;Preiss, J., et al., ""Quantitative Measurement of sn-1,2-Diaclglycerols Present in Platelets, Hepatocytes, and ras- and sis-Transformed Normal Rat Kidney Cells,"" J. Biol. Chem., 261(19): 8597-8600 (1986).;;Radin, N.S., ""Killing Cancer Cells by Poly-drug Elevation of Ceramide Levels, A Hypothesis Whose Time has Come:,"" Eur. J. Biochem. 268(2): 193-204 (2001).;;Radin, N.S., et al., ""Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances.""Advances in Lipid Research: Sphingolipids, Part B., R.M. Bell et al., Eds. (San Diego: Academic Press), 26: 183-213 (1993).;;Radin, N.S., et al., ""Ultrasonic Baths as Substitutes for Shaking Incubator Baths,"" Enzyme, 45: 867-70(1991).;;Radin, N.S., et al., ""Use of an Inhibitor of Glucosylceramide Synthesis, D-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol,"" In NeuroProtocols: A Companion to Methods in Neurosciences, S.K. Fisher, et al., Eds., (San Diego: Academic Press) 3: 145-155 (1993).;;Rosenwald, A.G., et al., ""Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway,"" Biochemistry, 31: 3581-3590 (1992).;;Rosenwald, A.G., et al., ""Effects of the Glucosphingolipid Synthesis Inhibitor, PDMP, on Lysosomes in Cultured Cells,"" J. Lipid Res., 35: 1232-1240 (1994).;;Rubino, MD., F., et al., ""Letter to the Editor,"" Annals of Surgery, 240(2):389-390 (2004).;;Sandhoff, K., et al., ""Biosynthesis and Degradation of Mammalian Glycosphingolipids,"" Phil. Trans. R. Soc. Lond, B 358:847-861 (2003).;;Sasaki, A., et al., ""Overexpression of Plasma Membrane-Associated Sialidase Attenuates Insulin Signaling in Transgenic Mice,"" The Journal of Biological Chemistry, 278(30):27896-27902 (2003).;;Shayman, J.A., et al., ""Glucosphingolipid Dependence of Hormone-Stimulated Inositol Trisphophate Formation,"" J. Biol. Chem., 265(21): 12135-12138 (1990).;;Shayman, J.A., et al., ""Modulation of Renal Epithelial Cell Growth by Glucosylceramide,"" The Journal of Biological Chemistry, 266(34):22968-22974 (1991).;;Shukla, A., et al., ""Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis and the synergistic action of an inhibitor of microsomal momooxygenase,"" J. Lipid Research, 32: 713-722 (1991).",INACTIVE
105,US,A1,US 2010/0256216 A1,126-732-222-600-996,2010-10-07,2010,US 60187108 A,2008-05-30,US 60187108 A;;US 99784607 P;;US 93237007 P;;US 2008/0006906 W,2007-05-31,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/126-732-222-600-996,Patent Application,yes,34,29,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,A61K31/4025;;A61K31/4015;;C07D207/00;;C07D405/06,514/422;;548/526;;548/556;;514/424,0,0,,,,INACTIVE
106,JP,A,JP 2017132814 A,138-498-212-626-597,2017-08-03,2017,JP 2017095022 A,2017-05-11,US 10254108 P,2008-10-03,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,"PROBLEM TO BE SOLVED: To provide 2-acylaminopropanol-type glucosylceramide synthase inhibitors.SOLUTION: The present invention provides a pharmaceutical composition for treating polycystic kidney disease, comprising a compound represented by one of predetermined structural formulas or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;DAVID J HARRIS;;ANGELES DIOS;;EDWARD LEE;;RICHARD SILVA;;LISA M CUFF;;MIKAELA LEVINE;;CASSANDRA A CELATKA;;THOMAS H JOZAFIAK;;FREDERIC VINICK;;XIANG YIBIN;;JOHN KANE;;JUNKAI LIAO,,https://lens.org/138-498-212-626-597,Patent Application,no,1,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;A61K31/403;;A61K31/427;;A61K31/428;;A61K31/4439;;A61K31/4709;;A61P13/12;;A61P43/00,,2,2,022-861-665-824-921;;006-530-492-820-511,11380803;;10.1046/j.1523-1755.2001.00716.x;;10.1046/j.1523-1755.2001.0590062005.x;;10.1016/s0022-2275(20)41159-9;;7806975,"KIDNEY INTERNATIONAL, vol. Vol.59, JPN6014031143, 2001, pages 2005 - 2022;;JOURNAL OF LIPID REASERCH, vol. 35, no. 9, JPN6015022418, 1994, pages 1611 - 1618",INACTIVE
107,US,A1,US 2016/0338996 A1,165-134-424-897-067,2016-11-24,2016,US 201615003207 A,2016-01-21,US 201615003207 A;;US 201213595251 A;;US 201113122135 A;;US 2009/0005435 W;;US 10254108 P,2008-10-03,2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-10-28),https://lens.org/165-134-424-897-067,Patent Application,yes,0,2,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025,,0,0,,,,INACTIVE
108,US,A1,US 2015/0225393 A1,195-226-791-909-724,2015-08-13,2015,US 201414571922 A,2014-12-16,US 201414571922 A;;US 201213595349 A;;US 60187110 A;;US 2008/0006906 W;;US 93237007 P;;US 99784607 P,2007-05-31,2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors,"A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.",GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;VINICK FREDERIC;;JOZEFIAK THOMAS H;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,GENZYME CORPORATION (2009-01-06),https://lens.org/195-226-791-909-724,Patent Application,yes,0,6,27,27,0,A61P3/08;;A61P3/10;;A61P13/12;;C07D417/14;;C07D417/14;;C07D295/125;;C07D295/125;;C07D319/18;;C07D319/18;;C07D405/06;;C07D405/06;;C07D405/12;;C07D405/12;;C07D405/14;;C07D405/14;;C07D407/12;;C07D407/12;;C07D409/12;;C07D409/12;;C07D409/14;;C07D409/14;;C07D411/12;;C07D411/12;;C07D413/12;;C07D413/12;;C07D413/14;;C07D413/14,C07D417/14;;C07D405/06;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
109,EP,B1,EP 2349255 B1,095-485-899-537-96X,2016-03-30,2016,EP 09741487 A,2009-10-02,US 2009/0005435 W;;US 10254108 P,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZEFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/095-485-899-537-96X,Granted Patent,yes,1,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
110,JP,A,JP 2018087232 A,119-641-634-355-096,2018-06-07,2018,JP 2018028160 A,2018-02-20,US 10254108 P,2008-10-03,2-ACYLAMINOPROPANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,PROBLEM TO BE SOLVED: To provide 2-acylaminopropanol-type glucosylceramide synthase inhibitors.SOLUTION: The present invention provides a compound represented by a predetermined structural formula and used for treating polycystic kidney disease or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;DAVID J HARRIS;;ANGELES DIOS;;EDWARD LEE;;RICHARD SILVA;;LISA M CUFF;;MIKAELA LEVINE;;CASSANDRA A CELATKA;;THOMAS H JOZAFIAK;;FREDERIC VINICK;;XIANG YIBIN;;JOHN KANE;;JUNKAI LIAO,,https://lens.org/119-641-634-355-096,Patent Application,no,1,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,C07D207/10;;A61K31/357;;A61K31/40;;A61K31/4025;;A61K31/4035;;A61K31/407;;A61K31/4192;;A61K31/42;;A61K31/422;;A61K31/4245;;A61K31/427;;A61K31/428;;A61K31/4402;;A61K31/4439;;A61K31/453;;A61K31/4709;;A61K31/4725;;A61K31/5377;;A61P13/12;;C07D207/12;;C07D213/40;;C07D217/16;;C07D263/06;;C07D277/64;;C07D295/13;;C07D317/58;;C07D319/18;;C07D319/20;;C07D333/20;;C07D333/28;;C07D405/06;;C07D405/12;;C07D407/12;;C07D409/12;;C07D409/14;;C07D413/04;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08,,0,0,,,,PENDING
111,MX,A,MX 2011003517 A,129-370-374-014-383,2011-05-25,2011,MX 2011003517 A,2009-10-02,US 10254108 P;;US 2009/0005435 W,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS.,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;LIAO JUNKAI;;KANE JOHN,,https://lens.org/129-370-374-014-383,Patent Application,no,0,0,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,C07C271/12;;A61K31/4025;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
112,WO,A1,WO 2010/039256 A1,131-191-174-845-199,2010-04-08,2010,US 2009/0005435 W,2009-10-02,US 10254108 P,2008-10-03,2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS,A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.,GENZYME CORP;;SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,SIEGEL CRAIG;;BASTOS CECILIA M;;HARRIS DAVID J;;DIOS ANGELES;;LEE EDWARD;;SILVA RICHARD;;CUFF LISA M;;LEVINE MIKAELA;;CELATKA CASSANDRA A;;JOZAFIAK THOMAS H;;VINICK FREDERIC;;XIANG YIBIN;;KANE JOHN;;LIAO JUNKAI,,https://lens.org/131-191-174-845-199,Patent Application,yes,3,14,30,30,0,C07D207/12;;C07D295/13;;C07D317/46;;C07D317/58;;C07D319/18;;C07D319/20;;C07D405/12;;C07D409/06;;C07D409/12;;C07D413/04;;C07D413/14;;C07D417/12;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61P13/12;;A61P43/00;;A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/10;;C07D405/14;;C07C271/12;;C07D317/60;;C07D319/18;;C07D319/20;;C07D333/16;;C07D407/06;;C07D407/12;;C07D409/04;;C07D413/04;;C07D417/12;;C07D207/12;;A61K31/4025,A61K31/4025;;C07C271/12;;C07D207/10;;C07D295/04;;C07D295/10;;C07D319/08;;C07D405/06;;C07D405/14;;C07D407/14;;C07D409/06;;C07D409/12;;C07D409/14;;C07D413/06;;C07D413/14;;C07D417/14,,3,3,101-441-717-112-268;;013-186-690-689-175;;037-256-760-224-384,10.1016/s0022-2275(20)39163-x;;8808768;;8724138;;10.1093/glycob/6.3.303;;17470562;;10.2337/db06-0719,"CHATTERJEE, S.; SHI, W.Y.; WILSON, P.; MAZUMDAR,A.: ""Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease"", JOURNAL OF LIPID RESEARCH, vol. 37, 1996, pages 1334 - 1344, XP002562795;;CHATTERJEE S ET AL: ""OXIDIZED LOW DENSITY LIPOPROTEIN STIMULATES AORTIC SMOOTH MUSCLE CELL PROLIFERATION"", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 6, no. 3, 1 January 1996 (1996-01-01), pages 303 - 311, XP009028471, ISSN: 0959-6658;;ZHAO HONGMEI ET AL: ""Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes"", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 56, no. 5, 1 May 2007 (2007-05-01), pages 1210 - 1218, XP002508439, ISSN: 0012-1797",PENDING
